Document:

qure_Ex10_5

		
			Exhibit 10.5
		

		
			CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.
		

		
			COLLABORATION AND LICENSE AGREEMENT
		

		
			 
		

		
			BY AND BETWEEN
		

		
			 
		

		
			4D MOLECULAR THERAPEUTICS, INC
		

		
			 
		

		
			AND
		

		
			 
		

		
			UNIQURE BIOPHARMA B.V.
		

		
			 
		

		
			August 6, 2019
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			 

		

		

		
			COLLABORATION AND LICENSE AGREEMENT
		

		
			This Collaboration and License Agreement (this “Agreement” or “New CLA”) is entered into and made effective on August 6, 2019 (the “New CLA Effective Date”), by and between 4D Molecular Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a principal office located at 5858 Horton St, Emerystation North, Suite 460, Emeryville, CA 94608 (“4DMT”), and uniQure biopharma B.V., a corporation organized and existing under the laws of The Netherlands and having a principal office located at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands (“uniQure”).
		

		
			INTRODUCTION
		

		
			1.         4DMT is a biopharmaceutical company focused on research, development, manufacturing and marketing of novel adeno-associated viral vectors for delivery of nucleic acids to target cells and gene therapy biopharmaceutical products based thereon.
		

		
			2.         uniQure is a biopharmaceutical company focused on the research, development, manufacturing and marketing of gene therapy based biopharmaceutical products.
		

		
			3.         4DMT and uniQure desire for 4DMT to conduct a new research program  to identify improved AAV Capsid Variants (as defined below) for delivery to liver (in the case of some such AAV Capsid Variants) or the central nervous system (in the case of others).
		

		
			4.         4DMT and uniQure have previously entered into a Collaboration and License Agreement effective on January 17th, 2014, (the “Original CLA”) pursuant to which, 4DMT and uniQure had a collaboration for the identification of novel AAV Capsid Variants for development and commercialization as therapeutic products in the Field (defined below), and the Parties are, concurrent with the execution of this Agreement, amending and restating the Original CLA in its entirety by entering into an Amended and Restated Collaboration and License Agreement, effective of even date herewith (the “Amended and Restated CLA”), and, through the execution of this Agreement and the Amended and Restated CLA, the Parties have resolved the matters that were referred to and described in correspondence between the Parties dated February 28, 2019 with respect to the Original CLA.
		

		
			5.         uniQure desires to receive from 4DMT exclusive rights under 4DMT’s intellectual property rights to research (subject to 4DMT’s retained rights to conduct research), develop, manufacture and commercialize certain gene therapy Products based on use of New Capsid Variants (defined below) to deliver Transgenes (defined below) based on Restricted Targets (defined below) in the Field pursuant to this Agreement, and subject to 4DMT’s Step-In Rights (defined below).
		

		
			6.         4DMT desires to retain non-exclusive rights to, exclude from the exclusive grant described above the non-exclusive rights to, and/or receive from uniQure non-exclusive rights under uniQure’s intellectual property rights to, research,  develop, manufacture and commercialize certain gene therapy products based on use of New Capsid Variants to deliver Transgenes based on Restricted Targets within and outside of the Field, in accordance with 4DMT’s Step-In Rights pursuant to this Agreement.
		

		
			 
		

		
			 
		

		
			

		 

		

			 

		

		

			 

		

		

		
			7.         uniQure also desires to receive from 4DMT non-exclusive rights under 4DMT’s intellectual property rights to research,  develop, manufacture and commercialize certain gene therapy products based on use of New Capsid Variants to deliver Transgenes based on targets other than Restricted Targets (Non-Restricted Targets, more particularly defined below), in accordance with uniQure’s Step-In Rights pursuant to this Agreement.
		

		
			8.         4DMT would retain all other rights to New Capsid Variants (e.g., rights to New Capsid Variants outside the Field and related to Non-Restricted Targets), subject to uniQure’s Step-In Rights for Non-Restricted Targets and information rights as described herein.
		

		
			NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt of which is hereby acknowledged, 4DMT and uniQure agree as follows effective as of the Effective Date:
		

		
			ARTICLE I
		

		
			 
		

		
			DEFINITIONS
		

		
			Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below:
		

		
			1.1      “4DMT AAV Capsid Variant”.  4DMT AAV Capsid Variant means any AAV Capsid Variant that does not carry a Gene Therapy Construct contained in a Royalty Bearing Construct or Royalty Bearing Product.
		

		
			1.2      “4DMT AAV Capsid Variant Library”.  4DMT AAV Capsid Variant Library means any AAV Capsid Variant Library constructed by or licensed to 4DMT, including all AAV Capsid Variant Libraries provided to 4DMT pursuant to the UCB Agreements.
		

		
			1.3      “4DMT Intellectual Property”.  4DMT Intellectual Property means the 4DMT Know-How and the 4DMT Patent Rights.
		

		
			1.4      “4DMT Know-How”.  4DMT Know-How means Know-How that is (a) Controlled by 4DMT or its Affiliates as of the Effective Date or during the Research Term, and (b) necessary or useful to conduct the Research Program or to research, Develop, make and have made, use or Commercialize any New Capsid Variant, or a Royalty Bearing Construct or Royalty Bearing Product due to the presence of such New Capsid Variant therein.  4DMT Know-How includes Core 4DMT Know-How but does not include Joint Know-How.
		

		
			1.5      “4DMT Patent Right”.  4DMT Patent Right means any Patent Right Controlled by 4DMT or its Affiliates as of the Effective Date or during the Term that Covers 4DMT Know-How.  4DMT Patent Rights include Core 4DMT Patent Rights but do not include Joint Patent Rights.
		

		
			1.6      “4DMT Product” . 4DMT Product means a Royalty Bearing Product that (a) delivers a Transgene that Affects a Non-Restricted Target (or variant of a Non-Restricted Target), or (b) that delivers a Transgene that Affects a Restricted Target (or variant of a Restricted Target), and, in the case of (b) (but to avoid doubt, this is not required for (a)), 4DMT has obtained
		

		
			
		

		
			

		 

		

			-  2  -

		

		

			 

		

		

		
			non-exclusive rights to Develop and Commercialize such Royalty-Bearing Product pursuant to the exercise of its Step-In Rights in Section 4.4.  Notwithstanding anything express or implied, no 4DMT Product shall deliver a Transgene that relates to any Restricted Target for which 4DMT has not obtained rights to deliver as part of a Royalty-Bearing Product pursuant to the exercise of its Step-In Rights under Section 4.4.
		

		
			1.7      “4D Product Patent”. 4D Product Patent means any Product Patent upon which 4DMT’s or its Affiliates’ personnel are properly named inventors (as determined under U.S. patent law) and uniQure’s and its Affiliates’ are not.
		

		
			1.8      “AAV”.  AAV means adeno-associated virus.
		

		
			1.9      “AAV Capsid Variant”.  AAV Capsid Variant means an AAV capsid that is modified as compared to the wild type sequence.
		

		
			1.10    “AAV Capsid Variant Library”.  AAV Capsid Variant Library means a collection of variant AAV capsid open reading frames inserted into an AAV genome in a manner that renders such variants genome replication-competent with the appropriate helper virus functions and capable of being selected and evolved to optimize their ability to deliver nucleic acid sequences to human or animal cells.
		

		
			1.11    “Accounting Standards”.  Accounting Standards means, with respect to uniQure and its Affiliates, International Financial Reporting Standards (“IFRS”) or, to the extent applicable, generally accepted accounting principles as practiced in the United States (“GAAP”), and with respect to 4DMT and its Affiliates, GAAP, in each case as they exist from time to time, consistently applied.
		

		
			1.12    “Affects”.  Affects, with respect to a Transgene and a Target, means that the Transgene (a) encodes such Target or a variant of such Target, (b) knocks down the mRNA corresponding to such Target or a variant of such Target, (c) encodes an antibody or other protein that specifically binds the protein encoded by such Target, or (d) otherwise directly affects such Target (e.g., via gene editing) or the protein that such Target encodes.
		

		
			1.13    “Affiliate”.  Affiliate means, with respect to a Party, any entity that directly or indirectly controls, is controlled by, or is under common control with such Party.  As used in this definition, the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an entity, whether through ownership of voting securities, by contract or otherwise.  For purposes of this definition, “control” shall be presumed to exist if one of the following conditions are met: (a) in the case of corporate entities, direct or indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (b) in the case of non-corporate entities, direct or indirect ownership of more than fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities.
		

		
			1.14    “Animal POC”.  Animal POC means demonstration of gene expression and/or gene function of a Transgene cassette for a Target, in an animal model or patient-derived cells; provided that such demonstration shall be in an established, relevant animal model of a disease, if available.
		

		
			
		

		
			

		 

		

			-  3  -

		

		

			 

		

		

		
			1.15    “Business Day”.  Business Day means a day that is not a Saturday, Sunday or a day on which banking institutions in New York, New York, USA or Amsterdam, The Netherlands are authorized by Law to remain closed.
		

		
			1.16    “Calendar Quarter”.  Calendar Quarter means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided,  however, that the first Calendar Quarter hereunder shall commence on the Effective Date and the final Calendar Quarter hereunder shall end on the effective date of termination or expiration of this Agreement.
		

		
			1.17    “Calendar Year”.  Calendar Year means each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided,  however, that the first Calendar Year hereunder shall commence on the Effective Date and the final Calendar Quarter hereunder shall end on the effective date of termination or expiration of this Agreement
		

		
			1.18    “CEO”.  CEO means the Chief Executive Officer of a Party or, if there is no Chief Executive Officer of a Party, the Board Chairperson or senior-most executive officer or equivalent of such Party.
		

		
			1.19    “CNS”.  CNS means the central nervous system. [***]
		

		
			1.20    “CNS Term”.  The CNS Term means the period beginning on the New CLA Effective Date and ending on the later of (a) [***] ([***]) years from the date of initiation of work under the Research Plan for CNS, and (b) the date on which 4DMT delivers [***] ([***]) (i.e., when it has delivered [***]) New CNS Variants to uniQure with the Vector Characterization Data with respect to each of such [***] ([***]) New CNS Variants that the Research Plan for CNS requires 4DMT to provide.  It is understood that the Selection Processes giving rise to such New CNS Variants shall be the Selection Processes directed at identifying CNS-targeted variants as defined and called for in the Research Plan, or, if such Selection Processes do not yield [***] ([***]) New CNS Variants meeting the Delivery Success Criteria (that can then proceed into the studies that generate Vector Characterization Data in accordance with the Research Plan for CNS), then Selection Processes for CNS-targeted AAV Capsid Variants that 4DMT conducts in addition or as follow-ups to (but in each case not in replacement or in lieu of) such CNS-directed Selection Processes called for in the Research Plan, and in any event meeting the requirements of Section 3.1. If 4DMT conducts such in-addition-to and/or follow-up CNS-directed Selection Processes, then the Vector Characterization Data that 4DMT would have to report to uniQure in order for the applicable New CNS Variants to count as one of the [***] ([***]) New CNS Variants of clause (b) of the first sentence of this definition, shall be equivalent to the Vector Characterization Data that 4DMT is required to report to uniQure under the Research Plan with respect to the New CNS Variants that it delivers thereunder.  uniQure’s information and input rights as to any such additional Selection Processes that 4DMT may choose to conduct are as provided for in Section 3.1.
		

		
			1.21    “Commercially Reasonable Efforts”.  Commercially Reasonable Efforts means, with respect to a Party, the efforts required in order to carry out a task in a diligent and sustained manner without undue interruption or delay, which level is at least commensurate with the level of effort that a similarly situated Third Party would devote to a product of similar market
		

		
			
		

		
			

		 

		

			-  4  -

		

		

			 

		

		

		
			potential and having similar commercial and scientific advantages and disadvantages resulting from its own research efforts or to which it has rights, taking into account its safety and efficacy, regulatory status, the competitiveness of the marketplace, its proprietary position, pricing, reimbursement, launching strategy and other market-specific factors, and all other relevant factors.
		

		
			1.22    “Commercialization” or “Commercialize”.  Commercialization or Commercialize means any activity directed to obtaining pricing or reimbursement approvals, marketing, promoting, distributing, importing, exporting, offering to sell or selling a product, or to have any such activity performed.  When used as a verb, “Commercialize” means to engage in Commercialization.
		

		
			1.23    “Construct”.  Construct means an AAV Capsid Variant carrying and comprising  a Gene Therapy Construct.
		

		
			1.24    “Confidential Information”.  Confidential Information means any and all information and data, including all uniQure Know-How, 4DMT Know-How and Joint Know-How, and all other scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided by one Party to the other Party in connection with this Agreement or the Prior Confidentiality Agreement.  All Core uniQure Know-How shall be considered the Confidential Information of uniQure, with respect to which: (a) uniQure shall be considered the disclosing Party, (b) 4DMT shall be considered the receiving Party, and (c) clauses (b) and (e) of Section 8.2 shall not apply.  All Core 4DMT Know-How shall be considered the Confidential Information of 4DMT, with respect to which: (i) 4DMT shall be considered the disclosing Party, (ii) uniQure shall be considered the receiving Party, and (iii) clauses (b) and (e) of Section 8.2 shall not apply.
		

		
			1.25    “Control”.  Control means, with respect to any item of or right under Patent Rights or Know-How, the possession (whether by ownership or license, other than a license pursuant to this Agreement) of the ability of a Party or, as applicable, its Affiliate (subject to Section 12.7), to grant access to, or a license or sublicense of, such items or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense.
		

		
			1.26    “Core 4DMT Intellectual Property”.  Core 4DMT Intellectual Property means Core 4DMT Know-How and Core 4DMT Patent Rights.
		

		
			1.27    “Core 4DMT Know-How”.  Core 4DMT Know-How means [***].
		

		
			1.28    “Core 4DMT Patent Right”.  Core 4DMT Patent Right means any Patent Right that Covers the Core 4DMT Know-How, including New Variant Patents.
		

		
			1.29    “Core uniQure Intellectual Property”.  Core uniQure Intellectual Property means Core uniQure Know-How and Core uniQure Patent Rights.
		

		
			1.30    “Core uniQure Know-How”.  Core uniQure Know-How means [***].
		

		
			
		

		
			

		 

		

			-  5  -

		

		

			 

		

		

		
			1.31    “Core uniQure Patent Right”.  Core uniQure Patent Right means any Patent Right that Covers the Core uniQure Know-How. For clarity, Core uniQure Patent Rights excludes New Variant Patents.
		

		
			1.32    “Cover”, “Covering” or “Covered”.  Cover, Covering or Covered means, with respect to a product, technology, process or method that, in the absence of ownership of or a license granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or the practice of such technology, process or method would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue). With respect to a composition, “Coverage” exists if the applicable Valid Claim claims such composition, its method of manufacture, or its methods of use.
		

		
			1.33    “Default”.  Default means with respect to a Party that (a) any representation or warranty of such Party set forth herein shall have been untrue in any material respect when made or (b) such Party shall have failed to perform any material obligation set forth in this Agreement.
		

		
			1.34    “Delivery Success Criteria”.  Delivery Success Criteria means the following criteria that determines whether a given AAV Capsid Variant demonstrates superior delivery to the CNS or liver for introduction into those additional validation and characterization studies that are defined in the applicable Research Plan:  [***].
		

		
			1.35    “Development” or “Develop”.  Development or Develop means pre-clinical and clinical drug development activities, including:  test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, development-stage manufacturing, quality assurance/quality control procedure development and performance with respect to clinical materials, statistical analysis and report writing and clinical studies, regulatory affairs, and all other pre-Regulatory Approval activities.  When used as a verb, “Develop” means to engage in Development.
		

		
			1.36    “EMA”.  EMA means the European Medicines Agency, or any successor agency.
		

		
			1.37    “European Union” or “EU”.  European Union or EU means the countries that are members of the European Union, as redefined from time to time.
		

		
			1.38    “FDA” or “Food and Drug Administration”.  FDA or Food and Drug Administration means the United States Food and Drug Administration, or any successor agency.
		

		
			1.39    “Field”.  Field means the delivery of Gene Therapy Constructs to cells in (a) the CNS or (b) the liver, in each case where such delivery is for the purpose of effecting expression of the applicable RNA or amino acid sequence in the targeted cells and is potentially useful for the diagnosis, treatment, cure, palliation or prevention of a disease or medical condition in humans or animals, irrespective of the administration site or mode of administration (e.g., intravenous, direct injection, subcutaneous or intrathecal) of the Construct used to effect delivery.  For clarity, intravenous or intrathecal administration of any Construct targeted to cells in other organs (i.e., not specifically targeted to liver or CNS tissues), including for treatment of neoplastic and eye disorders, are excluded from the Field.
		

		
			
		

		
			

		 

		

			-  6  -

		

		

			 

		

		

		
			1.40    “First Commercial Sale”.  First Commercial Sale means, with respect to any Royalty Bearing Product and a country, the first sale for end use or consumption of such Royalty Bearing Product in such country after all required approvals, including Regulatory Approval, have been granted by the Regulatory Authority of such country.  For clarity, sales for test marketing, sampling and promotional uses, clinical trials purposes or compassionate use shall not constitute a First Commercial Sale.
		

		
			1.41    “Gene Therapy Construct”.  Gene Therapy Construct means any Transgene that is packaged into an AAV Capsid Variant to form a Construct, and is intended to be delivered to a targeted tissue to treat, cure, prevent or ameliorate a disease or condition of the CNS or liver by any gene therapy application or modality.
		

		
			1.42    “Good Laboratory Practices”.  Good Laboratory Practices means the then-current good laboratory practice standards promulgated or endorsed by the FDA, as defined in 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the U.S. to the extent applicable to the relevant study, as they may be updated from time to time).
		

		
			1.43    “Governmental Authority”.  Governmental Authority means any United States federal, state or local or any foreign government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body.
		

		
			1.44    “IGT”.  IGT means Integrative Gene Therapeutics, Inc., a California corporation, which jointly owns with UC certain of the UC Patent Rights.
		

		
			1.45    “Indication”.  Indication means any disease, condition or syndrome.
		

		
			1.46    “Invention”.  Invention means any new and useful process, article of manufacture, Construct, composition of matter, formulation or apparatus, or any improvement thereof, discovery or finding, which is patentable.
		

		
			1.47    “Invoice”.  Invoice means an original invoice sent by 4DMT to uniQure with respect to any payment due hereunder substantially in the form attached hereto as Schedule 1.
		

		
			1.48    “Know-How”.  Know-How means (a) any scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, that is not in the public domain, including databases, practices, methods, techniques, specifications, formulations, formulae, protein sequences, nucleic acid sequences, AAV Capsid Variants, AAV Capsid Variant Libraries, Gene Therapy Constructs, Constructs, knowledge, know-how, trade secrets, skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data, and (b) any biological, chemical, or physical material or composition of matter that is not in the public domain or otherwise generally available to the public.
		

		
			
		

		
			

		 

		

			-  7  -

		

		

			 

		

		

		
			1.49    “Law”.  Law means all laws, statutes, rules, codes, regulations, orders, judgments or ordinances applicable to a Party, this Agreement or the activities contemplated hereunder.
		

		
			1.50     “Licensed IP”.  Licensed IP means the 4DMT Intellectual Property, the Joint Intellectual Property, and the Intellectual Property licensed by uniQure to 4DMT pursuant to Section 5.2.
		

		
			1.51    “Liver Term”.  The Liver Term means the period beginning on the New CLA Effective Date and ending on the later of (a) [***] ([***]) years from the date of initiation of work under the Research Plan for Liver, and (b) the date on which 4DMT delivers [***] ([***]) (i.e., when it has delivered [***]) New Liver Variants to uniQure with the Vector Characterization Data with respect to each of such [***] ([***]) New Liver Variants that the Research Plan for Liver requires 4DMT to provide.  It is understood that the Selection Processes giving rise to such New Liver Variants shall be the Selection Processes directed at identifying liver -targeted variants as defined and called for in the Research Plan, or, if such Selection Processes do not yield [***] ([***]) New Liver Variants meeting the Delivery Success Criteria (that can then proceed into the studies that generate Vector Characterization Data in accordance with the Research Plan for Liver), then Selection Processes for liver-targeted AAV Capsid Variants that 4DMT conducts in addition or as follow-ups to (but in each case not in replacement or in lieu of) such liver-directed Selection Processes called for in the Research Plan, and in any event meeting the requirements of Section 3.1. If 4DMT conducts such in-addition-to and/or follow-up liver -directed Selection Processes, then the Vector Characterization Data that 4DMT would have to report to uniQure in order for the applicable New Liver Variants to count as one of the [***] ([***]) New Liver Variants of clause (b) of the first sentence of this definition, shall be equivalent to the Vector Characterization Data that 4DMT is required to report to uniQure under the Research Plan with respect to the New Liver Variants that it delivers thereunder.  uniQure’s information and input rights as to any such additional Selection Processes that 4DMT may choose to conduct are as provided for in Section 3.1.
		

		
			1.52    “Materials”.  Materials means any tangible chemical or biological research materials that are provided or otherwise made available by one Party to the other Party under the terms of Section 3.3 for use in performance of the Research Program; provided,  however, that Materials will not include any AAV Capsid Variant Libraries.
		

		
			1.53    “NDA”.  NDA means a New Drug Application or Biologics License Application filed with the FDA or any other application required for the purpose of marketing or selling or commercially using a therapeutic or prophylactic product to be filed with a Regulatory Authority in a non-U.S. country or group of countries, including a Product License Application or Marketing Authorization Application (“MAA”) in the European Union or Japan.
		

		
			1.54    “Net Sales”.  Net Sales means, with respect to a Royalty Bearing Product (either a uniQure Product or a 4DMT Product, as applicable), the gross amount of sales of such Royalty Bearing Product invoiced by a Party or its Affiliates to Third Parties, less the following to the extent related to such Royalty Bearing Product and incurred by such Party or its Affiliates and invoiced to the Third Party:
		

		
			
		

		
			

		 

		

			-  8  -

		

		

			 

		

		

		
			(a)        sales returns and allowances actually paid, granted or accrued, including trade, quantity and cash discounts and any other adjustments, including those granted on account of price adjustments or billing errors;
		

		
			(b)        rejected goods, damaged or defective goods, recalls, returns;
		

		
			(c)        rebates, chargeback rebates, compulsory rebates, reimbursements or similar payments granted or given to wholesalers or other distributors, buying groups or health care insurance carriers;
		

		
			(d)        non-collectable receivables;
		

		
			(e)        customs or excise duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes); or
		

		
			(f)        charges for packing, freight, shipping and insurance.
		

		
			Each of the foregoing deductions shall be determined as incurred in the ordinary course of business in type and amount consistent with good industry practice and in accordance with  Accounting Standards on a basis consistent with such Party’s audited consolidated financial statements.  For clarity, sales by uniQure or its Affiliates of a Royalty Bearing Product to a Third Party Distributor of such Royalty Bearing Product in a given country shall be considered a sale to a Third Party customer.  All such discounts, allowances, credits, rebates, and other deductions shall be fairly and equitably allocated to the Royalty Bearing Products and other products of uniQure and its Affiliates such that the Royalty Bearing Product does not bear a disproportionate portion of such deductions.
		

		
			In the event any Royalty Bearing Product is sold for consideration other than cash, Net Sales for such sale shall be the average price of such Royalty Bearing Product sold for cash during the relevant period in the relevant country.
		

		
			In the event that any discount, reduction, payment or rebate is offered for a Royalty Bearing Product where such Royalty Bearing Product is sold to a Third Party customer as part of a grouped set of products, the applicable discount, reduction, payment or rebate for such Royalty Bearing Product in such arrangement shall be based on the weighted average discount, reduction, payment or rebate of such grouped set of products.
		

		
			Any Royalty Bearing Products used for promotional or advertising purposes (in reasonable and customary amounts) or used for Clinical Trials or other research purposes shall not be included in Net Sales.  Donations for charity reasons or compassionate use shall also not be included in Net Sales.
		

		
			1.55    “New Capsid Variant(s)”.  New Capsid Variant means any New CNS Variant or New Liver Variant.
		

		
			1.56    “New CNS Variant(s)”.  New CNS Variant means any AAV Capsid Variant identified by 4DMT or its Affiliate, or any Third Party pursuant to rights granted by 4DMT or its Affiliate, during the CNS Term in a Selection Process designed to identify AAV Capsid Variants
		

		
			
		

		
			

		 

		

			-  9  -

		

		

			 

		

		

		
			specifically targeting cells of the CNS, but excluding any such AAV Capsid Variants that are Selected Capsid Variants.  An AAV Capsid Variant is “identified” in a Selection Process when it is sequenced. An AAV Capsid Variant does not need to satisfy (or necessarily have been tested against) the applicable Delivery Success Criteria to qualify as a New CNS Variant.
		

		
			If data of the types listed in the definition of Vector Characterization Data that is generated by, for or under right from 4DMT demonstrate that an AAV Capsid Variant from any other Selection Process (i.e., one not under the Research Plan of this Agreement or one that was not designed to identify AAV Capsid Variants specifically targeting cells of the CNS) conducted by, for or under right from 4DMT during the CNS Term is improved or superior to the top [***] ([***]) New CNS Variants arising under the Research Program in the following ways, then 4DMT will share the Vector Characterization Data with uniQure:[***]
		

		
			In that case, any such AAV Capsid Variant with respect to which 4DMT is required to share such data of the types listed in Vector Characterization Data demonstrating such improvement or superiority ((a) or (b) or (c)) shall be deemed a New CNS Variant, and such data shall be deemed Vector Characterization Data.  It is understood that 4DMT is not under any obligation to generate such data (nor to have it generated for or under right from 4DMT), nor to perform any research or other activities not set forth in the Research Plan, but that, pursuant to the terms of this Agreement, uniQure may further investigate any such deemed New CNS Variants.
		

		
			1.57    “New Liver Variant(s)”.  New Liver Variant means any AAV Capsid Variant identified by 4DMT or its Affiliate, or any Third Party pursuant to rights granted by 4DMT or its Affiliate, during the Liver Term in a Selection Process designed to identify AAV Capsid Variants specifically targeting cells of the liver, but excluding any such AAV Capsid Variants that are Selected Capsid Variants.  An AAV Capsid Variant is “identified” in a Selection Process when it is sequenced. An AAV Capsid Variant does not need to satisfy (or necessarily have been tested against) the applicable Delivery Success Criteria to qualify as a New Liver Variant.
		

		
			If data of the types listed in the definition of Vector Characterization Data that is generated by, for or under right from 4DMT demonstrate that an AAV Capsid Variant from any other Selection Process (i.e., one not under the Research Plan of this Agreement or one that was not designed to identify AAV Capsid Variants specifically targeting cells of the liver) conducted by, for or under right from 4DMT during the Liver Term is improved or superior to the top [***] ([***]) New Liver Variants arising under the Research Program in the following ways, then 4DMT will share the Vector Characterization Data with uniQure:[***]
		

		
			In that case, any such AAV Capsid Variant with respect to which 4DMT is required to share such data of the types listed in Vector Characterization Data demonstrating such improvement or superiority ((a) or (b) or (c)) shall be deemed a New Liver Variant, and such data shall be deemed Vector Characterization Data.  It is understood that 4DMT is not under any obligation to generate such data (nor to have it generated for or under right from 4DMT), nor to perform any research or other activities not set forth in the Research Plan, but that, pursuant to the terms of this Agreement, uniQure may further investigate any such deemed New Liver Variants.
		

		
			
		

		
			

		 

		

			-  10  -

		

		

			 

		

		

		
			 
		

		
			1.58    “New Variant Patent”. New Variant Patent means any Patent Right Covering one or more New Capsid Variants (for clarity, whether by their composition, method of use, or method of manufacture).  It is understood that New Variant Patents (1) may include dependent claims directed to the combination of a New Capsid Variant and a Transgene and (2) do not include any Patent Rights claiming inventions that are conceived and reduced to practice solely by employees, agents and/or consultants of uniQure or its Affiliate independently and outside of the Research Program, without the use of information pertaining to a Selected Capsid Variant or New Capsid Variant sequence disclosed to uniQure under this Agreement or the Amended and Restated CLA.
		

		
			1.59    “Non-Restricted Targets” means all Targets within the Field that are not Restricted Targets.
		

		
			1.60    “Party” and “Parties”.  Party means uniQure or 4DMT individually, and Parties means uniQure and 4DMT collectively.
		

		
			1.61    “Patent Rights”.  Patent Rights means patents, patent applications or provisional patent applications, utility models and utility model applications, petty patents, innovation patents, patents of addition, divisionals, continuations, continuation-in-part applications, continued prosecution applications, requests for continued examinations, reissues, renewals, reexaminations and extensions and supplementary protection certificates granted in relation thereto, in any country of the world.  For clarity, Patent Rights shall include any Patent Right that claims priority to or common priority with such Patent Rights.
		

		
			1.62    “Product”.  Product means any preparation in final form, either for sale by prescription, over-the-counter or any other method, or for administration to human patients in clinical trials, for any and all uses, and in any and all formulations and combinations, which preparation contains a Construct.
		

		
			1.63    “Product Patent”. Any Patent Right Covering an invention invented pursuant to the activities conducted under this Agreement, the independent claims of which Patent Right are specifically drawn to a Construct combining (i) a New Capsid Variant and (ii) the Gene Therapy Construct of a given Product, and that does not claim priority to any New Variant Patent.
		

		
			1.64    “Prosecution and Maintenance”.  Prosecution and Maintenance means, with respect to a Patent Right, the preparation, filing, prosecution and maintenance of such Patent Right, as well as reexaminations, reissues and the like with respect to such Patent Right, together with the conduct of interferences, the defense of oppositions and other similar proceedings with respect to the particular Patent Right; and “Prosecute and Maintain” shall have the correlative meaning.
		

		
			1.65    “Regulatory Authority”.  Regulatory Authority means any applicable Governmental Authority involved in granting approvals for the manufacturing, marketing, reimbursement or pricing of a Royalty Bearing Product in the Territory or any portion thereof, including the FDA and EMA (as applicable), and any successor Governmental Authority having substantially the same function.
		

		
			
		

		
			

		 

		

			-  11  -

		

		

			 

		

		

		
			 
		

		
			1.66    “Research Plan for CNS”.  Research Plan for CNS means the research plan providing for one (1) or more Selection Processes intended to identify AAV Capsid Variants for delivery to the CNS, that is attached as Schedule 2.
		

		
			1.67    “Research Plan for Liver”.  Research Plan for Liver means the research plan providing for one (1) or more Selection Processes intended to identify AAV Capsid Variants for delivery to the liver, that is attached as Schedule 2.
		

		
			1.68    “Research Program”.  Research Program means, collectively, the program of research to be undertaken by 4DMT as described in the Research Plan for CNS and the Research Plan for Liver.
		

		
			1.69    “Research Term”.  Research Term means the period commencing on the New CLA Effective Date and ending on the date of expiration of the Liver Term or the CNS Term, whichever expires later.
		

		
			1.70    “Research Year”.  Research Year means a twelve (12) month period during the Research Term beginning on the Effective Date or on any anniversary thereof.
		

		
			1.71    “Restricted Target(s)”, Restricted Target(s) means, the [***] ([***]) Targets to be selected by uniQure from within the Field, each of such [***] ([***]) Targets is to be selected by uniQure within the [***] ([***]) day period commencing on the New CLA Effective Date, and each of which must relate to a disease or condition of the CNS or the liver.
		

		
			1.72    “Royalty Bearing Construct”.  Royalty Bearing Construct means a Construct containing a New Capsid Variant and a Gene Therapy Construct that Affects a Restricted Target or a Non-Restricted Target (but not any Target that is not a Restricted Target or a Non-Restricted Target).
		

		
			1.73    “Royalty Bearing Product”.  Royalty Bearing Product means a Product containing a Royalty Bearing Construct.
		

		
			1.74    “Royalty Term”.  Royalty Term means, with respect to a Royalty Bearing Product, on a Royalty Bearing Product-by-Royalty Bearing Product and a country-by-country basis, the period beginning on the First Commercial Sale of such Royalty Bearing Product in such country by a Party or any of its Affiliates or Sublicensees, and ending on latest of:  (a) the expiration of the last Valid Claim within the Licensed IP Covering such Royalty Bearing Product in such country, (b) the expiration of any applicable exclusivity, including orphan drug status or data exclusivity, and any extension thereto, granted by a Regulatory Authority in such country with respect to such Royalty Bearing Product, or (c) the tenth (10th) anniversary of the date of the First Commercial Sale by a Party or any of its Affiliates or Sublicensees of such Royalty Bearing Product in such country.
		

		
			1.75    “Selected Capsid Variant”.  Selected Capsid Variant means the AAV Capsid Variants listed in Schedule 3 to this Agreement.
		

		
			1.76    “Selection Process”.  Selection Process means the iterative evolution or isolation of lead AAV Capsid Variants from one or more AAV Capsid Variant Libraries in cells
		

		
			
		

		
			

		 

		

			-  12  -

		

		

			 

		

		

		
			(cultured or primary) in vitro or in animals in vivo intended to result in the identification of AAV Capsid Variants demonstrating properties suitable to a specified target tissue.  For clarity, a Selection Process can be one that is performed by 4DMT or its Affiliate either for itself or for, with or by any Third Party under rights granted by 4DMT to such Third Party, and need not be one that is conducted under the Research Program of this Agreement or designed for the same type of tissue in order to qualify under this definition. .
		

		
			1.77    “Step-In Rights”.  Step-In Rights means, on a AAV Capsid Variant-by-AAV Capsid Variant and Target-by-Target basis, the rights of uniQure or of 4DMT, respectively, to step-in and obtain non-exclusive license rights with respect to a New Capsid Variant for delivery of a Transgene that Affects a Non-Restricted Target (in the case of uniQure) or a Restricted Target (in the case of 4DMT), in each case pursuant to the provisions of Section 4.4.
		

		
			1.78    “Sublicensee”.  Sublicensee means, with respect to a Party, a Third Party to whom such Party (or its Affiliate or another of its Sublicensees) has granted a license or sublicense under the Licensed IP to Develop, make and have made, use or Commercialize a Royalty Bearing Product; provided,  however, that a Sublicensee shall not include any Third Party Distributor.
		

		
			1.79    “Target”. Target means the biological gene or genetic material of interest to affect a disease or condition of the CNS or liver.
		

		
			1.80    “Territory”.  Territory means all countries and territories in the world.
		

		
			1.81    “Third Party”.  Third Party means an entity other than uniQure, 4DMT and their respective Affiliates.
		

		
			1.82    “Third Party Distributor”.  Third Party Distributor means any Third Party that provides (but does not Develop) Royalty Bearing Products directly to customers under agreement with uniQure, its Affiliates or Sublicensees.
		

		
			1.83    “Transgene”. Transgene means (a) a given nucleic acid sequence that encodes an RNA sequence, and (b) any functionally equivalent sequence variants of such given nucleic acid sequence, [***].
		

		
			1.84    “UC AAV Capsid Variant”.  UC AAV Capsid Variant means any AAV Capsid Variant provided to 4DMT pursuant to the UCB Agreements.
		

		
			1.85    “UC Patent Right”.  UC Patent Right means any Patent Right licensed to 4DMT pursuant to the UCB Agreements.
		

		
			1.86    “UC Product”.  UC Product means a Royalty Bearing Product that is Covered by a UC Patent Right.
		

		
			1.87    “UCB Agreements”.  UCB Agreements means (a) the Exclusive License and Bailment Agreement between 4DMT and the Regents of the University of California (“UC”), Agreement Control No. 2014-03-0089, dated December 19, 2013; (b) the Exclusive License and Bailment Agreement between 4DMT and UC, Agreement Control No. 2014-03-0090, dated December 19, 2013; and (c) the Agreement for Use of Certain Biological Materials between
		

		
			
		

		
			

		 

		

			-  13  -

		

		

			 

		

		

		
			4DMT and UC, Agreement Control No. 2014-30-0088, dated December 19, 2013, in each case in the form provided to uniQure by 4DMT as of the Effective Date.
		

		
			1.88    “uniQure Intellectual Property”.  uniQure Intellectual Property means uniQure Know-How and uniQure Patent Rights.
		

		
			1.89     “uniQure Know-How”.  uniQure Know-How means Know-How that is (a) Controlled by uniQure or its Affiliates as of the Effective Date or during the Research Term, and (b) necessary or useful to conduct the Research Program or to research, Develop, make and have made, use or Commercialize the relevant New Capsid Variant, or a Royalty Bearing Compound or Royalty Bearing Product due to the presence of such New Capsid Variant therein.  uniQure Know-How includes Core uniQure Know-How but does not include Joint Know-How.
		

		
			1.90    “uniQure Patent Right”.  uniQure Patent Right means any Patent Right Controlled by uniQure or its Affiliates as of the Effective Date or during the Term that Covers uniQure Know-How.  uniQure Patent Rights include Core uniQure Patent Rights but do not include Joint Patent Rights.
		

		
			1.91    “uniQure Product”.  uniQure Product means a Royalty Bearing Product that (a) delivers a Transgene that  Affects a Restricted Target (or variant of a Restricted Target), or (b) that delivers a Transgene that  Affects a Non-Restricted Target (or variant of a Non-Restricted Target), and in the case of (b) uniQure has obtained non-exclusive rights to Develop and Commercialize such Royalty-Bearing Product pursuant to the exercise of its Step-In Rights in Section 4.4. Notwithstanding anything express or implied, no uniQure Product shall deliver any Transgene that relates to any Non-Restricted Target for which uniQure has not obtained rights to deliver as part of a Royalty-Bearing Product pursuant to the exercise of its Step-In Rights under Section 4.4.
		

		
			1.92    “uniQure Product Patent”. uniQure Product Patent means any Product Patent upon which uniQure’s or its Affiliates’ personnel are properly named inventors (as determined under U.S. patent law) and 4DMT and its Affiliates’ are not.
		

		
			1.93    “Valid Claim”.  Valid Claim means (a) a claim of an issued patent that has not expired or been abandoned, or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period), or (b) a claim within a patent application which application has not been pending for more than [***] ([***]) years from the date of its priority filing date and which claim has not been irretrievably revoked, irretrievably cancelled, irretrievably withdrawn, held invalid or abandoned by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period), or finally determined to be unallowable in a decision from which an appeal cannot or can no longer be taken; provided,  however, that with respect to the UC Patent Rights licensed under the Exclusive License and Bailment Agreement between 4DMT and UC, Agreement Control No. 2014-03-0089, the foregoing [***] ([***]) year limitation shall be extended to [***] ([***]) years.
		

		
			
		

		
			

		 

		

			-  14  -

		

		

			 

		

		

		
			“Vector Characterization Data” means any and all data, results and other Know-How that is generated either by or on behalf of a Party or its Affiliate, whether alone or together with, by or for any of its Third Party licensees, contractors or collaborators, with respect to any New Capsid Variant, in regards to any of the following with respect to such New Capsid Variant:[***]
		

		
			1.94    Additional Definitions. Each of the following definitions is set forth in the section of this Agreement indicated below:
		

			
					
						 

					
					
						 

				
	
					
						Definition:

					
					
						Section:

				
	
					
						 

					
					
						 

				
	
					
						4DMT

					
					
						Preamble

				
	
					
						4DMT Indemnitees

					
					
						9.5

				
	
					
						Additional Cure Period

					
					
						10.2(a)

				
	
					
						Agreement

					
					
						Preamble

				
	
					
						Audited Party

					
					
						6.5

				
	
					
						Auditing Party

					
					
						6.5

				
	
					
						Bankruptcy Code

					
					
						5.4

				
	
					
						CREATE Act

					
					
						7.10

				
	
					
						Damages

					
					
						9.5

				
	
					
						Defaulting Party

					
					
						10.2(a)

				
	
					
						Dispute

					
					
						11.1

				
	
					
						Effective Date

					
					
						Preamble

				
	
					
						Excluded Claim

					
					
						11.2

				
	
					
						Executives

					
					
						2.3(b)

				
	
					
						Fair Market Value

					
					
						6.3(b)(iii)

				
	
					
						GAAP

					
					
						1.11

				
	
					
						IFRS

					
					
						1.11

				
	
					
						Initiating Party

					
					
						7.6(d)

				
	
					
						Joint Counsel

					
					
						7.5

				
	
					
						Joint Intellectual Property

					
					
						7.2(a)

				
	
					
						Joint Know-How

					
					
						7.2(a)

				
	
					
						Joint Patent Rights

					
					
						7.2(a)

				
	
					
						JRSC

					
					
						2.1(a)

				
	
					
						M&A Event

					
					
						12.7

				
	
					
						MAA

					
					
						1.53

				
	
					
						Non-Defaulting Party

					
					
						10.2(a)

				
	
					
						Orange Book

					
					
						7.9(a)

				
	
					
						Paragraph IV Certification

					
					
						7.9(b)

				
	
					
						Paragraph IV Proceeding

					
					
						7.9(b)(ii)

				
	
					
						Records

					
					
						3.5(a)(i)

				
	
					
						SEC Filing

					
					
						8.5(c)

				
	
					
						Sublicense Consideration

					
					
						6.3(b)

				
	
					
						Sublicense Income Sharing Percentages

					
					
						6.3(a)

				
	
					
						Term

					
					
						10.1

				
	
					
						Third Party Claim

					
					
						9.5

				
	
					
						Trade Secret Election

					
					
						7.3(b)

				

		 

		

			-  15  -

		

		

			 

		

	

      

         

      

    	

      

         

      

    
	

      

        Definition:

      

    	

      

        Section:

      

    
	
					
						

					
						 

					
					
						 

				
	
					
						USPTO

					
					
						7.10

				
	
					
						UC

					
					
						1.87

				
	
					
						uniQure

					
					
						Preamble

				
	
					
						uniQure Indemnitees

					
					
						9.6

				

		
			 
		

		
			ARTICLE II
		

		
			 
		

		
			GOVERNANCE
		

		
			2.1      Joint Research Steering Committee.
		

		
			(a)        Composition.  Promptly after the Effective Date, the Parties shall establish a joint research steering committee (the “JRSC”).  The JRSC shall be comprised of at least [***] ([***]) named representatives of uniQure and at least [***] ([***]) named representatives of 4DMT, one of whom shall be David Schaffer (unless due to his death, illness or disability), or such other numbers as the Parties may agree in writing.  As soon as practicable after the Effective Date (but in no event more than [***] ([***]) Business Days after the Effective Date), each Party shall designate by written notice to the other Party its initial representatives on the JRSC.  Each Party may replace one or more of its non-mandatory representatives, in its sole discretion, effective upon written notice to the other Party of such change.  These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Research Program.  The JRSC shall be disbanded upon expiration of the Research Term.
		

		
			(b)        Function and Powers of the JRSC.  During the Research Term, the JRSC’s responsibilities shall include: (i) providing a forum for discussion of the Research Plan for Liver and the Research Plan for CNS, the status of the Research Program, and relevant data (but not making any decisions with respect thereto, other than as provided in clause (iii) of this sentence or as provided in Section 2.6); (ii) serving as a forum for informal resolution of disagreements that may arise in the relation to the Parties’ activities under the Research Program (but not deciding any such disagreement); and (iii) amending the Research Plan for Liver and/or the Research Plan for CNS, solely in the circumstances described in and under the terms and conditions of Section 2.6.
		

		
			2.2      Meetings.  The JRSC shall each hold at least [***] per Calendar Quarter during the Research Term.  Upon necessity, either Party shall be entitled to request additional meetings of the JRSC.  Meetings of the JRSC shall be effective only if at least [***] ([***]) representatives of each Party are present or participating.  The location of meetings shall be as agreed by the Parties, and may be held in person, alternating locations between the Parties, or by telephone conference call or by videoconference; provided,  however, that at least [***] ([***]) meetings of the JRSC each Calendar Year are held in person.  4DMT’s costs and expenses incurred in connection with preparing for and participating in all such meetings shall be paid for by uniQure in accordance with the budget for the Research Plan for Liver or Research Plan for CNS, as applicable.  Either Party may, from time to time, invite additional representatives or consultants to attend JRSC meetings; provided that at least [***] ([***]) Business Days’ prior
		

		
			
		

		
			

		 

		

			-  16  -

		

		

			 

		

		

		
			written notice is given of a Party’s intention to invite such other representatives or consultants and providing full details about the name, employer and professional background of such other representatives or consultants.  Each representative and consultant participating in or attending a JRSC meeting shall be bound by a written agreement with confidentiality obligations substantially the same as those set forth in ARTICLE VIII.  The JRSC shall be co-chaired by a representative from each Party.  The chairpersons shall set the agendas for the JRSC meeting in advance.  Within ten (10) Business Days prior to each scheduled meeting, each Party shall, in accordance with Section 3.5(b), provide a report to the JRSC detailing its progress with respect to the Research Program.  The Parties will rotate the responsibility for recording, preparing and issuing minutes for each JRSC meeting, to be circulated within [***] ([***]) Business Days after each meeting.
		

		
			2.3      Decision-making.
		

		
			(a)        Initial Dispute Resolution Procedures.  Subject to the provisions of this Section 2.3, actions to be taken by the JRSC shall be taken only following a unanimous vote, with each Party, through its representatives, having one (1) vote.  Notwithstanding the foregoing, and subject to Section 2.6, in the circumstances described in such Section, [***] shall have the final say and final decision-making authority on any and all disputes pertaining to any amendments to the Research Plan for CNS or amendments to the Research Plan for Liver, and any such final decision by [***] on such matters shall not be subject to further review by referral to Executives or otherwise under this Section 2.3 or under any of the dispute resolution provisions of this Agreement.
		

		
			(b)        Referral of Unresolved Matters to Executives.  If, in accordance with Section 2.3(a), the JRSC does not resolve any matter considered by it within [***] ([***]) Business Days after the matter is first considered by it, the matter may be referred by either Party to the CEO of 4DMT and CEO of uniQure (the “Executives”) to be resolved by negotiation in good faith as soon as practicable, but in no event later than [***] ([***]) Business Days after referral.  Such resolution, if any, of a referred issue by the Executives shall be final and binding on the Parties.  Any decision made by the Executives under this Section 2.3(b) shall be deemed a decision of the JRSC for purposes of this Agreement.
		

		
			(c)        Final Decision-Making.  If a dispute referred to the Executives pursuant to Section 2.3(b) has not been resolved in accordance with Section 2.3(b), then, subject to Section 2.3(d), [***] shall have the final decision-making authority.  Any decision made by [***] pursuant to this Section 2.3(c) shall be deemed a decision of the JRSC for purposes of this Agreement.
		

		
			(d)        Exceptions.  Notwithstanding Section 2.3(c), [***] shall not have the right to exercise such decision-making authority (i) in a manner that excuses [***] from any of its obligations specifically enumerated under this Agreement; (ii) in a manner that negates any consent rights or other rights specifically allocated to [***] under this Agreement; (iii) in a manner that would require [***] to perform activities (A) for which [***] (except as expressly set forth in this Agreement), (B) that [***], or (C) that [***]; (iv) in a manner that would take away [***]’s right to perform activities that [***] has previously agreed to perform as set forth in the Research Plan; (v) in a manner that would require [***] to perform any act that it reasonably believes to be
		

		
			
		

		
			

		 

		

			-  17  -

		

		

			 

		

		

		
			inconsistent with any Law or any approval, order, policy, guidelines of a Regulatory Authority or ethical requirements or ethical guidelines; (vi) to determine that [***] has fulfilled any obligation under this Agreement or that [***] has breached any obligation under this Agreement; or (vii) to amend the relevant Delivery Success Criteria.
		

		
			(e)        This Section 2.3 (and each of its subsections) shall not be used to imply any greater decision-making authority on the part of the JRSC than is set forth in Section 2.1(b) (i.e., the JRSC’s sole decision-making authority is to decide upon amendments to the Research Plan for CNS and the Research Plan For Liver, subject always and solely in the circumstance and manner stated in Section 2.6).
		

		
			2.4      Limitations on JRSC Authority.  The JRSC shall have only the powers assigned expressly to it in this ARTICLE II and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement.  In furtherance thereof, each Party shall retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the JRSC unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing.
		

		
			2.5      Sharing of Vector Characterization and Other Data at the JRSC.   Each Party shall share with and disclose to the other Party the Vector Characterization Data obtained by such Party with respect to New Capsid Variants, pursuant to the requirements of Section 4.3.  Each Party shall do so during the Research Term and thereafter, and whether such Vector Characterization Data is generated within or outside of the Research Program.  During the Research Term, 4DMT will keep the JRSC informed of: (a) any and all reasonably relevant data and information generated under the Research Program (including Vector Characterization Data; and (b) all New CNS Variants and New Liver Variants that have been identified by 4DMT,  [***], in connection with the next JRSC meeting after their identification.
		

		
			2.6      Amendments to Research Plans.  Notwithstanding anything express or implied in this Agreement, the JRSC shall only have the power to amend the Research Plan for CNS and the Research Plan for Liver in the following circumstances: (a) the then-current version of the applicable research plan (i.e., the Research Plan for CNS or the Research Plan for Liver) cannot be carried out as written; or (b) the JRSC achieves unanimous consensus (with no exercise of any final say) that a change needs to be made and as to the change.
		

		
			ARTICLE III
		

		
			 
		

		
			RESEARCH PROGRAM
		

		
			3.1      Objectives of the Research Program.  The Research Program under this Agreement shall be defined, collectively, by the activities as described in the Research Plan for CNS and the Research Plan for Liver, each as appended to this Agreement as of the Effective Date (or as they may be amended in accordance with this Agreement).  The objective of the Research Plan for CNS is for 4DMT to identify [***] ([***]) New CNS Variants that meet the applicable Delivery Success Criteria for entry into validation studies, the Vector Characterization Data from which validation studies will be the package of data that 4DMT is required to provide
		

		
			
		

		
			

		 

		

			-  18  -

		

		

			 

		

		

		
			to uniQure in order to satisfy its obligation to present [***] ([***]) New CNS Variants with the required Vector Characterization Data.  The objective for the Research Plan for Liver is to identify the New Liver Variants that meet the applicable Delivery Success Criteria, the Vector Characterization Data from which validation studies will be the package of data that 4DMT is required to provide to uniQure in order to satisfy its obligation to present [***] ([***]) New Liver Variants with the required Vector Characterization Data.  As and to the extent provided for in the Research Plan, 4DMT would provide quantities of such New Capsid Variants to uniQure for testing.  If the CNS Selection Processes or the liver Selection Processes of the Research Program do not yield at least [***] ([***]) New Capsid Variants meeting the applicable Delivery Success Criteria for entry into validation studies to generate the required Vector Characterization Data packages, then (a) if requested by 4DMT, uniQure may (but is not required to) [***]; and/or (b) [***].
		

		
			3.2      Conduct of the Research Program.
		

		
			(a)        4DMT shall initiate work on the Research Plan for Liver and the Research Plan for CNS within [***] ([***]) weeks after the New CLA Effective Date.  Any amendments to the Research Plan for CNS or the Research Plan for Liver will be only as agreed by the JRSC.
		

		
			(b)        4DMT shall use Commercially Reasonable Efforts to conduct the Research Program in accordance with the Research Plan for CNS and the Research Plan for Liver.  4DMT shall have an affirmative obligation during the term the Research Program and thereafter during the term of this Agreement to disclose all data and other information related to the Research Plan on a timely basis, including, without limitation, all Vector Characterization Data created pursuant to the Research Program, the Research Plan for Liver, and the Research Plan for CNS, as well as the existence and status of all New Capsid Variants generated outside the Research Program during the applicable CNS Term or Liver Term (as applicable based on whether the variant at issue is a New CNS Variant or a New Liver Variant), and all Vector Characterization Data associated with such New Capsid Variants.  For clarity, New CNS Variants only arise during the CNS Term, and New Liver Variants only arise during the Liver Term, even though they, or the Vector Characterization Data with respect thereto, may be later reported between the Parties.
		

		
			(c)        Either Party shall have the right to utilize the services of any Third Party to perform its obligations under the Research Plan to the extent that such Third Party is specifically approved in the Research Plan or otherwise approved by the JRSC, provided that any permitted Third Party must have entered into a written agreement with such Party that includes terms and conditions (i) protecting and limiting use and disclosure of Confidential Information at least to the same extent as under ARTICLE VIII, and (ii) requiring the Third Party and its personnel to assign to such Party all right, title and interest in and to any intellectual property (and intellectual property rights) created or conceived in connection with performance of subcontracted activities.  Each Party shall remain at all times fully liable for its responsibilities under this Agreement.
		

		
			(d)        4DMT and uniQure shall conduct the Research Program in accordance with all applicable Laws, including, if and as applicable, Good Laboratory Practices.  Each Party hereby certifies that it will not employ or otherwise use in any capacity in performing any activity hereunder the services of any person or entity known to it to be debarred under 21 USC
		

		
			
		

		
			

		 

		

			-  19  -

		

		

			 

		

		

		
			§335a.  For clarity, each of the New CNS Variants and each of the New Liver Variants to be entered into validation studies under the Research Program shall meet the applicable Delivery Success Criteria as defined in the Research Plans unless the Parties in their discretions agree otherwise in writing.
		

		
			3.3      Materials and Know-How Transfer/Use of Constructs.
		

		
			(a)        In order to facilitate the Research Program, each Party shall, to the extent set forth in the Research Plan, provide to the other Party certain Materials and, subject to Section 3.4, Know-How Controlled by the supplying Party for use by the other Party in furtherance of the Research Program.  All Materials and Know-How provided by one Party to the other Party remain the sole property of the supplying Party.
		

		
			(b)        All Materials transferred pursuant to the Research Program shall be used (i) only for the specific purpose provided for in the Research Plan, and (ii) solely under the control of the receiving Party.  The Materials may not be used or delivered to or for the benefit of any Third Party without the prior written consent of the supplying Party, and shall not be used in research or testing involving human subjects, except as expressly contemplated in the Research Plan or in accordance with this Agreement.  All Materials shall be returned to the supplying Party or destroyed (at the election of the supplying Party) promptly after completion of the use permitted under this Agreement.
		

		
			(c)        THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHT OF ANY THIRD PARTY.
		

		
			(d)        At the end of the Research Term, to the extent that samples have not already been provided to uniQure under the Research Program, 4DMT shall promptly provide to uniQure samples of New Capsid Variants that are at that time in 4DMT’s possession.  For clarity, this means the quantities specified in the Research Plan, not all quantities of New Capsid Variants at that time in 4DMT’s possession.  Other than as may be provided in the Research Plan, 4DMT shall not be required to transfer any Royalty Bearing Constructs to uniQure, unless the Parties mutually otherwise agree in writing in their discretions at a later date.
		

		
			3.4      Third Party Intellectual Property.  The conduct of activities under the Research Plan may use Patent Rights or Know-How licensed by 4DMT pursuant to the UCB Agreements, subject to the terms and conditions of the UCB Agreements.  4DMT shall be solely responsible for all obligations under the UCB Agreements, including any and all payments and royalties due thereunder.  In developing the Research Plan, the Parties shall discuss whether any Third Party Patent Rights or Know-How, other than Patent Rights or Know-How licensed by 4DMT pursuant to the UCB Agreements, will be utilized in the conduct of activities under the Research Plan.  4DMT shall disclose to uniQure the details of any restrictions on use or payment obligations of which it is aware that would be triggered by such use of Third Party Patent Rights or Know-How in the Research Program.  If the Parties mutually agree to use any inventions
		

		
			
		

		
			

		 

		

			-  20  -

		

		

			 

		

		

		
			claimed in any Patent Right or use any Know-How that is licensed to or has been acquired by 4DMT other than pursuant to the UCB Agreements, and if such use would require the payment of additional consideration to the Third Party from which the Patent Rights or Know-How was licensed or acquired, then such Patent Right or Know-How shall be deemed under the Control of 4DMT, provided that uniQure expressly agrees in writing to bear any such additional consideration actually to be paid by 4DMT to the Third Party (which amounts uniQure may offset pursuant to Section 6.2(c)(ii)) with respect to the Development, manufacture or Commercialization of Royalty Bearing Constructs or Royalty Bearing Products.  For clarity, nothing in this Section 3.4 shall limit uniQure’s rights to obtain from a Third Party, independent of 4DMT, a license or other right with respect to such Third Party’s Patent Rights or Know-How.
		

		
			3.5      Records and Reports.
		

		
			(a)        Records.
		

		
			(i)         4DMT shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the performance of the Research Program by or on behalf of 4DMT (the “Records”), including the procedures, techniques and methodologies used, the progress made, and any Invention conceived or reduced to practice or otherwise made within the scope of or in connection with the Research Program.  As part of keeping the Records, 4DMT shall ensure that all of its personnel, and all of its agents that are involved in the Research Program, will keep accurate laboratory notebooks, which laboratory notebooks: (A) shall be duly signed, dated and witnessed; and (B) shall be created and maintained in accordance with its standard operating procedures that would be sufficient to allow for said laboratory notebooks to be used in any proceeding before the United States Patent and Trademark Office or United States courts, in order to establish the date of invention for any Invention in accordance with the United States patent laws.  During the Term, 4DMT shall, upon written request by uniQure, which shall not be unreasonably made:  (1) make all Records available for inspection and review by uniQure during normal business hours in a timely manner; and (2) provide copies of the Records or any part thereof to uniQure, as reasonably requested by uniQure.
		

		
			(ii)       In connection with uniQure’s exercise of its back-up right for patent filing as relates to the New Variant Patents (if applicable), uniQure shall have the right to request that a copy of the relevant portions of the laboratory notebooks relating to all stages of the generation of the applicable New Capsid Variants be provided by 4DMT to uniQure. After such request by uniQure, 4DMT shall provide such copies of the laboratory notebooks promptly to uniQure, which shall be maintained by uniQure as 4DMT’s Confidential Information.
		

		
			(b)        Reports to the JRSC.  Between [***] ([***]) and [***] ([***]) Business Days prior to each scheduled JRSC meeting, the Parties shall provide to the JRSC a written report on the progress of the Research Program, summarizing the work performed under the Research Program and evaluating the work performed in relation to the goals of the Research Program.  Each Party shall provide such other information required by the Research Program or reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of the Research Program.
		

		
			
		

		
			

		 

		

			-  21  -

		

		

			 

		

		

		
			ARTICLE IV
		

		
			 
		

		
			DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS; DILIGENCE
		

		
			4.1      Responsibility.
		

		
			(a)        uniQure shall have the full right, but not the obligation, at its sole expense, for the worldwide research, Development, manufacturing and Commercialization of uniQure Products pursuant to the exercise by uniQure of its rights under this Agreement (including its ownership rights and/or its exercise of any of the licenses granted to uniQure under Section 5.1(b)) in accordance with the terms and conditions and limitations of such license rights, and, subject to the payment obligations under Article VI and all other relevant terms and conditions of this Agreement.  For clarity, this does not apply to those 4D Products, if any, addressing Restricted Targets pursuant to 4DMT’s non-exclusive rights after an exercise of 4DMT’s Step-In Rights that results in 4DMT obtaining non-exclusive rights to such 4DMT Products addressing Restricted Targets.  Moreover, it does not apply to any 4DMT Products directed to a Non-Restricted Target, even after an exercise by uniQure of its Step-In Rights related to a uniQure Product to such Non-Restricted Target.
		

		
			(b)        4DMT shall have the full right, but not the obligation, at its sole expense, for the worldwide research, Development, manufacturing and Commercialization of 4DMT Products pursuant to the exercise by 4DMT of its rights under this Agreement (including its ownership rights and/or its exercise of any of the licenses granted to 4DMT under Section 5.2(c)) in accordance with the terms and conditions and limitations of such license rights, and subject to the payment obligations under Article VI and all other relevant terms and conditions of this Agreement.  For clarity, this does not apply to those uniQure Products, if any, addressing Non-Restricted Targets pursuant to uniQure’s non-exclusive rights after an exercise of uniQure’s Step-In Rights that results in uniQure obtaining non-exclusive rights to such uniQure Products addressing Non-Restricted Targets.
		

		
			4.2      Diligence.  No Party will have any diligence obligations with respect to either 4DMT Products or uniQure Products, except as provided in Section 4.4 with respect to Proposed Products, and the circumstance in which either a not-stepping-in Party chooses to pursue a Proposed Product in lieu of allowing the other Party to obtain rights thereto pursuant to such other Party’s Step-In Rights, or in the circumstance in which the stepping-in Party obtains non-exclusive rights to such Proposed Product.
		

		
			4.3      Obligation to Share Vector Characterization Data for AAV Capsid Variants.
		

		
			(a)        Commencing on the New CLA Effective Date and continuing throughout the Term, uniQure shall provide, within [***] ([***]) days after each January 31st and July 31st of each Calendar Year, a written report to 4DMT that summarizes the Vector Characterization Data generated by or on behalf of uniQure or its Affiliate or Sublicensee with respect to each New Capsid Variant for which any research, Development, Commercialization or other vector characterization activities were conducted by or on behalf of uniQure or its Affiliate or Sublicensee during the [***].
		

		
			
		

		
			

		 

		

			-  22  -

		

		

			 

		

		

		
			(b)        Commencing on the New CLA Effective Date and continuing throughout the Term, 4DMT shall provide, within [***] ([***]) days after each January 31st and July 31st of each Calendar Year, a written report to uniQure that summarizes the Vector Characterization Data generated by or on behalf of uniQure or its Affiliate or Sublicensee with respect to each AAV Capsid Variant or New Capsid Variant for which any research, Development, Commercialization or other vector characterization activities were conducted by or on behalf of 4DMT or its Affiliate or Sublicensee during the [***].
		

		
			(c)        Either Party may terminate its obligation to provide written reports pursuant to this Section 4.3 after the Research Term, if it ceases all research, development, commercialization or other activities that would result in the generation of any further unreported Vector Characterization Data with respect to New Capsid Variants, and the Party provides written notice to the other Party so stating and also certifying that all Vector Characterization Data that is required to be reported with respect to New Capsid Variants has been so reported.
		

		
			4.4      Step-In Rights of each Party for Proposed Products.
		

		
			(a)        Step-In Rights of 4DMT.
		

		
			(i)         At any time after the expiration of the CNS Term (for products based on New CNS Variants) or the Liver Term (for products based on New Liver Variants), 4DMT may make a bona fide proposal to uniQure for Developing and Commercializing a Product using a New Capsid Variant in the Field to deliver a Transgene that Affects any Restricted Target (each, a “4DMT Proposed Product”), including a development plan and a plan to finance such activities.  Within [***] ([***]) days after receipt of a notice from 4DMT of a 4DMT Proposed Product, uniQure shall notify 4DMT whether uniQure is conducting or is interested in conducting research or Development of such 4DMT Proposed Product, or a Product that uniQure believes in good faith is or would be competitive with such 4DMT Proposed Product (a “Competitive Product”).  4DMT shall have the right to select a maximum total of [***] ([***]) Proposed Products as 4DMT Proposed Products per calendar year under this Section 4.4 and under Section 4.4 of the Amended and Restated CLA, such total to be determined in the aggregate under this Agreement and the Amended and Restated CLA, taken collectively.
		

		
			(ii)       If uniQure notifies 4DMT in good faith that uniQure is conducting or is interested in conducting research or Development of such 4DMT Proposed Product or Competitive Product, uniQure shall within [***] ([***]) months after such notice, deliver to 4DMT a plan (including projected timelines) for the research and Development thereof and, thereafter, shall use Commercially Reasonable Efforts to research, Develop, manufacture and Commercialize such 4DMT Proposed Product or Competitive Product in accordance with such plan.  Each progress report provided to 4DMT under Section 4.3 from and after the date of uniQure’s notice under this Section shall contain a summary of the activities undertaken and the status of uniQure’s research and Development efforts with respect to such Third Party Proposed Product, 4DMT Proposed Product, uniQure Proposed Product or Competitive Product during the [***].
		

		
			(iii)      If uniQure notifies 4DMT that uniQure is not conducting and is not interested in conducting research or Development of such 4DMT Proposed Product, or
		

		
			
		

		
			

		 

		

			-  23  -

		

		

			 

		

		

		
			Competitive Product, then the date of uniQure’s such written notice (or the deadline therefor, if uniQure is required to provide such notice and fails to provide notice by such date whether clause (ii) above or this clause (iii) would otherwise), then this shall be the “Effective Time” for such 4DMT Proposed Product and the applicable Restricted Target, and the license to 4DMT in Section 5.2(c) shall become effective as of the Effective Time.
		

		
			(b)        Step-In Rights of uniQure.
		

		
			(i)         At any time after the expiration of the CNS Term (for products based on New CNS Variants) or the Liver Term (for products based on New Liver Variants), uniQure may make a bona fide proposal to 4DMT for Developing and Commercializing a Product using a New Capsid Variant in the Field to deliver a Transgene that Affect any Non-Restricted Target (each, a “uniQure Proposed Product”), including a development plan and a plan to finance such activities.  Within [***] ([***]) days after receipt of a notice from uniQure of a uniQure Proposed Product, 4DMT shall notify uniQure whether 4DMT is conducting or is interested in conducting research or Development of such uniQure Proposed Product, or a Product that 4DMT believes in good faith is or would be competitive with such uniQure Proposed Product (a “4D Competitive Product”).  uniQure shall have the right to select a maximum total of [***] ([***]) Proposed Products as uniQure Proposed Products per year under this Section 4.4.
		

		
			(ii)       If 4DMT notifies uniQure in good faith that 4DMT is conducting or is interested in conducting research or Development of such uniQure Proposed Product or Competitive Product, 4DMT shall within [***] ([***]) months after such notice, deliver to uniQure a plan (including projected timelines) for the research and Development thereof and, thereafter, shall use Commercially Reasonable Efforts to research, Develop, manufacture and Commercialize such uniQure Proposed Product or Competitive Product in accordance with such plan.  Each progress report provided to uniQure under Section 4.3 from and after the date of 4DMT’s notice under this Section shall contain a summary of the activities undertaken and the status of 4DMT’s research and Development efforts with respect to such Third Party Proposed Product, uniQure Proposed Product, 4DMT Proposed Product or Competitive Product during the [***].
		

		
			(iii)      If 4DMT notifies uniQure that 4DMT is not conducting and is not interested in conducting research or Development of such uniQure Proposed Product, or Competitive Product, then the date of 4DMT’s such written notice (or the deadline therefor, if 4DMT is required to provide such notice and fails to provide notice by such date whether clause (ii) above or this clause (iii) would otherwise apply), then this shall be the “UQ Effective Time” for such uniQure Proposed Product and the applicable Non-Restricted Target, and the license to uniQure in Section 5.1(b)(ii) shall become effective as of the UQ Effective Time.
		

		
			(c)        General Rights of 4DMT Related to Non-Restricted Targets.  For clarity, 4DMT owns the New Variant Patents and has the right to pursue 4DMT Products delivering Transgenes that Affect Non-Restricted Targets, without the need to obtain any rights under this Section 4.4 (i.e., as a default matter 4DMT has the right to pursue 4DMT Products delivering Transgenes that Affect Non-Restricted Targets, with no need to “step in” to obtain such rights, and for that reason, 4DMT’s Step-In Rights under this Section 4.4 do not apply to 4DMT Products delivering Transgenes that Affect Non-Restricted Targets).
		

		
			
		

		
			

		 

		

			-  24  -

		

		

			 

		

		

		
			4.5      Pharmacovigilance.  Within [***] ([***]) months after the Effective Date, the Parties shall enter into an agreement governing the exchange of adverse event safety data (including post-marketing spontaneous reports) received by a Party and its Affiliates, including such data received from, in the case of uniQure, its Sublicensees or, in the case of 4DMT, its licensees, relating to any AAV Capsid Variant provided to uniQure by 4DMT hereunder in order to monitor the safety of all Constructs and Products and to meet reporting requirements with any applicable Regulatory Authority.  Such data sharing agreement shall not require the sharing of data that would disclose confidential know-how or trade secrets of a Party or its Affiliates, or in the case of uniQure, its Sublicensees or, in the case of 4DMT, its licensees, if such data may be cross-referenced, such as through a Drug Master File, to satisfy the requirements of Law and any applicable Regulatory Authority.
		

		
			4.6      Marking.  Prior to the issuance in the United States of Patent Rights included in the UC Patent Rights, uniQure agrees to mark Royalty Bearing Product(s) Covered by any UC Patent Right (or their containers or labels) sold in the United States under the licenses granted in this Agreement with the words “Patent Pending,” and following the issuance in the United States of one or more Patent Rights included in the UC Patent Rights, with the patent numbers of the UC Patent Right(s) Covering such Royalty Bearing Product.  All Royalty Bearing Products Covered by any UC Patent Right sold in other countries will be marked in such manner as to conform with the patent Laws and practice of such countries.
		

		
			ARTICLE V
		

		
			 
		

		
			GRANTS OF RIGHTS
		

		
			5.1      Licenses to uniQure.
		

		
			(a)        Research License to uniQure.  Subject to the terms and conditions of this Agreement, 4DMT hereby grants to uniQure, and uniQure hereby accepts, during the Research Term, an exclusive (but not as to 4DMT), worldwide, royalty-free, non-sublicenseable license under the 4DMT Intellectual Property and 4DMT’s interest in the Joint Intellectual Property, solely to (i) conduct activities assigned to uniQure under the Research Plan for Liver or the Research Plan for CNS, (ii) evaluate Constructs, or (iii) evaluate the data developed in the conduct of activities under the Research Program or during the Research Term.  This license is intended to include the right for uniQure to make sequence modifications to New Capsid Variants solely for the purpose of (1) adapting New Capsid Variants to insect cells or insect cell expression vectors and systems, and/or (2) modifying any “Selected Capsid Variants” as defined in the Amended and Restated CLA with or to include any motif, mutation, or substitution identified under this New CLA; provided that (x) uniQure shall promptly disclose to 4DMT all AAV Capsid Variants resulting from such activities, (y) such resulting AAV Capsid Variants shall be deemed New Capsid Variants for all purposes under this Agreement, and (z) the Patent Rights that may be filed with respect to such resulting deemed New Capsid Variants shall be deemed New Variant Patents for all purposes under this Agreement, and the Know-How with respect thereto shall be deemed the subject matter of New Variant Patents (whether or not Patent Rights are ever filed with respect to such Know-How) and therefore Core 4DMT Know-How, for all purposes under this Agreement.  For clarity, the obligations of uniQure under the foregoing clauses (x), (y) and (z) with respect to any uniQure-modified New Capsid Variants or any uniQure-modified Selected
		

		
			
		

		
			

		 

		

			-  25  -

		

		

			 

		

		

		
			Capsid Variants as described in the foregoing sentence shall not apply to any AAV Capsid Variant (or any modification or improvement thereof) that is identified or generated by uniQure or any of its Affiliates or Sublicensees independently and outside of the Research Program, without the use of any information disclosed to uniQure pursuant to this Agreement or the Amended and Restated CLA as to the sequence of any New Capsid Variant or Selected Capsid Variant.
		

		
			(b)        Development and Commercialization Licenses to uniQure.
		

		
			Exclusive License for use of New Capsid Variants in connection with the Restricted Targets.  Subject to the terms and conditions of this Agreement, and on a New Capsid Variant-by-New Capsid Variant basis, 4DMT hereby grants to uniQure, and uniQure hereby accepts, an exclusive (even as to 4DMT, except solely to the extent that 4DMT obtains non-exclusive rights within the scope of this license pursuant to an exercise of 4DMT’s Step-In Rights), worldwide, royalty-bearing license, including the right to grant sublicenses in accordance with Section 5.3, under the 4DMT Intellectual Property (including all Vector Characterization Data reported by 4DMT to uniQure under this Agreement) and 4DMT’s interest in the Joint Intellectual Property, to research (subject to 4DMT’s retained rights to conduct research under the Research Program and to research Constructs related to Restricted Targets for potential exercise of 4DMT’s Step-In Rights in relation thereto), Develop, make and have made, use, import, sell and Commercialize the New Capsid Variants, and any modifications or improvements thereto, as and into Royalty Bearing Constructs and Royalty Bearing Products in the Field.  For clarity, the license granted to uniQure under this paragraph shall expressly include the right to create improvements or modifications to the sequence or composition of matter of any New Capsid Variant, provided that such improved or modified sequence or composition of matter is used solely in connection with  the applicable Restricted Target in the Field, and (x) uniQure shall promptly disclose to 4DMT all resulting AAV Capsid Variants made, (y) such resulting AAV Capsid Variants shall be deemed New Capsid Variants for all purposes under this Agreement, and (z) the Patent Rights that may be filed with respect to such resulting deemed New Capsid Variants shall be deemed New Variant Patents for all purposes under this Agreement, and the Know-How with respect thereto shall be deemed the subject matter of New Variant Patents (whether or not Patent Rights are ever filed with respect to such Know-How) and therefore Core 4DMT Know-How, for all purposes under this Agreement.  For clarity, the obligations of uniQure under the foregoing clauses (x), (y) and (z) with respect to any uniQure-modified New Capsid Variants described in the foregoing sentence shall not apply to any AAV Capsid Variant (or any modification or improvement thereof) that is identified or generated by uniQure or any of its Affiliates or Sublicensees independently and outside of the Research Program, without the use of any information disclosed to uniQure pursuant to this Agreement or the Amended and Restated CLA as to the sequence of any New Capsid Variant or Selected Capsid Variant.
		

		
			(c)        Non-Exclusive License for Proposed Products elected by uniQure pursuant to its Step-In Rights under Section 4.4.
		

		
			(i)         Subject to the terms and conditions of this Agreement (including 4DMT’s retained rights related to Products delivering Transgenes related to the applicable Non-Restricted Target), and on a New Capsid Variant by New Capsid Variant basis, effective upon the UQ Effective Time for the applicable Non-Restricted Target and New Capsid Variant under Section 4.4(b), 4DMT hereby grants to uniQure, and uniQure hereby accepts, a non-
		

		
			
		

		
			

		 

		

			-  26  -

		

		

			 

		

		

		
			exclusive, worldwide, royalty-bearing license, including the right to grant sublicenses in accordance with Section 5.3, under the 4DMT Intellectual Property (including all Vector Characterization Data reported by 4DMT to uniQure under this Agreement) and 4DMT’s interest in the Joint Intellectual Property, to research, Develop, make and have made, use and Commercialize the uniQure Proposed Product to the applicable Non-Restricted Target as Royalty Bearing Constructs and Royalty Bearing Products within the Field.  Such license may become effective one (1) or more times, in connection with one (1) or more elections by uniQure under Section 4.4 that result in the UQ Effective Time occurring under Section 4.4(b) for the applicable uniQure Proposed Product, Non-Restricted Target, and New Capsid Variant.  For clarity, the license granted under this paragraph to uniQure shall expressly include the right to create improvements or modifications to the sequence or composition of matter of any New Capsid Variant, provided that such improved or modified sequence or composition of matter is used solely in connection with  the applicable Non-Restricted Target in the Field.
		

		
			(ii)       In order to enable uniQure to research Constructs related to Non-Restricted Targets for the potential exercise of uniQure’s Step-In Rights pursuant to Section 4.4, uniQure shall have, and 4DMT hereby grants to uniQure, a non-exclusive research-use-only license to use any and all Vector Characterization Data reported to uniQure by 4DMT and any other necessary 4DMT Intellectual Property, on a New Capsid Variant by New Capsid Variant basis, regardless of whether such New Capsid Variant was generated or identified under this Agreement or outside of this Agreement, to the extent necessary for uniQure to evaluate whether to exercise its Step-In Rights pursuant to Section 4.4.
		

		
			(d)        Recordation.  Following the Effective Date or at any time during the Term, 4DMT at the request and expense of uniQure shall promptly register or record the licenses granted to uniQure under this Agreement with the appropriate patent offices in all applicable countries of the Territory; provided that such registration or recordation specifies the applicable limitations of such license, and provided further that such registration shall have no effect on the allocation of Prosecution and Maintenance rights and obligations set forth in ARTICLE VII.  In the event any of the licenses granted to uniQure under this Agreement are terminated in accordance with the terms of this Agreement, uniQure shall promptly take such actions and execute such documents as are reasonably requested by 4DMT to cancel such registration(s) or recordation(s) in the applicable countries with respect to the terminated license grants.
		

		
			(e)        Grant-Back License to uniQure. 4DMT hereby grants to uniQure, and uniQure hereby accepts, a non-exclusive, worldwide, royalty-free license, including the right to grant sublicenses through multiple tiers, under the 4DMT Patent Rights and 4DMT Know-How that (i) arise from activities that are conducted under this Agreement in connection with Royalty Bearing Constructs and Royalty Bearing Products in the course of making modifications to New Capsid Variants and (ii) claim or cover compositions of matter or general methods of use of New Capsid Variants (for clarity, including such Patent Rights and Know-How claiming or covering compositions combining Gene Therapy Constructs in general and AAV Capsid Variants in general or general methods of making or using such combinations of Gene Therapy Constructs and AAV Capsid Variants), to research, Develop, make and have made, use, import, sell and Commercialize New Capsid Variants, and Products containing New Capsid Variants in connection solely with the Restricted Targets and any Non-Restricted Targets licensed to uniQure pursuant to the Step-In Rights under Section 4.4.
		

		
			
		

		
			

		 

		

			-  27  -

		

		

			 

		

		

		
			5.2      Licenses to 4DMT.
		

		
			(a)        Research License to 4DMT.  Subject to the terms and conditions of this Agreement, uniQure hereby grants to 4DMT, and 4DMT hereby accepts, during the Research Term, a non-exclusive, worldwide, royalty-free, non-sublicenseable license under the uniQure Intellectual Property, solely to the extent necessary to conduct activities assigned to 4DMT under the Research Program during the Research Term.
		

		
			(b)        Grant-Back License to 4DMT.  uniQure hereby grants to 4DMT, and 4DMT hereby accepts, a non-exclusive, worldwide, royalty-free license, including the right to grant sublicenses through multiple tiers, under the Patent Rights and Know-How Controlled by uniQure pursuant to the licenses granted by 4DMT to uniQure in Section 5.1 (including such Patent Rights and Know-How licensed to uniQure pursuant to Section 5.1 claiming or covering compositions combining Gene Therapy Constructs in general and AAV Capsid Variants in general or general methods of making or using such combinations of Gene Therapy Constructs and AAV Capsid Variants), and to use the Vector Characterization Data reported by uniQure to 4DMT under this Agreement, to research, Develop, make and have made, use and Commercialize New Capsid Variants, and Products containing New Capsid Variants, in all cases outside the Field or within 4D Products within the scope of rights within which 4DMT is entitled to research, Develop, and Commercialize 4D Products under this Agreement.  For the avoidance of doubt, 4DMT’s practice of the foregoing license shall be subject to the license rights of uniQure under Section 5.1 and its right to grant sublicenses under Section 5.3.
		

		
			(c)        Non-Exclusive License for Proposed Products elected by 4DMT pursuant to its Step-In Rights under Section 4.4.  Subject to the terms and conditions of this Agreement (including uniQure’s retained rights related to Products delivering Transgenes that Affect the applicable Restricted Target), and on a New Capsid Variant-by-New Capsid Variant basis, effective upon the Effective Time with respect to the given 4DMT Proposed Product and Restricted Target pursuant to Section 4.4(a), uniQure hereby grants to 4DMT, and 4DMT hereby accepts, a non-exclusive, worldwide, royalty-bearing license, including the right to grant sublicenses in accordance with Section 5.3, under the uniQure Intellectual Property that is necessary or useful due to the presence of the applicable New Capsid Variant (including all Vector Characterization Data reported by uniQure to 4DMT under this Agreement) and uniQure’s interest in the Joint Intellectual Property, to research, Develop, make and have made, use and Commercialize such 4DMT Proposed Products as Royalty Bearing Constructs and Royalty Bearing Products within the Field.  Any licenses granted pursuant to this Section are limited to only uniQure Intellectual Property that specifically relates to New Capsid Variants, including patent claims specifying a New Capsid Variant (if any) or specifically claiming any methods of use or making any New Capsid Variants (if any), and excluding all other uniQure Intellectual Property, including compositions of matter or methods of making compositions of matter and methods of manufacturing Products (but not the New Capsid Variants therein) pursuant to this Agreement.  Such license may become effective one (1) or more times, in connection with one (1) or more elections by 4DMT under Section 4.4 that result in the Effective Time occurring under Section 4.4(a)(iii) for the applicable Proposed Product and Restricted Target.
		

		
			5.3      Sublicenses.  Each Party  shall have the right to grant sublicenses (through multiple tiers) under the license granted to it under Section 5.1(b) (in the case of uniQure) or
		

		
			
		

		
			

		 

		

			-  28  -

		

		

			 

		

		

		
			Section 5.2(c) (in the case of 4DMT) to its Affiliates and Third Parties; provided that any sublicense granted to a Third Party under this Agreement shall be pursuant to a written agreement that subjects such Sublicensee to all relevant restrictions and limitations set forth in this Agreement.  Each Party granting a sublicense shall provide the other Party  with the name and address of each Sublicensee of its rights under this ARTICLE V, the date of the grant of the sublicense and a description of the rights granted promptly after the execution and delivery of the sublicense agreement.  The Party granting the sublicense shall remain responsible for the performance of its Sublicensees, and shall ensure that each Sublicensee complies with the applicable terms and conditions of this Agreement.
		

		
			5.4      Rights Retained by the Parties.  Except as expressly set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, in any Confidential Information of the other Party or under any Patent Right or Know-How in which such other Party or its Affiliates has rights.  Without limiting the generality of the foregoing, any of 4DMT’s rights to 4DMT Intellectual Property not specifically licensed to uniQure shall be retained by 4DMT, and any of uniQure’s rights to uniQure Intellectual Property not specifically licensed to 4DMT shall be retained by uniQure.
		

		
			5.5      Section 365(n) of the Bankruptcy Code.  All rights and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended or any comparable Law outside the United States (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code.  The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code.  Each Party agrees that the other Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable Law outside the United States that provide similar protection for “intellectual property.” The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code or analogous provisions of applicable Law outside the United States, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) the intellectual property licensed to such other Party and all embodiments of such intellectual property, to the extent necessary for such other Party to practice the licenses granted to it pursuant to this Agreement under such intellectual property, which, if not already in such other Party’s possession, will be promptly delivered to it upon such other Party’s written request thereof.  Any agreement supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code
		

		
			5.6      UCB Agreement Pass-Through Provisions.  uniQure acknowledges that 4DMT has provided it with a copy of the executed UCB Agreements, and agrees that this Agreement is subject in all respects to the terms and conditions of the UCB Agreements.  Notwithstanding the generality of the foregoing:
		

		
			(a)        uniQure acknowledges that UC (and, to the extent applicable, IGT) may publish any and all technical data resulting from any research performed by UC (and, to the extent applicable, IGT) relating to the inventions disclosed in the UC Patent Rights, and UC (and, to the extent applicable, IGT) expressly reserves the right to use such inventions, UC AAV Capsid
		

		
			
		

		
			

		 

		

			-  29  -

		

		

			 

		

		

		
			Variants and related technology for its educational and research purposes, to disseminate the UC AAV Capsid Variants and other tangible materials associated with, or required to practice such inventions or the UC Patent Rights to researchers at nonprofit institutions for their educational and research purposes, and to permit other nonprofit institutions to use the UC AAV Capsid Variants to practice the UC Patent Rights for education and research purposes.
		

		
			(b)        uniQure shall keep 4DMT informed of its large/small entity status, as defined in 15 U.S.C. 632.
		

		
			(c)        uniQure acknowledges that certain of the inventions disclosed in the UC Patent Rights were funded in part by the U.S. Government, and agrees that in accordance with 35 U.S.C. 204, to the extent required by Law, any products covered by the UC Patent Rights and sold in the United States will be substantially manufactured in the United States.
		

		
			(d)        uniQure acknowledges that 4DMT’s exclusive rights, privileges, and licenses under the UCB Agreements will expire on the date of the last-to-expire Valid Claim under the UC Patent Rights covered in each agreement, respectively, unless earlier terminated.
		

		
			(e)        For any sublicense under the UC Patent Rights that uniQure grants under Section 5.3, uniQure shall ensure that (i) such further sublicense is subject to a written sublicense agreement and is bound by all of the applicable terms, conditions, obligations, restrictions and other covenants of the UCB Agreements that protect or benefit UC’s (and, if applicable, the U.S. Government’s) rights and interests to the same extent that this Agreement does, and (ii) it or the Sublicensee shall, within [***] ([***]) days after executing such sublicense agreement, furnish to 4DMT for delivery to UC, subject to any confidentiality provisions, all material terms of such sublicense pertaining to UC’s interests, including the Sublicensee’s name and address, and indemnification of UC as provided in this Agreement.
		

		
			(f)        The Parties acknowledge and agree that upon termination of the UCB Agreements for any reason, uniQure’s sublicenses under the UC Patent Rights under this Agreement will remain in effect and will be assigned to UC, except that UC will not be bound to perform any duties or obligations set forth herein that extend beyond the duties and obligations of UC set forth in the UCB Agreements.
		

		
			(g)        uniQure acknowledges that nothing contained in this Agreement will be construed as conferring any right to use in advertising, publicity or other promotional activities any name, trademark, trade name, or other designation of UC (including any contraction, abbreviation, or simulation of any of the foregoing), and that unless required by Law, regulation, or rules of a securities exchange, or consented to in writing by UC, the use by uniQure of the name “The Regents of the University of California” or the name of any University of California campus in advertising, publicity or other promotional activities is expressly prohibited.
		

		
			ARTICLE VI
		

		
			 
		

		
			PAYMENTS; ROYALTIES AND REPORTS
		

		
			6.1       [Intentionally omitted].
		

		
			
		

		
			

		 

		

			-  30  -

		

		

			 

		

		

		
			6.2      Royalties.
		

		
			(I)        Royalties Payable by uniQure for uniQure Products.
		

		
			On a Royalty Bearing Product-by-Royalty Bearing Product basis, uniQure shall pay to 4DMT royalties on worldwide Net Sales of uniQure Products as provided in this Section 6.2:
		

		
			(a)        Royalty Rate.  uniQure shall pay to 4DMT royalties on Net Sales of each Royalty Bearing Product Commercialized by uniQure and its Affiliates equal to [***] percent ([***]%) of all such Net Sales of such Royalty Bearing Product achieved during the applicable Calendar Year.
		

		
			(b)        Royalty Term.  uniQure’s royalty obligations to 4DMT under this Section 6.2 for uniQure Products shall be in effect on a country-by-country and Royalty Bearing Product-by-Royalty Bearing Product basis during the relevant Royalty Term.  Upon expiration of the Royalty Term for a Royalty Bearing Product in a country, the license under Section 5.1(b) shall be fully paid-up, irrevocable, perpetual and exclusive under the relevant Licensed IP for such Royalty Bearing Product in such country.
		

		
			(c)        Royalty Adjustments.
		

		
			(i)         Non-Patented Product.  If a Royalty Bearing Product is sold in a country and the composition of matter, formulation, or method of use of such Royalty Bearing Product is not Covered by a Valid Claim within the Licensed IP in such country at the time of sale, then the royalty rate for such Royalty Bearing Product in such country shall be reduced by [***] percent ([***]%) of the applicable rate determined pursuant to Section 6.2(I)(a), unless such Royalty Bearing Product embodies an Invention with respect to which uniQure made a Trade Secret Election, in which case no such reduction shall apply.
		

		
			(ii)       Third Party Offset.  If uniQure is required, in order to avoid infringement of any Patent Right not licensed hereunder that Covers the composition of matter, formulation, or method of use of a Royalty Bearing Product, to obtain a license from a Third Party in order to Develop, make, have made, use or Commercialize such Royalty Bearing Product in a country in the Territory and to pay a royalty or other consideration under such license (including in connection with the settlement of a patent infringement claim), then the royalty payments due under Section 6.2(I)(a) with respect to Net Sales for such Royalty Bearing Product in such country shall be reduced by [***] percent ([***]%) of the amounts payable by uniQure to such Third Party for such license that are reasonably and appropriately allocable to such Royalty Bearing Product in such country, provided that in no event shall the foregoing reduce the amount of royalties payable to 4DMT in any [***] by more than [***] percent ([***]%) of the amount determined pursuant to Section 6.2(I)(a), as adjusted by application of the terms of Section 6.2(I)(c)(i).
		

		
			(iii)      Limits on Deductions.  Except as expressly provided in this Section 6.2, there shall not be any offset to or deduction from the royalties payable pursuant to this Section 6.2.  Notwithstanding Sections 6.2(c)(i) and (ii) to the contrary, in no event shall the cumulative effect of the deductions in Sections 6.2(I)(c)6.2(c)(i) and (ii) reduce the royalties to less than [***] percent ([***]%) of the amounts determined pursuant to Section 6.2(I)(a).
		

		
			
		

		
			

		 

		

			-  31  -

		

		

			 

		

		

		
			(II)       Royalties Payable by 4DMT for 4DMT Products.
		

		
			 On a Royalty Bearing Product-by-Royalty Bearing Product basis, for each 4DMT Product Commercialized by 4DMT and its Affiliates, 4DMT shall pay to uniQure royalties on annual worldwide Net Sales of such 4DMT Product as provided in this Section 6.2:
		

		
			(a)        Royalty Rate.  4DMT shall pay to uniQure royalties on Net Sales of each Royalty Bearing Product Commercialized by 4DMT and its Affiliates equal to [***] percent ([***]%) of all such Net Sales of such Royalty Bearing Product achieved during the applicable Calendar Year.
		

		
			(b)        Royalty Term.  4DMT’s royalty obligations to uniQure under this Section 6.2 shall be in effect on a country-by-country and Royalty Bearing Product-by-Royalty Bearing Product basis during the relevant Royalty Term.  Upon expiration of the Royalty Term for a Royalty Bearing Product in a country, the license under Section 5.2(c) shall be fully paid-up, irrevocable, perpetual and non-exclusive under the relevant Licensed IP for such Royalty Bearing Product in such country.
		

		
			(c)        Royalty Adjustments.
		

		
			(i)         Non-Patented Product.  If a Royalty Bearing Product is sold in a country and the composition of matter, formulation, or method of use of such Royalty Bearing Product is not Covered by a Valid Claim within the Licensed IP in such country at the time of sale, then the royalty rate for such Royalty Bearing Product in such country shall be reduced by [***] percent ([***]%) of the applicable rate determined pursuant to Section 6.2(a), unless such Royalty Bearing Product embodies an Invention with respect to which 4DMT made a Trade Secret Election, in which case no such reduction shall apply.
		

		
			(ii)       Third Party Offset.  If 4DMT is required, in order to avoid infringement of any Patent Right not licensed hereunder that Covers the composition of matter, formulation, or method of use of a Royalty Bearing Product, to obtain a license from a Third Party in order to Develop, make, have made, use or Commercialize such Royalty Bearing Product in a country in the Territory and to pay a royalty or other consideration under such license (including in connection with the settlement of a patent infringement claim), then the royalty payments due under Section 6.2(a) with respect to Net Sales for such Royalty Bearing Product in such country shall be reduced by [***] percent ([***]%) of the amounts payable by 4DMT to such Third Party for such license that are reasonably and appropriately allocable to such Royalty Bearing Product in such country, provided that in no event shall the foregoing reduce the amount of royalties payable to uniQure in any [***] by more than [***] percent ([***]%) of the amount determined pursuant to Section 6.2(a), as adjusted by application of the terms of Section 6.2(c)(i).
		

		
			(iii)      Limits on Deductions.  Except as expressly provided in this Section 6.2, there shall not be any offset to or deduction from the royalties payable pursuant to this Section 6.2.  Notwithstanding Sections 6.2(II)(c)(i) and (ii) to the contrary, in no event shall the cumulative effect of the deductions in Sections 6.2(c)(i) and (ii) reduce the royalties to less than [***] percent ([***]%) of the amounts determined pursuant to Section 6.2(II)(a).
		

		
			6.3      Sublicense Consideration.
		

		
			
		

		
			

		 

		

			-  32  -

		

		

			 

		

		

		
			(a)        uniQure shall pay to 4DMT the following percentages (“Sublicense Income Sharing Percentages”) of Sublicense Consideration received by uniQure for sublicenses under the Licensed IP under this Agreement:
		

		
			(i)         [***] percent ([***]%) for any sublicense that (A) is granted prior to initiating Animal POC for any Construct or Product that is subject of the sublicense and (B) does not require uniQure to manufacture any such Construct or Product for Clinical Trial or commercial purposes;
		

		
			(ii)       [***] percent ([***]%) for any sublicense that (A) is granted prior to initiating Animal POC for any Construct or Product that is subject of the sublicense and (B) requires uniQure to manufacture any such Construct or Product for Clinical Trial or commercial purposes;
		

		
			(iii)      [***] percent ([***]%) for any sublicense that does not meet the criteria set forth in Section 6.3(a)(i) or Section 6.3(a)(ii) above;
		

		
			provided,  however, that none of subsections (i), (ii) or (iii) shall result in uniQure paying to 4DMT under this Section 6.3 a percentage of any Sublicense Consideration consisting of royalties from Sublicensees on sales of UC Products during the applicable Royalty Term that is less than [***] percent ([***]%) of Net Sales by such Sublicensee of such UC Products.
		

		
			(b)        The term “Sublicense Consideration” shall mean consideration of any kind received by uniQure from a Sublicensee for the grant of a sublicense under this Agreement, such as upfront fees, royalties or milestone fees and including any premium paid by the Sublicensee over the Fair Market Value (as defined below) for stock of uniQure in consideration for such sublicense; provided,  however, the following are not included in Sublicense Consideration:
		

		
			(i)         Support for activities of uniQure relating to the research, Development, manufacturing or Commercialization of Royalty Bearing Products, which shall not exceed the fully burdened cost (and in the case of manufacturing costs, the Fully Burdened Manufacturing Cost) for undertaking such activities performed by or for uniQure (including Third Parties on uniQure’s behalf) by more than [***] percent ([***]%);
		

		
			(ii)       Proceeds derived from debt financing and any loans to uniQure by the Sublicensee;
		

		
			(iii)      Consideration received for the purchase of stock in uniQure or its Affiliate to the extent that the price per share for such equity does not exceed the Fair Market Value of such stock.  The term “Fair Market Value” shall mean the average price at which the stock in question is publicly trading at for [***] ([***]) days prior to the earlier of (A) the date of the announcement of its purchase by the Sublicensee or (B) the date of its purchase by the Sublicensee, or if the stock is not publicly traded, the value of such stock as determined in good faith by the Board of Directors of uniQure or its applicable Affiliate as of the time of receipt of payment; and
		

		
			
		

		
			

		 

		

			-  33  -

		

		

			 

		

		

		
			(iv)       Reimbursement of uniQure’s patent costs related to Patent Rights.
		

		
			 
		

		
			(c)        4DMT shall pay to uniQure the following percentages (“4D Sublicense Income Sharing Percentages”) of 4D Sublicense Consideration received by 4DMT for sublicenses under the Licensed IP under this Agreement:
		

		
			(i)         [***] percent ([***]%) for any sublicense that (A) is granted prior to initiating Animal POC for any Construct or Product that is subject of the sublicense and (B) does not require 4DMT to manufacture any such Construct or Product for Clinical Trial or commercial purposes;
		

		
			(ii)       [***] percent ([***]%) for any sublicense that (A) is granted prior to initiating Animal POC for any Construct or Product that is subject of the sublicense and (B) requires 4DMT to manufacture any such Construct or Product for Clinical Trial or commercial purposes;
		

		
			(iii)      [***] percent ([***]%) for any sublicense that does not meet the criteria set forth in Section 6.3(a)(i) or Section 6.3(a)(ii) above;
		

		
			provided,  however, that none of subsections (i), (ii) or (iii) shall result in 4DMT paying to uniQure under this Section 6.3 a percentage of any 4D Sublicense Consideration consisting of royalties from Sublicensees on sales of UC Products during the applicable Royalty Term that is less than [***] percent ([***]%) of Net Sales by such Sublicensee of such UC Products.
		

		
			(d)        The term “4D Sublicense Consideration” shall mean consideration of any kind received by 4DMT from a Sublicensee for the grant of a sublicense under this Agreement, such as upfront fees, royalties or milestone fees and including any premium paid by the Sublicensee over the Fair Market Value (as defined below) for stock of 4DMT in consideration for such sublicense; provided,  however, the following are not included in Sublicense Consideration:
		

		
			(i)         Support for activities of 4DMT relating to the research, Development, manufacturing or Commercialization of Royalty Bearing Products, which shall not exceed the fully burdened cost (and in the case of manufacturing costs, the Fully Burdened Manufacturing Cost) for undertaking such activities performed by or for 4DMT (including Third Parties on 4DMT’s behalf) by more than [***] percent ([***]%);
		

		
			(ii)       Proceeds derived from debt financing and any loans to 4DMT by the Sublicensee;
		

		
			(iii)      Consideration received for the purchase of stock in 4DMT or its Affiliate to the extent that the price per share for such equity does not exceed the Fair Market Value of such stock.  The term “Fair Market Value” shall mean the average price at which the stock in question is publicly trading at for [***] ([***]) days prior to the earlier of (A) the date of the announcement of its purchase by the Sublicensee or (B) the date of its purchase by the
		

		
			
		

		
			

		 

		

			-  34  -

		

		

			 

		

		

		
			Sublicensee, or if the stock is not publicly traded, the value of such stock as determined in good faith by the Board of Directors of 4DMT or its applicable Affiliate as of the time of receipt of payment; and
		

		
			(iv)       Reimbursement of 4DMT’s patent costs related to Patent Rights.
		

		
			(e)        For purposes of this Article 6, “Sublicense Consideration received by uniQure” shall include Sublicense Consideration received by uniQure’s Affiliates (applying the definition of Sublicense Consideration mutatis mutandis to such Affiliates) and “4D Sublicense Consideration received by 4D” shall include 4D Sublicense Consideration received by 4DMT’s Affiliates (applying the definition of Sublicense Consideration mutatis mutandis to such Affiliates).
		

		
			6.4      Reports; Payments.  Within [***] ([***]) days after the end of each Calendar Quarter during which there are Net Sales giving rise to a payment obligation under Section 6.2 or uniQure (or 4DMT, as applicable) received Sublicense Consideration or 4D Sublicense Consideration giving rise to a payment obligation under Section 6.3, (a) uniQure (or 4DMT as applicable) shall submit to 4DMT (or uniQure as applicable) a report (i) identifying for each Royalty Bearing Product the Net Sales for such Royalty Bearing Product for each country for such Calendar Quarter, the calculation of royalties (including gross sales and all deductions taken from gross sales and all reductions pursuant to Section 6.2(c)), and the royalties payable to 4DMT (or uniQure as applicable) and (ii) identifying the Sublicense Consideration received by uniQure (or 4DMT as applicable) in such Calendar Quarter and the one or more Sublicense Income Sharing Percentages applicable to such Sublicense Consideration, or 4D Sublicense Income Sharing Percentages applicable to such 4D Sublicense Consideration and (b) uniQure (or 4DMT as applicable) shall pay to 4DMT (or uniQure as applicable) all royalties payable under Section 6.2 and portions of Sublicense Consideration or 4D Sublicense Consideration payable under Section 6.3.
		

		
			6.5      Books and Records; Audit Rights.  Each Party (the “Audited Party”) shall keep (and shall cause its Affiliates and Sublicensees to keep) complete, true and accurate books and records in accordance with its Accounting Standards in sufficient detail for the other Party (the “Auditing Party”) to determine the payments due under this Agreement.  Each Auditing Party shall have the right, once annually at its own expense, to have an independent, certified public accounting firm of nationally recognized standing, selected by the Auditing Party and reasonably acceptable to the Audited Party, review any such records of the Audited Party in the location(s) where such records are maintained by the Audited Party upon reasonable notice (which shall be no less than [***] ([***]) days prior notice) and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the accuracy of the amounts paid under this Agreement within a [***] period preceding the date of the request for review.  The report of such accounting firm shall be limited to a certificate stating whether any report made or invoice or payment submitted by the Audited Party during such period is accurate or inaccurate, and the amount of any Net Sales, Sublicense Consideration, 4D Sublicense Consideration, royalty or other payment discrepancy.  No other information shall be provided to the Auditing Party.  The Audited Party shall receive a copy of each such report concurrently with receipt by the Auditing Party.  Should such inspection lead to the discovery of a discrepancy to the Auditing Party’s
		

		
			
		

		
			

		 

		

			-  35  -

		

		

			 

		

		

		
			detriment, the Audited Party shall pay the amount of the discrepancy within [***] ([***]) days after its receipt from the accounting firm of the certificate showing the amount of the discrepancy.  The Auditing Party shall pay the full cost of the review unless the audit determined an underpayment of royalties by the Audited Party which is greater than [***] percent ([***]%) of the amount due for the applicable period, in which case the Audited Party shall pay the reasonable costs charged by such accounting firm for such review.  Any overpayment of royalties by uniQure (or 4DMT, as applicable) revealed by an inspection shall be fully creditable against future royalty payments by such Audited Party under Section 6.2.
		

		
			6.6      Withholding Taxes.
		

		
			 (a) Subject to the provisions of Section 12.7, if Laws require withholding by uniQure of taxes imposed upon 4DMT on account of any royalty or other payment paid under this Agreement, such taxes shall be deducted by uniQure as required by Law from such remittable royalty or other payment and shall be paid by uniQure to the proper tax authorities; provided that before making any such deduction or withholding, uniQure shall give 4DMT notice of the intention to make such deduction or withholding, which notice shall include the authority, basis and method of calculation for the proposed deduction or withholding, and shall be provided to the extent practicable at least a reasonable period of time before such deduction or withholding is required, in order for 4DMT to obtain reduction of or relief from such deduction or withholding.  Official receipts of payment of withholding taxes shall be secured and sent to 4DMT as evidence of such payment.  The Parties shall exercise their best efforts to ensure that any withholding tax imposed is reduced as far as possible under the provisions of any relevant tax treaty.
		

		
			(b) Subject to the provisions of Section 12.7, if Laws require withholding by 4DMT of taxes imposed upon uniQure on account of any royalty or other payment paid under this Agreement, such taxes shall be deducted by 4DMT as required by Law from such remittable royalty or other payment and shall be paid by 4DMT to the proper tax authorities; provided that before making any such deduction or withholding, 4DMT shall give uniQure notice of the intention to make such deduction or withholding, which notice shall include the authority, basis and method of calculation for the proposed deduction or withholding, and shall be provided to the extent practicable at least a reasonable period of time before such deduction or withholding is required, in order for uniQure to obtain reduction of or relief from such deduction or withholding.  Official receipts of payment of withholding taxes shall be secured and sent to uniQure as evidence of such payment.  The Parties shall exercise their best efforts to ensure that any withholding tax imposed is reduced as far as possible under the provisions of any relevant tax treaty.
		

		
			6.7      United States Dollars.  All dollar ($) amounts specified in this Agreement are United States dollar amounts.
		

		
			6.8      Payment Method and Currency Conversion.  Except as otherwise provided herein, all payments due to a Party hereunder shall be due and payable within [***] ([***]) days after receipt of an invoice from the other Party and shall be paid via a bank wire transfer to such bank account as such Party shall designate.  For the purposes of determining the amount of any payment due hereunder for the relevant Calendar Quarter under Section 6.2 or Section 6.3, amounts received by a Party in any foreign currency shall be converted into United States dollars
		

		
			
		

		
			

		 

		

			-  36  -

		

		

			 

		

		

		
			in accordance with the normal business practice of such Party , as applied consistently across its business.
		

		
			6.9      Blocked Payments.  (a)  If, by reason of applicable Laws in any country in the Territory, it becomes impossible or illegal for uniQure or any of its Affiliates or Sublicensees to transfer, or have transferred on its behalf, royalties or other payments to 4DMT, uniQure shall promptly notify 4DMT of the conditions preventing such transfer and such royalties or other payments shall be deposited in local currency in the relevant country to the credit of 4DMT in a recognized banking institution with a good creditworthiness, such banking institution to be designated by 4DMT or, if none is designated by 4DMT within [***] ([***]) days, in a recognized banking institution selected by uniQure or its Affiliate or Sublicensee, as the case may be, and identified in a written notice given to 4DMT.  If so deposited in a foreign country, uniQure shall provide, or cause its Affiliate or Sublicensee to provide, reasonable cooperation to 4DMT so as to allow 4DMT to assume control over such deposit as promptly as practicable.
		

		
			(b)  If, by reason of applicable Laws in any country in the Territory, it becomes impossible or illegal for 4DMT or any of its Affiliates or Sublicensees to transfer, or have transferred on its behalf, royalties or other payments to uniQure, 4DMT shall promptly notify uniQure of the conditions preventing such transfer and such royalties or other payments shall be deposited in local currency in the relevant country to the credit of uniQure in a recognized banking institution with a good creditworthiness, such banking institution to be designated by uniQure or, if none is designated by uniQure within [***] ([***]) days, in a recognized banking institution selected by 4DMT or its Affiliate or Sublicensee, as the case may be, and identified in a written notice given to uniQure.  If so deposited in a foreign country, 4DMT shall provide, or cause its Affiliate or Sublicensee to provide, reasonable cooperation to uniQure so as to allow uniQure to assume control over such deposit as promptly as practicable.
		

		
			6.10    Late Payments.  Any payment not made within [***] ([***]) Business Days after the due date for such payment pursuant to the terms of this Agreement shall bear interest at a rate of the thirty-day U.S. dollar LIBOR rate effective for the date that payment was due (as published in The Wall Street Journal, Eastern Edition) plus [***] per annum.  Calculation of interest will be made for the exact number of days the payment was past due based on a year of 360 days (actual days/360).
		

		
			ARTICLE VII
		

		
			 
		

		
			PATENTS
		

		
			7.1      Disclosure.  Each Party shall promptly disclose to the other Party any Inventions that it or its Affiliates or Sublicensees or their employees, independent contractors, or agents solely or jointly make, conceive, reduce to practice, or otherwise discover under this Agreement, and each Party shall maintain and make available to the other Party records regarding any Inventions that it has an obligation to assign under Section 7.2(a).
		

		
			
		

		
			

		 

		

			-  37  -

		

		

			 

		

		

		
			7.2      Ownership.
		

		
			(a)        uniQure shall solely own all Core uniQure Intellectual Property, and 4DMT shall solely own all Core 4DMT Intellectual Property.   Without limiting the generality of the foregoing, this means that 4DMT shall own the New Variant Patents, and uniQure shall own the uniQure Product Patents.  All other Inventions arising under this Agreement or the Parties’ activities hereunder, shall be owned by inventorship.  Without additional consideration, each Party shall assign and hereby does assign to the other Party such of its right, title, and interest in and to such Inventions, Know-How and Patent Rights (and shall require its Affiliates and Sublicensees, and all employees, independent contractors and their employees, and agents of such Party and its Affiliates and Sublicensees to so assign to the other Party such of their right, title, and interest) and agrees to take all necessary actions and execute any documents as is necessary to effectuate the allocation of right, title, and interest as set forth in this Section 7.2(a).
		

		
			(b)        Except as otherwise expressly set forth in Section 7.2(a), as between the Parties, (i) each Party shall solely own all Know-How and Inventions invented solely by employees, agents and consultants of such Party or its Affiliates, and any Patent Right related thereto, subject to the licenses granted under ARTICLE V, and (ii) Know-How and Inventions invented jointly by employees, agents, or consultants of the Parties or their Affiliates (“Joint Intellectual Property”, which includes any Patent Right Covering such Know-How and Inventions (“Joint Patent Rights”) and any Know-How included in such Joint Intellectual Property (“Joint Know-How”)) shall be jointly owned, subject to the licenses granted under ARTICLE V.  Inventorship shall be determined in accordance with U.S. patent Laws for purposes of determining ownership in accordance with the foregoing.  Except as explicitly provided for herein, the nature of the ownership rights in Joint Patent Rights shall be equivalent to the rights of co-inventors under U.S. patent law in the absence of a written agreement.
		

		
			(c)        Except as expressly provided in this Agreement, and subject to any restriction herein (including the licenses granted under ARTICLE V), (i) each joint owner may engage in research, Development, manufacturing and Commercialization activities relating to Joint Intellectual Property, and (ii) each may assign, license, sell or otherwise encumber or transfer any such interest without the prior written approval of the other Party and without obligation to account or provide compensation to the other Party.
		

		
			7.3      uniQure Prosecution and Maintenance of Patent Rights.
		

		
			(a)        uniQure shall be solely responsible for the Prosecution and Maintenance of the uniQure Patent Rights, including the Core uniQure Patent Rights, at its sole expense and its sole discretion.  uniQure shall give 4DMT an opportunity to review the text of each application, office action response or other substantive document for a Core uniQure Patent Right specifically relating to [***] (but not any other uniQure Patent Right) before filing with any patent office in the Territory, shall consider 4DMT’s reasonable comments with respect thereto, and shall supply 4DMT with a copy of each such application, office action response or other substantive document as filed, together with notice of its filing date and serial number.
		

		
			(b)        uniQure shall have the sole right to determine whether any patent application is filed with respect to any Core uniQure Know-How and whether to maintain any
		

		
			
		

		
			

		 

		

			-  38  -

		

		

			 

		

		

		
			Invention included in the Core uniQure Know-How as a trade secret.  uniQure shall provide 4DMT with written notice if uniQure elects not to file a patent application claiming any particular Invention included in the Core uniQure Know-How (each, a “Trade Secret Election”).
		

		
			(c)        Notwithstanding anything express or implied and provided that a Patent Right has not been filed hereunder with respect to a New Capsid Variant, uniQure shall give reasonable notice to 4DMT (no less than [***] ([***]) days) prior to filing a uniQure Product Patent disclosing a New Capsid Variant, and the Parties shall cooperate reasonably in the filing of such uniQure Product Patent, including coordinating the timely filing of a Patent Right with respect to a New Capsid Variant and, where appropriate, the simultaneous filing of such patents by each Party.
		

		
			7.4      4DMT Prosecution and Maintenance of Patent Rights.
		

		
			(a)        4DMT shall be solely responsible for the Prosecution and Maintenance of the 4DMT Patent Rights, including the Core 4DMT Patent Rights, at its sole expense and its sole discretion.  4DMT will reasonably inform uniQure regarding the Prosecution and Maintenance of 4DMT Patent Rights ([***]).  Notwithstanding the foregoing, the Parties acknowledge that UC will handle the Prosecution and Maintenance of the UC Patent Rights in accordance with the terms of the UCB Agreements.
		

		
			(b)        4DMT shall have the sole right to determine whether any patent application is filed with respect to any Core 4DMT Know-How and whether to maintain any Invention included in the Core 4DMT Know-How as a trade secret.  4DMT shall provide uniQure with written notice if 4DMT elects not to file a patent application claiming any particular Invention included in the Core 4DMT Know-How specifically relating to compositions of matter of, methods of use of, or methods of making any New Capsid Variant because 4DMT prefers to maintain such Invention as a trade secret (each, a “Trade Secret Election”).
		

		
			(c)        4DMT shall notify uniQure at least [***] ([***]) days in advance of any applicable deadline if (i) 4DMT decides that it does not wish to continue the Prosecution and Maintenance of a published Core 4DMT Patent Right specifically relating to [***] for which no substitute has been filed, or (ii) 4DMT decides that it intends to abandon claim scope in a [***], which claim scope is intended to be maintained by uniQure, in which case, with respect to this clause (ii), uniQure may assume responsibility for such claim scope by filing a divisional application restricted to such claim scope.  In such cases (i) or (ii), 4DMT shall allow uniQure to assume responsibility for Prosecution and Maintenance of such Core 4DMT Patent Right or divisional application [***].  If uniQure assumes such responsibility, then uniQure may designate any counsel of its choice reasonably acceptable to 4DMT to handle the Prosecution and Maintenance of such Core 4DMT Patent Right or divisional application (which shall otherwise continue to be part of the Core 4DMT Patent Rights).
		

		
			7.5      Prosecution and Maintenance of Joint Patent Rights.  The Prosecution and Maintenance of any Joint Patent Right shall be through a mutually selected patent counsel.  Within [***] ([***]) days following the Effective Date, the Parties shall agree on a patent counsel (“Joint Counsel”) who shall be engaged by both Parties for the Prosecution and Maintenance of all such Joint Patent Rights.  The following terms shall apply to each Joint Patent Right:
		

		
			
		

		
			

		 

		

			-  39  -

		

		

			 

		

		

		
			(a)        The Parties shall instruct Joint Counsel to conduct its activities as follows:  The Joint Counsel shall give uniQure and 4DMT (or each Party’s designee) an opportunity to review the text of each application, office action response or other substantive document for a Joint Patent Right before filing with any patent office in the Territory, shall incorporate uniQure’s and 4DMT’s (or each Party’s designee) reasonable comments with respect thereto, and shall supply uniQure and 4DMT (or each Party’s designee) with a copy of each such application, office action response or other substantive document as filed, together with notice of its filing date and serial number.  In the event that 4DMT and uniQure provide Joint Counsel with conflicting instructions regarding the Prosecution and Maintenance of a Joint Patent Right, Joint Counsel shall make the Parties aware of such conflicting instructions and, if the Parties are not able to resolve such conflict within a reasonable time prior to the applicable filing deadline, the Joint Counsel shall take such action as would reasonably be expected to maximize the scope, extent and coverage of such Joint Patent Right.
		

		
			(b)        Both Parties shall cooperate with Joint Counsel in Prosecution and Maintenance of patent applications for Joint Patent Rights, including providing Joint Counsel with data and other information as appropriate with respect thereto.
		

		
			(c)        Joint Counsel shall keep uniQure and 4DMT advised of the status of the Prosecution and Maintenance of Joint Patent Rights, including actual and prospective patent filings for Joint Patent Rights, and shall provide each Party with advance copies of any and all papers related thereto.  Joint Counsel shall promptly give notice to uniQure and 4DMT of the grant, lapse, revocation, surrender, invalidation or abandonment of any Joint Patent Right.
		

		
			(d)        The Parties shall equally share all fees and costs charged by Joint Counsel with respect to the Prosecution and Maintenance of Joint Patent Rights and all other mutually agreed and approved out-of-pocket costs and expenses incurred by either Party in connection with such Prosecution and Maintenance of Joint Patent Rights.
		

		
			(e)        uniQure shall notify 4DMT and Joint Counsel at least [***] ([***]) days in advance of the next deadline if (A) uniQure decides that it does not wish to continue paying for the Prosecution and Maintenance of a particular Joint Patent Right for which no substitute has been filed, or (B) uniQure decides that it intends to abandon claim scope in a Joint Patent Right which claim scope is intended to be maintained by 4DMT, in which case, with respect to this clause (B), 4DMT may assume responsibility for such claim scope by filing a divisional application restricted to such claim scope.  In such cases (A) or (B), uniQure shall allow 4DMT to assume responsibility for Prosecution and Maintenance of the respective Patent Rights, including [***].  If 4DMT assumes such responsibility, then: (i) 4DMT may designate any counsel of its choice to handle the Prosecution and Maintenance of such Joint Patent Right or of the divisional application and it shall cease to be a part of the Joint Patent Rights; (ii) uniQure shall lose its licenses to such former Joint Patent Right or divisional application under ARTICLE V and such former Joint Patent Right or divisional application shall be deemed a 4DMT Patent Right; and (iii) uniQure shall and hereby does transfer and assign all right, title and interest in said former Joint Patent Right or of the divisional application to 4DMT as the sole owner.  If 4DMT decides not to assume such responsibility, then it shall instruct Joint Counsel to abandon the Prosecution and Maintenance of such Joint Patent Right or not to file such divisional application.
		

		
			
		

		
			

		 

		

			-  40  -

		

		

			 

		

		

		
			(f)        4DMT shall notify uniQure and Joint Counsel at least [***] ([***]) days in advance of the next deadline if (A) 4DMT decides that it does not wish to continue paying for the Prosecution and Maintenance of a particular Joint Patent Right for which no substitute has been filed, or (B) 4DMT decides that it intends to abandon claim scope in a Joint Patent Right which claim scope is intended to be maintained by uniQure, in which case, with respect to this clause (B), uniQure may assume responsibility for such claim scope by filing a divisional application restricted to such claim scope.  In such cases (A) or (B), 4DMT shall allow uniQure to assume responsibility for Prosecution and Maintenance of the respective Patent Rights, including [***].  If uniQure assumes such responsibility, then: (i) uniQure may designate any counsel of its choice to handle the Prosecution and Maintenance of such Joint Patent Right or of the divisional application and it shall cease to be a part of the Joint Patent Rights and no further uniQure royalty obligations shall exist under this Agreement with respect thereto; (ii) 4DMT shall lose its licenses to such former Joint Patent Right or divisional application under ARTICLE V and such former Joint Patent Right or divisional application shall be deemed a uniQure Patent Right; and (iii) 4DMT shall and hereby does transfer and assign all right, title and interest in said former Joint Patent Right or of the divisional application to uniQure as the sole owner.  If uniQure decides not to assume such responsibility, then it shall instruct Joint Counsel to abandon the Prosecution and Maintenance of such Joint Patent Right or not to file such divisional application.
		

		
			7.6      Third Party Infringement.
		

		
			(a)        Notice.  Each Party shall promptly report in writing to the other Party any known or suspected (i) infringement of any of the 4DMT Patent Rights, uniQure Patent Rights or Joint Patent Rights, or (ii) unauthorized use or misappropriation of any of the 4DMT Know-How, uniQure Know-How or Joint Know-How, of which such Party becomes aware and shall provide the other Party with all available evidence regarding such known or suspected infringement or unauthorized use.
		

		
			(b)        Enforcement of Solely Owned Patent Rights.  uniQure shall have the sole right to enforce the uniQure Patent Rights, including the Core uniQure Patent Rights.  Subject to UC’s rights under the UCB Agreements with respect to any UC Patent Right included in the 4DMT Patent Rights, 4DMT shall have the sole right to enforce any 4DMT Patent Right, including the Core 4DMT Patent Rights.  Each Party shall cooperate in the prosecution of any such suit brought by the enforcing Party as may be reasonably requested by the enforcing Party; provided that the enforcing Party shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by the non-enforcing Party in connection with such cooperation.
		

		
			(c)        Enforcement of Joint Patent Rights.
		

		
			(i)         Restricted Target Products.  uniQure shall have the first right, but not the obligation, to initiate a lawsuit or take other reasonable action to enforce the Joint Patent Rights against any infringement in the Field by a Product that delivers a Transgene related to a Restricted Target.  4DMT shall cooperate in the prosecution of any such suit as may be reasonably requested by uniQure, including joining any action as party-plaintiff at uniQure’s sole discretion; provided that uniQure shall promptly reimburse all out-of-pocket expenses (including
		

		
			
		

		
			

		 

		

			-  41  -

		

		

			 

		

		

		
			reasonable counsel fees and expenses) actually incurred by 4DMT in connection with such cooperation.
		

		
			(ii)       Non-Restricted Target Products.  4DMT shall retain any and all rights to initiate a lawsuit or take other reasonable action to enforce the Joint Patent Rights against any infringement that is (A) outside the Field, and/or (B) by Products related to Non-Restricted Targets.  uniQure  shall cooperate in the prosecution of any such suit as may be reasonably requested by 4DMT, including joining any action as party-plaintiff at 4DMT’s sole discretion; provided that 4DMT shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by uniQure in connection with such cooperation.
		

		
			(iii)      Step-In Right of 4D.  If uniQure does not initiate a lawsuit or take other reasonable action pursuant to this Section 7.6(c) regarding infringement or alleged infringement of a New Variant Patent, then 4DMT shall have the right, but not the obligation, to initiate such lawsuit or take such other action, after providing [***] ([***]) days’ notice to uniQure and giving good faith consideration to  uniQure’s reason(s) for not initiating a lawsuit or taking other action.  For this purpose, uniQure shall cooperate in the prosecution of any such suit as may be reasonably requested by 4DMT, including joining any action as party-plaintiff if needed for standing purposes; provided, that 4DMT shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by uniQure in connection with such cooperation.
		

		
			(d)        Conduct of Certain Actions; Costs.  The Party initiating legal action shall have the sole and exclusive right to select counsel for any suit initiated by it pursuant to Section 7.6(b) or 7.6(c) (the “Initiating Party”).  The Initiating Party shall bear its own out-of-pocket costs incurred in any such legal action, including the fees and expenses of the counsel selected by it.  The other Party shall have the right to participate and be represented in any such legal action (in cases where such other Party has standing) by its own counsel at its own expense.  The Initiating Party shall have the final say about the strategy and decisions in the suit and any settlement.
		

		
			(e)        Recoveries.  Any amount recovered in any action or settlement of any such action shall be allocated first to equally reimburse each Party’s actual out-of-pocket costs (including reasonable attorneys’ fees and expenses) incurred in such action and any amount remaining shall be allocated to the Initiating Party; provided that for recoveries for infringement within the Field, the amount of remaining recovery received by the Initiating Party or its Affiliate will be [***].
		

		
			7.7      Patent Invalidity Claim.  Each Party shall promptly notify the other in the event of any legal or administrative action by any Third Party against a 4DMT Patent Right, uniQure Patent Right or Joint Patent Right of which it becomes aware, including any nullity, revocation, reexamination or compulsory license proceeding.  To the extent such action is in connection with an enforcement of such Patent Right under Section 7.6, the Parties’ rights with
		

		
			
		

		
			

		 

		

			-  42  -

		

		

			 

		

		

		
			respect to defending any such Patent Right in any such proceeding shall correspond to those set forth in Section 7.6.
		

		
			7.8      Patent Term Extensions.
		

		
			(a)        uniQure shall have full and exclusive right to determine and control all filings of requests for any patent term extension or supplemental patent certificate or their equivalents in any country in the Territory for any uniQure Patent Right, including any Core uniQure Patent Right, and all costs and expenses relating thereto shall be paid by uniQure.
		

		
			(b)        4DMT shall have full and exclusive right to determine and control all filings of requests for any patent term extension or supplemental patent certificate or their equivalents in any country in the Territory for any 4DMT Patent Right, including any Core 4DMT Patent Right, and all costs and expenses relating thereto shall be paid by 4DMT.
		

		
			(c)        The Parties shall jointly determine how to defend any such action relating to any Joint Patent Right.
		

		
			(d)        The Parties shall reasonably cooperate with each other in obtaining patent term extensions or supplemental protection certificates or their equivalents in any country in the Territory.
		

		
			7.9      Orange Book; Paragraph IV Certification.
		

		
			(a)        uniQure shall have the right, but not the obligation, to list any uniQure Patent Rights in the then-current edition of the FDA publication “Approved Drug Products With Therapeutic Equivalence Evaluations” (the “Orange Book”), or equivalent patent listings in other countries.  4DMT shall have the right, but not the obligation, to list any 4DMT Patent Rights in the then-current edition of the Orange Book, or equivalent patent listings in other countries.
		

		
			(b)        With respect to any notification provided by a Third Party to uniQure or 4DMT under 21 U.S.C. § 355(j)(2)(B) making a certification described in 21 U.S.C. § 355(j)(2)(A)(vii)(IV) with respect to any uniQure Patent Right that is listed for a Royalty Bearing Product in the Orange Book, or equivalent actions in other countries, (each a “Paragraph IV Certification”), the following shall apply notwithstanding Sections 7.6 and 7.7:
		

		
			(i)         Without any avoidable delay, however at the latest within [***] ([***]) Business Days after receipt of any notification of a Paragraph IV Certification, such Party shall notify the other Party in writing and attach of copy of such notification.  uniQure and 4DMT shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding, including the negotiation of the offer of confidential access.
		

		
			(ii)       With respect to any uniQure Patent Right, uniQure shall have the sole right to initiate any infringement proceeding as a result of such Paragraph IV Certification (a “Paragraph IV Proceeding”) with respect to a Royalty Bearing Product, including by commencing a patent infringement action under 35 U.S.C. § 271(e)(2)(A), and shall bear the expense of any such Paragraph IV Proceeding and, if legally required, may commence such action
		

		
			
		

		
			

		 

		

			-  43  -

		

		

			 

		

		

		
			in 4DMT’s or the relevant 4DMT Affiliate’s name and on 4DMT’s or the relevant 4DMT Affiliate’s behalf.
		

		
			(iii)      Section 7.6(e) shall apply if any amount is recovered in any Paragraph IV Proceeding or settlement of any Paragraph IV Proceeding under this Section 7.9(b).
		

		
			7.10    CREATE Act.  Each Party acknowledges and agrees that this Agreement is a “joint research agreement” as contemplated by 35 U.S.C. § 102(c), and that all Inventions are intended to have the benefit of the rights and protections conferred by the Cooperative Research and Enhancement Act of 2004 (the “CREATE Act”).  In the event that a Party seeks to rely on the foregoing and to invoke the CREATE Act with respect to any Invention, such Party will give prior written notice to the other Party of its intent to invoke the CREATE Act and of each submission or disclosure such Party intends to make to the United States Patent and Trademark Office (the “USPTO”) pursuant to the CREATE Act, including: (a) any disclosure of the existence or contents of this Agreement to the USPTO, (b) the disclosure of any “subject matter developed by the other Party” (as such term is used in the CREATE Act) in an information disclosure statement or otherwise, or (c) the filing of any terminal disclaimer over the intellectual property of the other Party, it being agreed that no such submission, disclosure or filing shall be made by such Party without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed, except that no such consent shall be required to disclose to the USPTO, through an information disclosure statement or otherwise, any “subject matter developed by the other Party” that was previously published or included in a published patent application by the other Party.  The other Party will provide reasonable cooperation to such Party in connection with such Party’s efforts to invoke and rely on the CREATE Act.
		

		
			ARTICLE VIII
		

		
			 
		

		
			CONFIDENTIALITY AND PUBLICATION
		

		
			8.1      Confidentiality Obligations.  Each Party shall (a) maintain in confidence the Confidential Information of the other Party to the same extent such Party maintains its own confidential information, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the other Party, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement.  Such obligations shall survive for a period of [***] ([***]) years after termination or expiration of this Agreement, except that such obligations shall survive with respect to any Confidential Information identified by the disclosing Party as a trade secret for so long as such Confidential Information remains a trade secret.
		

		
			8.2      Exceptions to Confidentiality.  Notwithstanding the foregoing, the obligations of confidentiality set forth in Section 8.1 shall not apply to information that, in each case as demonstrated by competent written documentation:
		

		
			(a)        is publicly disclosed or made generally available to the public by the disclosing Party, either before or after it becomes known to the receiving Party;
		

		
			
		

		
			

		 

		

			-  44  -

		

		

			 

		

		

		
			(b)        was known to the receiving Party, without any obligation to keep it confidential, prior to the date of first disclosure by the disclosing Party to the receiving Party, as shown by the receiving Party’s files and records;
		

		
			(c)        is subsequently disclosed to the receiving Party by a Third Party lawfully in possession thereof without obligation to keep it confidential and without a breach of such Third Party’s obligations of confidentiality;
		

		
			(d)        has been publicly disclosed or made generally available to the public other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement; or
		

		
			(e)        has been independently developed by the receiving Party without the aid, application or use of the disclosing Party’s Confidential Information (the competent written proof of which must be contemporaneous with such independent development).
		

		
			8.3      Authorized Disclosure.  Notwithstanding Section 8.1, a Party may disclose Confidential Information of the other Party to the extent such disclosure is reasonably necessary in the following instances:
		

		
			(a)        Prosecuting and Maintaining Patent Rights in accordance with this Agreement;
		

		
			(b)        making filings with Regulatory Authorities in accordance with this Agreement;
		

		
			(c)        complying with applicable Laws or submitting information to tax or other Governmental Authorities; provided that if a Party is required by Law to make any public disclosure of Confidential Information of the other Party, to the extent it may legally do so, it will give reasonable advance notice to the other Party of such disclosure and will use its reasonable efforts to secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise);
		

		
			(d)        to its Affiliates, and to prospective and actual acquirers, licensees, sublicensees, employees, consultants, agents, accountants, lawyers, advisors, investors and underwriters, on a need to know basis, each of whom prior to disclosure must be bound by written or professional ethical obligations of confidentiality and non-use equivalent in scope to those set forth in this ARTICLE VIII and that are of reasonable duration in view of the circumstances of the disclosure; or
		

		
			(e)        to the extent mutually agreed to in writing by the Parties.
		

		
			8.4      Scientific Publications.  During the Research Term, neither Party shall first publish or first present in a public forum the scientific or technical results of any activity performed pursuant to this Agreement without the opportunity for prior review and comment by and obtaining the permission of the other Party, except that either Party may publish or first present in a public forum any information related to the Research Program and/or any pre-clinical or clinical results obtained by such Party pertaining to any New Capsid Variants, without the need
		

		
			
		

		
			

		 

		

			-  45  -

		

		

			 

		

		

		
			to obtain the other Party’s review or permission, provided that the publication or presentation does not disclose the sequence of any New Capsid Variant for which a Patent Right has not yet been filed under this Agreement, and provided in the case of uniQure that the publication must only present data and information as to a Royalty-Bearing Construct or Royalty-Bearing Product for which uniQure at that time holds a commercialization license under this Agreement, not a New Capsid Variant outside the context of a Royalty-Bearing Construct or Royalty-Bearing Product for which uniQure at that time holds a commercialization license under this Agreement.
		

		
			8.5      Press Releases and Other Permitted Disclosures.
		

		
			(a)        4DMT and uniQure each agree not to disclose any of the terms and conditions of this Agreement to any Third Party, except as described below in this Section 8.5.  The Parties will cooperate in the release of a mutually agreed upon press release announcing the collaboration contemplated by this Agreement as soon as practicable after the Effective Date.  Subject to the other provisions of this Agreement, no other press release, public statement or public disclosure concerning the existence or terms of this Agreement shall be made, either directly or indirectly, by either Party, without first obtaining the written approval of the other Party, which such approval shall not be unreasonably withheld or delayed beyond [***] ([***]) Business Days (or [***] ([***]) Business Days if the Party wishing to make such disclosure or any of its controlling Affiliates is then a public company) following submission to the approving Party of a draft of the respective press release, public statement or public disclosure.  In no event shall any such subsequent press release, public statement or public disclosure by 4DMT disclose, if previously undisclosed, the identity of any Construct or Product or the stage of development of any Construct or Product that uniQure is researching, Developing, manufacturing, or Commercializing; provided that for clarity, uniQure may disclose, without the written approval of 4DMT, the identity of any Construct or Product or the stage of development of any Construct or Product that uniQure is researching, Developing, manufacturing, or Commercializing.  In no event shall any such subsequent press release, public statement or public disclosure by a Party disclose, if previously undisclosed, the financial terms of this Agreement; provided that 4DMT may disclose the receipt of, and uniQure may disclose the payment of, any payment but not the amount of such payment; provided,  further,  however, that if disclosure of the amount of a payment is required by applicable Law, by applicable stock exchange regulation, or by order or other ruling of a competent court, as set forth in Section 8.5(c), then 4DMT or uniQure, as the case may be, may also disclose such amount in a public statement or disclosure.  Once any public statement or public disclosure has been approved in accordance with this Section 8.5, then either Party may appropriately communicate information contained in such permitted statement or disclosure.
		

		
			(b)        Either Party may disclose the existence and terms of this Agreement in confidence to its attorneys, to UC, and to each of the following, under an agreement with terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement and, as applicable, to use such information solely for the purpose permitted pursuant to the applicable subsection of this Section 8.5(b):
		

		
			(i)         professional accountants, consultants, or auditors;
		

		
			
		

		
			

		 

		

			-  46  -

		

		

			 

		

		

		
			(ii)       bankers or other financial advisors, in connection with an initial public offering, private financing or other strategic transaction, or corporate valuation for internal purposes;
		

		
			(iii)      potential acquirers (and their respective attorneys and professional advisors), in connection with a potential merger, acquisition or reorganization; provided that the Party making the disclosure has a bona fide offer (e.g., a signed term sheet or letter of intent, even if non-binding) from such Third Party for such a transaction;
		

		
			(iv)       to actual or potential investors, lenders or permitted assignees of such Party (and their respective attorneys and professional advisors); or
		

		
			(v)        to actual or potential licensees or sublicensees of such Party (and their respective attorneys and professional advisors); provided that such disclosure in the case of 4DMT shall not include any financial terms, the Delivery Success Criteria, nor any other contents of the Research Plan for Liver nor the Research Plan for CNS.
		

		
			(c)        Notwithstanding the foregoing provisions of this ARTICLE VIII, a Party may disclose the existence and terms of this Agreement, however excluding, as far as legally possible, Schedule 2, or the Parties’ activities under this Agreement, where required, as reasonably determined by the legal counsel of the disclosing Party, by applicable Law, by applicable stock exchange regulation or by order or other ruling of a competent court, although, to the extent practicable, the other Party shall be given [***] ([***]) Business Days advance notice of any such legally required disclosure to comment and reasonably consider such comments provided by such other Party on the proposed disclosure.  In case either Party is obliged to publish this Agreement as a “material agreement” in accordance with the U.S. stock exchange regulations (“SEC Filing”), this Agreement shall be redacted by the filing Party as far as legally possible, and the filing Party shall cooperate with the other Party reasonably in advance to such SEC Filing to enable the other Party to review and comment on the scope of such redaction.
		

		
			ARTICLE IX
		

		
			 
		

		
			REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION
		

		
			9.1      Representations and Warranties of the Parties.  uniQure and 4DMT each represent, warrant and covenant to the other that:
		

		
			(a)        as of the Effective Date, it has the authority and right to enter into and perform this Agreement and grant the rights embodied herein, and it is not aware of any legal impediment that could inhibit its ability to perform its obligations under this Agreement;
		

		
			(b)        as of the Effective Date, its execution, delivery and performance of this Agreement does not conflict with, or constitute a breach of, any order, judgment, agreement or instrument to which it is a party or is otherwise bound;
		

		
			(c)        it shall comply in all material respects with all Laws applicable to its actions under this Agreement; and
		

		
			
		

		
			

		 

		

			-  47  -

		

		

			 

		

		

		
			(d)        as of the Effective Date, no consent of any Third Party is required for such Party to grant the licenses and rights granted to the other Party under this Agreement or to perform its obligations hereunder.
		

		
			9.2      Representations and Warranties of 4DMT.  4DMT represents, warrants and covenants to uniQure that:
		

		
			(a)        [Intentionally omitted.]
		

		
			(b)        as of the Effective Date, 4DMT has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in 4DMT Intellectual Property in a manner inconsistent with the terms hereof;
		

		
			(c)        as of the Effective Date, 4DMT has valid and existing licenses, free and clear of all liens, charges and encumbrances, to the 4DMT Patent Rights not owned by 4DMT;
		

		
			(d)        as of the Effective Date, to 4DMT’s knowledge, the conception, development and reduction to practice of the 4DMT Intellectual Property has not constituted or involved the misappropriation of trade secrets of any Third Party or the infringement of issued Patent Rights of any Third Party;
		

		
			(e)        as of the Effective Date, 4DMT has not received any written notice of any unauthorized use, infringement, or misappropriation by any person or entity, including any current or former employee or consultant of 4DMT, of any 4DMT Intellectual Property;
		

		
			(f)        as of the Effective Date, to 4DMT’s knowledge, there are no claims, judgments, settlements pending or any action with respect to the 4DMT Intellectual Property;
		

		
			(g)        as of the Effective Date, to 4DMT’s knowledge, uniQure’s use of the 4DMT Intellectual Property, as reasonably anticipated to be used in the conduct of the Research Program, will not infringe any valid Patent Right existing as of the Effective Date and owned by any Third Party;
		

		
			(h)        all of 4DMT’s personnel and employees, and Third Parties, including agents and consultants, hired by 4DMT and involved in the Research Program are, or when hired will be, under a written obligation to assign to 4DMT any right they may have in any Invention first invented, discovered, made, conceived or reduced to practice in the conduct of activities pursuant to the Research Program, and all intellectual property rights therein;
		

		
			(i)         it will not, after the Effective Date, enter into any written or oral contractual obligation with any Third Party that would be inconsistent with the obligations that arise on its part out of this Agreement or that would deprive uniQure of the benefits of or rights granted under this Agreement;
		

		
			(j)         as of the Effective Date, each of the UCB Agreements is in full force and effect, and 4DMT will not, after the Effective Date, terminate, amend or otherwise modify any of the terms thereof without prior written consent from uniQure, or take any action or refrain from taking any action that would permit UC to terminate any UCB Agreement (it being recognized
		

		
			
		

		
			

		 

		

			-  48  -

		

		

			 

		

		

		
			that if the New Capsid Variants are not UC AAV Capsid Variants, and UC terminates any UCB Agreement, 4DMT shall not be deemed to be in breach of the foregoing), and 4DMT shall promptly provide uniQure with a copy of each notice it receives from UC under any UCB Agreement; and
		

		
			(k)        if, during the Term, 4DMT has reason to believe that it or any of its employees, officers, subcontractors, or consultants rendering services hereunder (i) is or shall be debarred or convicted of a crime under 21 U.S.C. Section 335a, or (ii) is or shall be under indictment under said Section 335a, then 4DMT shall immediately notify uniQure in writing.
		

		
			For purposes of this Section 9.2, “knowledge” shall mean the actual knowledge of 4DMT, including [***].
		

		
			9.3      Representations and Warranties of uniQure.  uniQure represents, warrants and covenants to 4DMT that:
		

		
			(a)        all of uniQure’s personnel and employees, and Third Parties, including agents and consultants, hired by uniQure and involved in the Research Program are, or when hired will be, under a written obligation to assign to uniQure any right they may have in any Invention first invented, discovered, made, conceived or reduced to practice in the conduct of activities pursuant to the Research Program, and all intellectual property rights therein;
		

		
			(b)        it will not, after the Effective Date, enter into any written or oral contractual obligation with any Third Party that would be inconsistent with the obligations that arise on its part out of this Agreement or that would deprive 4DMT of the benefits of or rights granted under this Agreement;
		

		
			(c)        if, during the Term, uniQure has reason to believe that it or any of its employees, officers, subcontractors, or consultants rendering services hereunder (i) is or shall be debarred or convicted of a crime under 21 U.S.C. Section 335a, or (ii) is or shall be under indictment under said Section 335a, then uniQure shall immediately notify 4DMT in writing.
		

		
			9.4      No Other Warranties.
		

		
			(a)        EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND PARTICULARLY THAT PRODUCT(S) WILL BE SUCCESSFULLY DEVELOPED HEREUNDER, AND IF PRODUCT(S) ARE DEVELOPED, WITH RESPECT TO SUCH PRODUCT(S), THE PARTIES DISCLAIM ALL IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.
		

		
			(b)        uniQure acknowledges that UC has not warranted to 4DMT under the UCB Agreements as to the validity of any Patent Rights or that practice under such Patent Rights shall be free of infringement.  UNIQURE, ITS AFFILIATES AND ITS SUBLICENSEE(S) AGREE THAT (I) THE LICENSES GRANTED PURSUANT TO THE UCB AGREEMENTS, THE UC AAV CAPSID VARIANTS, AND THE ASSOCIATED INVENTIONS ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
		

		
			
		

		
			

		 

		

			-  49  -

		

		

			 

		

		

		
			PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED; (II) UC MAKES NO REPRESENTATION OR WARRANTY THAT ANY INVENTION CLAIMED BY THE UC PATENT RIGHTS, THE UC AAV CAPSID VARIANTS, THE UC PATENT RIGHTS, OR THE UC PRODUCTS WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT; AND (III) IN NO EVENT WILL UC BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THE LICENSES GRANTED PURSUANT TO THE UCB AGREEMENTS OR THE USE OF ANY INVENTION CLAIMED BY THE UC PATENT RIGHTS, THE UC AAV CAPSID VARIANTS, THE UC PATENT RIGHTS, OR THE UC PRODUCTS.
		

		
			9.5      Indemnification by uniQure.  uniQure shall indemnify, hold harmless and defend 4DMT, its Affiliates and all of their respective officers, directors, employees, agents and shareholders (collectively, the “4DMT Indemnitees”) from and against any and all losses, damages, liabilities, judgments, fines, amounts paid in settlement, expenses and costs of defense (including reasonable attorneys’ fees and witness fees) (collectively, “Damages”) resulting from any demand, claim, action or proceeding brought or initiated by a Third Party (each a “Third Party Claim”) against any 4DMT Indemnitee to the extent arising out of: (a) a Default by uniQure; (b) the negligence or willful misconduct of a uniQure Indemnitee; or (c) the use, Development, Commercialization, storage or other exploitation of any Construct or Product by uniQure, its Affiliates, Sublicensees, Third Party Distributors, or Third Party independent contractors; provided that (i) the 4DMT Indemnitees shall comply with the procedures set forth in Section 9.7(a); and (ii) such indemnity shall not apply to the extent such Third Party Claim is subject to indemnification by 4DMT under Section 9.6.
		

		
			9.6      Indemnification by 4DMT.  4DMT shall indemnify, hold harmless and defend uniQure, its Affiliates and all of their respective officers, directors, employees, agents, and shareholders (collectively, the “uniQure Indemnitees”) from and against any and all Damages resulting from any Third Party Claim against any uniQure Indemnitee to the extent arising out of: (a) a Default by 4DMT; (b) the negligence or willful misconduct of a 4DMT Indemnitee; or (c) the use, Development, Commercialization, storage or other exploitation of any 4DMT AAV Capsid Variant, Construct or Product (other than a uniQure Product Developed, or Commercialized by uniQure, its Affiliate, or Sublicensee) by 4DMT, its Affiliates, Sublicensees or Third Party independent contractors; provided that (i) the uniQure Indemnitees shall comply with the procedures set forth in Section 9.7(b); and (ii) such indemnity shall not apply to the extent such Third Party Claim is subject to indemnification by uniQure under Section 9.5.
		

		
			9.7      Procedure.
		

		
			(a)        To be eligible for the 4DMT Indemnitees to be indemnified hereunder, 4DMT shall provide uniQure with prompt notice of the Third Party Claim giving rise to the indemnification obligation under Section 9.5 and the exclusive ability to defend or settle any such claim; provided however that uniQure shall not enter into any settlement for damages, or that imposes upon 4DMT any obligation or liability, without 4DMT’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned. 4DMT shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by uniQure.
		

		
			
		

		
			

		 

		

			-  50  -

		

		

			 

		

		

		
			(b)        To be eligible for the uniQure Indemnitees to be indemnified hereunder, uniQure shall provide 4DMT with prompt notice of the Third Party Claim giving rise to the indemnification obligation under Section 9.6 and the exclusive ability to defend or settle any such claim; provided however that 4DMT shall not enter into any settlement for damages, or that imposes upon uniQure any obligation or liability, without uniQure’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned.  uniQure shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by 4DMT.
		

		
			9.8      uniQure Indemnity to UC.  uniQure shall, and shall require its Sublicensees to, indemnify, defend, and hold harmless UC and IGT, and their officers, employees, and agents; sponsor(s) of the research that led to the inventions disclosed in the UC Patent Rights and the UC AAV Capsid Variants; and the inventors of any UC Patent Rights and their employers against any and all losses, damages, costs, fees, and expenses resulting from Third Party claims and suits arising out of uniQure’s activities under this Agreement or of any Sublicensee activities under any sublicense agreement granting rights under the UC Patent Rights or the UC AAV Capsid Variants, or any use or possession of the UC AAV Capsid Variants resulting from uniQure’s exploitation of its rights thereto.  This indemnification will include any product liability claims.  uniQure will keep UC informed of its defense of any claims pursuant to this Section 9.8, and UC will cooperate reasonably in any such suit.  If UC invokes the provisions of this Section 9.8, UC will not make any admissions or take any actions in such claim or suit that may prejudice or impair uniQure’s ability to defend such claim or suit without uniQure’s prior written consent, and uniQure will not admit liability or wrongdoing on behalf of UC without UC’s prior written consent.
		

		
			9.9      Insurance.  Each Party shall procure and maintain insurance or self-insurance, including general liability insurance and product liability insurance, adequate to cover its obligations hereunder and that are consistent with normal business practices of prudent companies similarly situated, at all times during which any Research Construct, Royalty Bearing Construct, or Royalty Bearing Product is being Developed, clinically tested in human subjects or Commercialized by or on behalf of such Party, its Affiliates or sublicensees, including, in the case of uniQure, its Sublicensees.  It is understood that any such insurance or self-insurance shall not be construed to create a limit of a Party’s liability with respect to its indemnification obligations under this ARTICLE IX.  Each Party shall provide the other Party with written evidence of such insurance or self-insurance upon request.  Each Party shall provide the other Party with written notice at least [***] ([***]) days prior to the cancellation, non-renewal or material change in such insurance or self-insurance which could adversely affect rights hereunder.  Without limiting the generality of the foregoing:
		

		
			(a)        uniQure, at its sole cost and expense, will ensure that the applicable entity performing activities in connection with any work performed hereunder, whether uniQure, an Affiliate, or a Sublicensee, will obtain, keep in force, and maintain the following insurance:
		

		
			(i)         prior to the start of Clinical Trials of a UC Product, commercial form general liability insurance (contractual liability included) with limits as follows:
		

		
			 
		

		
			
		

		
			

		 

		

			-  51  -

		

		

			 

		

		

		
			 
		

			
					
						Each Occurrence 

					
					
						$[***]

				
	
					
						Products/Completed Operations Aggregate

					
					
						$[***]

				
	
					
						Personal and Advertising Injury

					
					
						$[***]

				
	
					
						General Aggregate

					
					
						$[***]

				

		
			 
		

		
			(ii)       Upon the start of any Clinical Trials of a UC Product, commercial form general liability insurance (contractual liability included), and product liability insurance if not otherwise included, with limits as follows:
		

		
			 
		

			
					
						Each Occurrence

					
					
						$[***]

				
	
					
						Products/Completed Operations Aggregate

					
					
						$[***]

				
	
					
						Personal and Advertising Injury

					
					
						$[***]

				
	
					
						General Aggregate

					
					
						$[***]

				

		
			 
		

		
			(iii)      Upon the First Commercial Sale of a UC Product, commercial form general liability insurance (contractual liability included), and product liability insurance if not otherwise included, with limits as follows:
		

			
					
						 

					
						 

					
						 

					
						 

					
					
						 

					
						 

					
						 

					
						 

				
	
					
						Each Occurrence

					
					
						$[***]

				
	
					
						Products/Completed Operations Aggregate

					
					
						$[***]

				
	
					
						Personal and Advertising Injury

					
					
						$[***]

				
	
					
						General Aggregate

					
					
						$[***]

				

		
			 
		

		
			If the above insurance is written on a claims-made form, it shall continue for [***] ([***]) years following termination or expiration of this Agreement.
		

		
			(iv)       worker’s compensation as legally required in the jurisdiction in which uniQure, an Affiliate, or a Sublicensee, as applicable, is doing business.
		

		
			uniQure will promptly notify UC of any material reduction in the insurance coverages below the amounts required hereunder.
		

		
			(b)        Within [***] ([***]) days after the Effective Date, uniQure will furnish 4DMT with certificates of insurance evidencing compliance with all requirements.  Such certificates will:
		

		
			(i)         where possible, provide for [***] ([***]) days’ ([***] ([***]) days for non-payment of premium) advance written notice to 4DMT and UC of any cancellation of insurance coverages described above in Section 9.9(a);
		

		
			(ii)       indicate that 4DMT and UC have been endorsed as additional insureds under the coverage described above in Section 9.9(a); and
		

		
			
		

		
			

		 

		

			-  52  -

		

		

			 

		

		

		
			(iii)      include a provision that the coverages described above in Section 9.9(a) will be primary and will not participate with, nor will be excess over, any valid and collectable insurance or program of self-insurance maintained by 4DMT or UC.
		

		
			9.10    No Consequential or Punitive Damages.  EXCEPT WITH RESPECT TO (a) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER THIS AGREEMENT WITH RESPECT TO THIRD PARTY CLAIMS, (b) A BREACH OF THE CONFIDENTIALITY OBLIGATIONS OF ARTICLE VIII, (c) A BREACH OF SECTION 5.6, OR (d) A PARTY’S WILLFUL MISCONDUCT, NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES.
		

		
			ARTICLE X
		

		
			 
		

		
			TERM AND TERMINATION
		

		
			10.1    Term and Expiration.  This Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to Section 10.2, this Agreement shall continue in effect until the expiration of all of uniQure’s and 4DMT’s payment obligations hereunder (the “Term”).  Upon expiration, all licenses granted hereunder shall be fully paid-up, perpetual and irrevocable.
		

		
			10.2    Termination.
		

		
			(a)        Termination of Agreement for Cause.
		

		
			(i)         This Agreement may be terminated at any time during the Term upon written notice by either Party (the “Non-Defaulting Party”) upon Default of the other Party (the “Defaulting Party”), which Default remains uncured for ninety (90) days after written notice requesting cure of such Default.  The Non-Defaulting Party shall provide written notice to the Defaulting Party, which notice shall identify the Default, the intent to so terminate and the actions or conduct that it considers would be an acceptable cure of such Default.  If the Defaulting Party disputes the Default under this Section 10.2(a), then the issue of whether the Non-Defaulting Party may properly terminate this Agreement on expiration of the applicable cure period shall be resolved in accordance with ARTICLE XI.  If, as a result of such dispute resolution process, it is determined that the alleged Defaulting Party committed a Default and the Defaulting Party does not cure such Default within sixty (60) days after the date of such dispute resolution award (the “Additional Cure Period”), then such termination shall be effective as of the expiration of the Additional Cure Period.  If the Parties dispute whether such Default was so cured, either Party alone may request the same tribunal to determine whether it was so cured, and the Parties shall cooperate to allow such determination to be made within thirty (30) days after such request by either Party.  Any such dispute resolution proceeding does not suspend any obligation of either Party hereunder, and each Party shall use reasonable efforts to mitigate any damage.  If, as a result of any such dispute resolution proceeding, it is determined that the alleged Defaulting Party did not commit such Default (or such Default was cured in accordance with this Section 10.2(a)), then no termination shall be effective, and this Agreement shall continue in full force and effect.
		

		
			
		

		
			

		 

		

			-  53  -

		

		

			 

		

		

		
			Notwithstanding the foregoing, if the claimed Default relates to one or more Royalty-Bearing Constructs or Royalty-Bearing Products, and not this entire Agreement, then this Agreement shall be terminated only with respect to the Indication for which such Royalty-Bearing Construct(s) or Royalty-Bearing Product(s) were intended to treat and if uniQure was the Defaulting Party then additionally such Indication shall be removed from the Field.
		

		
			(b)        Termination for Bankruptcy.  To the extent allowed under applicable Law, either Party shall have the right to terminate this Agreement in the event of the commencement of any proceeding in or for bankruptcy, insolvency, dissolution or winding up by or against the other Party (other than pursuant to a corporate restructuring) that is not dismissed or otherwise disposed of within sixty (60) days thereafter.
		

		
			(c)        Termination for Futility.  uniQure shall have the right terminate this Agreement immediately upon written notice to 4DMT summarizing the basis for such termination if, at any point prior to the first (1st) anniversary of the Effective Date, the JRSC determines that (i) it would be futile to continue the Research Program, including if the JRSC determines that any Delivery Success Criteria cannot be met through use of the 4DMT Intellectual Property following the reasonable efforts of 4DMT to achieve such Delivery Success Criteria or (ii) 4DMT is not making bona fide efforts to achieve the timelines set forth in the Research Plan.
		

		
			(d)        Termination for Convenience.  uniQure shall have the right terminate this Agreement at any time after the Research Term, for any reason or for no reason, by giving 4DMT ninety (90) days’ prior written notice thereof.
		

		
			10.3    Effect of Termination
		

		
			(a)        If uniQure terminates this Agreement under Section 10.2(a) or Section 10.2(b):
		

		
			(i)         uniQure’s licenses pursuant to this Agreement shall continue; provided however that uniQure shall continue to fulfill uniQure’s payment obligations with respect to royalties and Sublicense Consideration under ARTICLE VI; and provided further that uniQure may reduce such payment obligations by the amount of monetary damage suffered by uniQure as a direct result of 4DMT’s Default, as determined (A) in a final decision of the arbitrators in accordance with Section 11.2 or, with respect to an Excluded Claim, a court of competent jurisdiction, which decision is not appealable or has not been appealed within the time allowed for appeal, or (B) by the Parties in a settlement agreement;
		

		
			(ii)       4DMT shall, within [***] ([***]) days after the effective date of such termination, return or cause to be returned to uniQure, copies of all uniQure’s Confidential Information and uniQure Intellectual Property and all Materials provided by uniQure, except that 4DMT may retain one copy of uniQure’s Confidential Information solely for legal archive purposes and to exercise the licenses granted to 4DMT which survive termination of this Agreement;
		

		
			(iii)      For clarity, uniQure shall be released of its ongoing diligence obligations under Section 4.4 (if any) and uniQure and 4DMT shall be released of their disclosure and information exchange obligations under ARTICLE III and ARTICLE IV;
		

		
			
		

		
			

		 

		

			-  54  -

		

		

			 

		

		

		
			(iv)       For clarity, the JRSC and its subcommittees shall not meet anymore; and
		

		
			Notwithstanding the foregoing, if such termination is under Section 10.2(a) solely with respect to one or more  given Indication(s), then uniQure’s licenses pursuant to Section 5.1  will not terminate but the Field is automatically narrowed to exclude the relevant Indication(s); the license granted to 4DMT under Section 5.2(b) shall be automatically adjusted to include the relevant Indication(s) rather than all fields of use; and uniQure’s obligations under subsection (ii) shall be limited to copies of 4DMT’s Confidential Information and 4DMT Intellectual Property and Materials that relate solely to the relevant Indication(s).
		

		
			(b)        Upon termination of this Agreement by uniQure under Section 10.2(c) or Section 10.2(d), or by 4DMT under Section 10.2(a) or Section 10.2(b):
		

		
			(i)         For clarity, uniQure’s licenses pursuant to Section 5.1 and Step-In Rights under Section 4.4 shall terminate as of the effective date of such termination;
		

		
			(ii)       Effective as of the effective date of such termination, the license granted to 4DMT under Section 5.2(b) shall be automatically expanded to include the New Capsid Variants and all fields of use;
		

		
			(iii)      uniQure shall, within [***] ([***]) days after the effective date of such termination, return or cause to be returned to 4DMT, copies of all 4DMT’s Confidential Information and 4DMT Intellectual Property and all Materials provided by 4DMT; except that uniQure may retain one copy of the 4DMT Confidential Information solely for legal archive purposes;
		

		
			(iv)       4DMT shall, within [***] ([***]) days after the effective date of such termination, return or cause to be returned to uniQure, copies of all uniQure’s Confidential Information and uniQure Intellectual Property and all Materials provided by uniQure, except that 4DMT may retain one copy of uniQure’s Confidential Information solely for legal archive purposes and to exercise the licenses granted to 4DMT which survive termination or are granted upon termination of this Agreement; and
		

		
			(v)        For a period of [***] ([***]) months, if termination occurs after Regulatory Approval of Royalty Bearing Products, uniQure and its Affiliates shall be entitled to finish work in progress and to sell any of the Royalty Bearing Products remaining in inventory in accordance with the terms of this Agreement to the extent such Royalty Bearing Products were being sold in the Territory at the time of termination, provided that such sales shall be subject to the royalty provisions of this Agreement.
		

		
			10.4    Effect of Expiration or Termination; Survival.
		

		
			(a)        Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination.  Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including the obligation to pay royalties for Royalty Bearing Product(s) sold prior to such expiration or
		

		
			
		

		
			

		 

		

			-  55  -

		

		

			 

		

		

		
			termination.  Termination of this Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the reason for the termination.
		

		
			(b)        The provisions of ARTICLE I, ARTICLE VII (but not Sections 7.4(c) nor 7.6-7.9), ARTICLE VIII, ARTICLE XI, ARTICLE XII, and Sections 4.5, 5.2(b), 5.4, 5.5, 5.6, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 9.10, 10.3 and 10.4 shall survive any expiration or termination of this Agreement, and with respect to those Royalty Bearing Products in such countries for which uniQure retains a Development and Commercialization license after the expiration or termination of this Agreement, the provisions of ARTICLE VI shall also survive as to uniQure Products in such countries.
		

		
			ARTICLE XI
		

		
			 
		

		
			DISPUTE RESOLUTION
		

		
			11.1    Seeking Consensus.  If any dispute arises out of, in connection with or related to this Agreement, including disputes over the interpretation, performance, enforcement or breach of this Agreement, including any dispute that is not within the jurisdiction of the JRSC, (a “Dispute”), excluding any dispute resolved in accordance with Section 2.3(c) (subject to Section 2.3(d)), then upon the written request of either Party, the matter shall be referred to the Executives, who shall meet in a good faith effort to resolve the dispute within [***] ([***]) days.  If the Parties’ Executives cannot agree on a resolution of the Dispute within such [***] ([***]) day period, then it shall be resolved pursuant to the remaining provisions of this ARTICLE XI.
		

		
			11.2    Arbitration.  If the Parties do not fully settle a Dispute pursuant to Section 2.3 (only as to those matters that may be referred to arbitration) or 11.1, as applicable, and a Party wishes to pursue the matter, each such Dispute that is not an Excluded Claim (as defined below) shall be finally resolved by binding arbitration in accordance with the Rules of Arbitration of the ICC (International Chamber of Commerce) and judgment on the arbitration award may be entered in any court having jurisdiction thereof.
		

		
			(a)        The arbitration shall be conducted by a panel of three (3) persons.  Within [***] ([***]) days after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within [***] ([***]) days after their appointment.  If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the ICC.  The place of arbitration shall be New York City, New York, and all proceedings and communications shall be in English.
		

		
			(b)        Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the Dispute is otherwise resolved.  Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award.  The scope of the authority of the arbitrators shall be limited to the strict application of law.  The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages, except as permitted by Section 9.10.
		

		
			
		

		
			

		 

		

			-  56  -

		

		

			 

		

		

		
			Each Party participating in an arbitration pursuant to the terms of this Agreement shall, [***].  The arbitrators shall have the power to award recovery of all costs (including reasonable attorney’s fees, administrative fees, arbitrators’ fees and court costs) to the prevailing Party.
		

		
			(c)        Neither Party shall be required to give general discovery of documents, but may be required to produce documents or testimony that are relevant or considered relevant by the arbitrators to the Dispute.  It is the objective and intent of the Parties that any arbitration proceeding be conducted in such a manner that a decision will be rendered by the arbitrators within [***] ([***]) days after the third arbitrator is appointed to the panel, and the Parties and the panel selected in the manner provided above will adopt rules and procedures intended to implement such objective and intent.
		

		
			(d)        Except to the extent necessary to confirm or vacate an award or as may be required by Law (including applicable securities laws or the rules of any stock exchange on which a Party’s securities may then be listed), neither a Party nor an arbitrator may disclose the existence, content, or results of arbitration without the prior written consent of both Parties.  In no event shall arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations.
		

		
			(e)        The Parties agree that any payment made pursuant to this Agreement pending resolution of the Dispute shall be refunded or credited if the arbitrators or court determines that such payments are not due.
		

		
			As used in this Section 11.2, the term “Excluded Claim” shall mean a Dispute that concerns (a) the validity, enforceability, scope or infringement of a patent, trademark or copyright; or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory.
		

		
			ARTICLE XII
		

		
			 
		

		
			MISCELLANEOUS
		

		
			12.1    Governing Law.  This Agreement shall be governed by and construed in accordance with the Laws of the State of New York, other than any principle of conflict or choice of laws that would cause the application of the Laws of any other jurisdiction.
		

		
			12.2    Waiver.  Waiver by a Party of a breach hereunder by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision.  No delay or omission by a Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder shall operate as a waiver of any right, power or privilege by such Party.  No waiver shall be effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the Party granting the waiver.
		

		
			12.3    Notices.  All notices, instructions and other communications hereunder or in connection herewith shall be in writing, shall be sent to the address specified in this Section 12.3 and shall be: (a) delivered personally; (b) transmitted by facsimile; (c) sent by registered or certified mail, return receipt requested, postage prepaid; or (d) sent via a reputable international
		

		
			
		

		
			

		 

		

			-  57  -

		

		

			 

		

		

		
			overnight delivery service.  Any such notice, instruction or communication shall be deemed to have been delivered (i) upon receipt if delivered by hand, (ii) when transmitted with electronic confirmation of receipt, if transmitted by facsimile (if such transmission is on a Business Day; otherwise, on the next Business Day following such transmission), provided that an original document is sent via an internationally recognized overnight delivery service (receipt requested), (iii) three (3) Business Days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) Business Day after it is sent via a reputable international overnight delivery service.
		

			
					
						If to 4DMT, to:

					
					
						4D Molecular Therapeutics, Inc.
5858 Horton St

					
						Emerystation North, Suite 460

					
						Emeryville, CA 94608

					
						Attention: CEO
Facsimile:

				
	
					
						 

					
					
						 

				
	
					
						with a copy to:

					
					
						Latham & Watkins LLP
140 Scott Drive
Menlo Park, CA 94025
Attention:  [***]
Facsimile:  [***]

				
	
					
						 

					
					
						 

				
	
					
						And a required email copy to:

					
					
						[***]

				
	
					
						 

					
					
						 

				
	
					
						If to uniQure, to:

					
					
						uniQure biopharma B.V.
P.O. Box 22506
1100 DA Amsterdam
The Netherlands
Attention:  CEO
Facsimile:  [***]

				
	
					
						 

					
					
						 

				
	
					
						with a copy to:

					
					
						[***]

				

		
			 
		

		
			or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith.
		

		
			12.4    Entire Agreement; Amendment.  This Agreement (including its Exhibits and Schedules) contains the complete understanding of the Parties with respect to the subject matter hereof and supersedes all prior understandings and writings relating to such subject matter.  In particular, it supersedes and replaces the Prior Confidentiality Agreement and any and all term sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties or their Affiliates prior to the Effective Date.  No amendment, change or addition to this Agreement will be effective or binding on either Party unless reduced to writing and duly executed on behalf of both Parties.
		

		
			
		

		
			

		 

		

			-  58  -

		

		

			 

		

		

		
			12.5    Headings.  Headings in this Agreement are for convenience of reference only and shall not be considered in construing this Agreement.
		

		
			12.6    Severability.  If any provision or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same shall not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible.  In any such event, this Agreement shall be construed as if such clause of portion thereof had never been contained in this Agreement, and there shall be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by applicable Law.
		

		
			12.7    Assignment.  Neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred by any Party without the consent of the other Party; provided,  however, that any Party may, without such consent, assign this Agreement, in whole or in part: (a) to any of its respective Affiliates; provided that the assigning Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned, or (b) to any successor in interest by way of merger, acquisition or sale of all or substantially all of its assets to which this Agreement relates (an “M&A Event”).  Any assignment not in accordance with this Section 12.7 shall be void.  Each Party agrees that, notwithstanding any provision of this Agreement to the contrary, neither the assignment of this Agreement by a Party in connection with an M&A Event, nor the occurrence of such M&A Event (whether or not a formal assignment of this Agreement occurs), shall provide the non-assigning Party with rights or access to any intellectual property or technology of the acquirer of the assigning Party or its Affiliates that were not Affiliates of the assigning Party prior to such M&A Event.  If uniQure assigns its rights and obligations hereunder to an Affiliate or Third Party outside the United States or The Netherlands pursuant to this Section 12.7, and if such Affiliate or Third Party shall be required by applicable Law to withhold additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment, then any such amount payable under this Agreement shall be increased to take into account the additional taxes withheld as may be necessary so that, after making all required withholdings, 4DMT receives an amount equal to the sum it would have received had no such assignment been made.
		

		
			12.8    Counterparts.  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.  Signatures provided by facsimile transmission or in Adobe Portable Document Format (PDF) sent by electronic mail shall be deemed to be original signatures.
		

		
			12.9    Force Majeure.  No Party shall be liable for failure of or delay in performing obligations (other than payment obligations) set forth in this Agreement, and no Party shall be deemed in breach of its obligations, if such failure or delay is due to a natural disaster, explosion, fire, flood, tornado, thunderstorm, hurricane, earthquake, war, terrorism, riot, embargo, loss or shortage of power, labor stoppage, substance or material shortage, events caused by reason of laws of any Governmental Authority, events caused by acts or omissions of a Third Party or any other cause reasonably beyond the control of such Party, if the Party affected gives prompt notice of any such cause to the other Party.  The Party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it
		

		
			
		

		
			

		 

		

			-  59  -

		

		

			 

		

		

		
			is so disabled, provided,  however, that such affected Party commences and continues to use its Commercially Reasonable Efforts to cure such cause.
		

		
			12.10  Third Party Beneficiaries.  None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party, other than a 4DMT Indemnitee under Section 9.5 or uniQure Indemnitee under Section 9.6.  No such Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either Party.
		

		
			12.11  Relationship of the Parties.  Each Party shall bear its own costs incurred in the performance of its obligations hereunder without charge or expense to the other, except as expressly provided in this Agreement.  Neither Party shall have any responsibility for the hiring, termination or compensation of the other Party’s employees or for any employee compensation or benefits of the other Party’s employees.  No employee or representative of a Party shall have any authority to bind or obligate the other Party for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on the other Party without said other Party’s approval.  For all purposes, and notwithstanding any other provision of this Agreement to the contrary, the legal relationship under this Agreement of each Party to the other Party shall be that of independent contractor.  Nothing in this Agreement shall be construed to establish a relationship of partners or joint ventures between the Parties.
		

		
			12.12  Performance by Affiliates.  To the extent that this Agreement imposes obligations on Affiliates of a Party or permits a Party to exercise its rights or perform its obligations through its Affiliates, such Party agrees to cause its Affiliates to perform such obligations and shall guarantee performance of this Agreement by its Affiliates.  If any disagreement arises out of the performance of this Agreement by an Affiliate of a Party, or the alleged failure of an Affiliate to comply with the conditions and obligations of this Agreement, the Party seeking to resolve such dispute shall have the right do so directly with the other Party, without any obligation to first pursue an action against, or recovery from, the Affiliate which is alleged to have caused a breach of this Agreement.
		

		
			12.13  Construction.  Each Party acknowledges that it has been advised by counsel during the course of negotiation of this Agreement, and, therefore, that this Agreement shall be interpreted without regard to any presumption or rule requiring construction against the Party causing this Agreement to be drafted.  Any reference in this Agreement to an ARTICLE, Section, subsection, paragraph, clause, or Schedule shall be deemed to be a reference to any article, section, subsection, paragraph, clause, schedule or exhibit, of or to, as the case may be, this Agreement.  Except where the context otherwise requires, (a) wherever used, the use of any gender will be applicable to all genders; (b) the word “or” is used in the inclusive sense (and/or); (c) any definition of or reference to any agreement, instrument or other document refers to such agreement, instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restriction on such amendments, supplements or modifications set forth herein or therein); (d) any reference to any Law refers to such Law as from time to time enacted, repealed or amended; (e) the words “herein”, “hereof” and hereunder”, and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof; and (f) the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “but not limited to”, “without limitation” or words of similar import.
		

		
			
		

		
			

		 

		

			-  60  -

		

		

			 

		

		

		
			[Signature page follows]
		

		
			 
		

		
			
		

		
			

		 

		

			-  61  -

		

		

			 

		

		

		
			IN WITNESS WHEREOF, the Parties have executed this Collaboration and License Agreement as of the New CLA Effective Date.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						UNIQURE BIOPHARMA B.V.

					
					
						    

					
					
						4D MOLECULAR THERAPEUTICS, INC.

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						BY:

					
					
						s/s Lilly Burggraaf

					
					
						 

					
					
						BY:

					
					
						s/s David Kirn

				
	
					
						NAME:

					
					
						Lilly Burggraaf

					
					
						 

					
					
						NAME:

					
					
						David Kirn, MD

				
	
					
						TITLE: 

					
					
						Vice President, Global Human Resources

					
					
						 

					
					
						TITLE:

					
					
						Chief Executive Officer

				

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			-  62  -

		

		

			 

		

		

		
			SCHEDULE 1
		

		
			DRAFT INVOICE
		

		
			[***]
		

		
			 
		

		
			 
		

		
			

		 

		

			 SCHEDULE 1.47 - Page 1

		

		

			 

		

		

		
			 
		

		
			SCHEDULE 2
		

		
			RESEARCH PLAN
		

		
			[***]
		

		
			 
		

		
			 
		

		
			

		 

		

			SCHEDULE 1.66- Page 1

		

		

			 

		

		

		
			 
		

		
			 
		

		
			SCHEDULE 3
		

		
			SELECTED CAPSID VARIANTS
		

		
			[***]Exhibit

PORTLAND GENERAL ELECTRIC COMPANY

TO

WELLS FARGO BANK, NATIONAL ASSOCIATION
(AS SUCCESSOR TO HSBC BANK USA, NATIONAL ASSOCIATION)
Trustee.

Seventy-sixth Supplemental Indenture

Dated:  October 15, 2019

$270,000,000 First Mortgage Bonds,
3.34% Second Series due 2049
3.34% Series due 2050

Supplemental to Indenture of Mortgage and Deed of Trust,
dated July 1, 1945 of Portland General Electric Company.

THIS INSTRUMENT GRANTS A SECURITY INTEREST BY A TRANSMITTING UTILITY
THIS INSTRUMENT CONTAINS AFTER-ACQUIRED PROPERTY PROVISIONS

This SEVENTY-SIXTH SUPPLEMENTAL INDENTURE (hereinafter this "Supplemental Indenture"), dated October 15, 2019, is made by and between Portland General Electric Company, an Oregon corporation (hereinafter called the "Company"), and Wells Fargo Bank, National Association (as successor to HSBC Bank USA, National Association), a national banking association, as Trustee (hereinafter called the "Trustee").

WHEREAS, the Company has heretofore executed and delivered its Indenture of Mortgage and Deed of Trust (herein sometimes referred to as the "Original Indenture"), dated July 1, 1945, to the Trustee to secure an issue of First Mortgage Bonds of the Company; and

WHEREAS, bonds in the aggregate principal amount of $34,000,000 have heretofore been issued under and in accordance with the terms of the Original Indenture as bonds of an initial series designated "First Mortgage Bonds, 3-1/8% Series due 1975" (herein sometimes referred to as the "Bonds of the 1975 Series"); and

WHEREAS, the Company has heretofore executed and delivered to the Trustee several supplemental indentures which provided, among other things, for amendment of the Original Indenture and for the creation or issuance of several new series of First Mortgage Bonds under the terms of the Original Indenture as follows:

	
									
	Supplemental
Indenture
	Dated
	Series Designation
	Principal Amount
	

	 

	First
	11/1/2047
	3-1/2
	%
	Series due 1977
	$
	6,000,000
	

	(1)

	Second
	11/1/2048
	3-1/2
	%
	Series due 1977
	4,000,000
	

	(1)

	Third
	5/1/2052
	3-1/2
	%
	Second Series due 1977
	4,000,000
	

	(1)

	Fourth
	11/1/2053
	4-1/8
	%
	Series due 1983
	8,000,000
	

	(2)

	Fifth
	11/1/2054
	3-3/8
	%
	Series due 1984
	12,000,000
	

	(1)

	Sixth
	9/1/2056
	4-1/4
	%
	Series due 1986
	16,000,000
	

	(1)

	Seventh
	6/1/2057
	4-7/8
	%
	Series due 1987
	10,000,000
	

	(1)

	Eighth
	12/1/2057
	5-1/2
	%
	Series due 1987
	15,000,000
	

	(3)

	Ninth
	6/1/2060
	5-1/4
	%
	Series due 1990
	15,000,000
	

	(1)

	Tenth
	11/1/2061
	5-1/8
	%
	Series due 1991
	12,000,000
	

	(1)

	Eleventh
	2/1/2063
	4-5/8
	%
	Series due 1993
	15,000,000
	

	(1)

	Twelfth
	6/1/2063
	4-3/4
	%
	Series due 1993
	18,000,000
	

	(1)

	Thirteenth
	4/1/2064
	4-3/4
	%
	Series due 1994
	18,000,000
	

	(1)

	Fourteenth
	3/1/2065
	4.70
	%
	Series due 1995
	14,000,000
	

	(1)

	Fifteenth
	6/1/2066
	5-7/8
	%
	Series due 1996
	12,000,000
	

	(1)

	Sixteenth
	10/1/2067
	6.60
	%
	Series due October 1, 1997
	24,000,000
	

	(1)

	Seventeenth
	4/1/1970
	8-3/4
	%
	Series due April 1, 1977
	20,000,000
	

	(1)

	Eighteenth
	11/1/1970
	9-7/8
	%
	Series due November 1, 2000
	20,000,000
	

	(4)

	Nineteenth
	11/1/1971
	8
	%
	Series due November 1, 2001
	20,000,000
	

	(4)

	Twentieth
	11/1/1972
	7-3/4
	%
	Series due November 1, 2002
	20,000,000
	

	(4)

	Twenty-first
	4/1/1973
	7.95
	%
	Series due April 1, 2003
	35,000,000
	

	(4)

	Twenty-second
	10/1/1973
	8-3/4
	%
	Series due October 1, 2003
	17,000,000
	

	(4)

	Twenty-third
	12/1/1974
	10-1/2
	%
	Series due December 1, 1980
	40,000,000
	

	(1)

	Twenty-fourth
	4/1/1975
	10
	%
	Series due April 1, 1982
	40,000,000
	

	(1)

	Twenty-fifth
	6/1/1975
	9-7/8
	%
	Series due June 1, 1985
	27,000,000
	

	(1)

	
									
	Twenty-sixth
	12/1/1975
	11-5/8
	%
	Series due December 1, 2005
	50,000,000
	

	(4)

	Twenty-seventh
	4/1/1976
	9-1/2
	%
	Series due April 1, 2006
	50,000,000
	

	(4)

	Twenty-eighth
	9/1/1976
	9-3/4
	%
	Series due September 1, 1996
	62,500,000
	

	(4)

	Twenty-ninth
	6/1/1977
	8-3/4
	%
	Series due June 1, 2007
	50,000,000
	

	(4)

	Thirtieth
	10/1/1978
	9.40
	%
	Series due January 1, 1999
	25,000,000
	

	(4)

	Thirty-first
	11/1/1978
	9.80
	%
	Series due November 1, 1998
	50,000,000
	

	(4)

	Thirty-second
	2/1/1980
	13-1/4
	%
	Series due February 1, 2000
	55,000,000
	

	(4)

	Thirty-third
	8/1/1980
	13-7/8
	%
	Series due August 1, 2010
	75,000,000
	

	(4)

	Thirty-sixth
	10/1/1982
	13-1/2
	%
	Series due October 1, 2012
	75,000,000
	

	(4)

	Thirty-seventh
	11/15/1984
	11-5/8
	%
	Extendable Series A due 
November 15, 1999
	75,000,000
	

	(4)

	Thirty-eighth
	6/1/1985
	10-3/4
	%
	Series due June 1, 1995
	60,000,000
	

	(4)

	Thirty-ninth
	3/1/1986
	9-5/8
	%
	Series due March 1, 2016
	100,000,000
	

	(4)

	Fortieth
	10/1/1990
	 
	 
	Medium Term Note Series
	200,000,000
	

	 

	Forty-first
	12/1/1991
	 
	 
	Medium Term Note Series I
	150,000,000
	

	(1)

	Forty-second
	4/1/1993
	7-3/4
	%
	Series due April 15, 2023
	150,000,000
	

	(4)

	Forty-third
	7/1/1993
	 
	 
	Medium Term Notes Series II
	75,000,000
	

	(1)

	Forty-fourth
	8/1/1994
	 
	 
	Medium Term Notes Series III
	75,000,000
	

	(1)

	Forty-fifth
	5/1/1995
	 
	 
	Medium Term Notes Series IV
	75,000,000
	

	(1)

	Forty-sixth
	8/1/1996
	 
	 
	Medium Term Notes Series V
	50,000,000
	

	(1)

	Forty-seventh
	12/14/2001
	 
	 
	Second Series due 2002
	150,000,000
	

	(4)

	Forty-eighth
	6/1/2002
	 
	 
	Collateral Series due 2003
	72,000,000
	

	(1)

	Forty-ninth
	6/1/2002
	 
	 
	Second Collateral Series due 2003
	150,000,000
	

	(1)

	Fiftieth
	10/1/2002
	8-1/8
	%
	Series due 2010
	150,000,000
	

	(4)

	Fifty-first
	10/1/2002
	5.6675
	%
	Series due 2012
	100,000,000
	

	(1)

	
									
	Fifty-second
	4/1/2003
	5.279
	%
	Series due 2013
	50,000,000
	

	(4)

	Fifty-third
	5/1/2003
	 
	 
	Collateral Series A due 2033
Collateral Series B due 2033
Collateral Series C due 2033
	142,400,000
	

	 

	Fifty-fourth
	5/1/2003
	 
	 
	Collateral Series due 2004
	150,000,000
	

	(1)

	Fifty-fifth
	7/1/2003
	 
	 
	Medium Term Notes Series VI
	150,000,000
	

	(5)

	Fifty-sixth
	5/1/2006
	6.31
6.26
	%
%
	Series due 2036
Series due 2031
	175,000,000
100,000,000
	

	 

	Fifty-seventh
	12/1/2006
	5.80
	%
	Series due 2039
	170,000,000
	

	 

	Fifty-eighth
	4/1/2007
	5.81
	%
	Series due 2037
	130,000,000
	

	 

	Fifty-ninth
	10/1/2007
	5.80
	%
	Series due 2018
	75,000,000
	

	(4)

	Sixtieth
	4/1/2008
	4.45
	%
	Second Series due 2013
	50,000,000
	

	(1)

	Sixty-first
	1/15/2009
	6.50
6.80
	%
%
	Series due 2014
Series due 2016
	63,000,000
67,000,000
	

	(4)
(4)

	Sixty-second
	4/1/2009
	6.10
	%
	Series due 2019
	300,000,000
	

	 

	Sixty-third
	11/1/2009
	5.43
	%
	Series due 2040
	150,000,000
	

	 

	Sixty-fourth
	1/15/2010
	3.46
	%
	Series due 2015
	70,000,000
	

	(1)

	Sixty-fifth
	6/15/2010
	3.81
	%
	Series due 2017
	58,000,000
	

	(4)

	Sixty-sixth
	5/29/2013
	N/A
	 
	 
	N/A
	

	(6)

	Sixty-seventh
	6/15/2013
	4.47
4.47
	%
%
	Series due 2044
Series due 2043
	150,000,000
75,000,000
	

	 

	Sixty-eighth
	10/15/2013
	4.74
4.84
	%
%
	Series due 2042
Series due 2048
	105,000,000
50,000,000
	

	 

	Sixty-ninth
	8/1/2014
	4.39
4.44
3.51
	%
%
%
	Series due 2045
Series due 2046
Series due 2024
	100,000,000
100,000,000
80,000,000
	

	 

	Seventieth
	1/1/2015
	3.55
	%
	Series due 2030
	75,000,000
	

	 

	Seventy-first
	5/15/2015
	3.50
	%
	Series due 2035
	70,000,000
	

	 

	Seventy-second
	1/1/2016
	2.51
	%
	Series due 2021
	140,000,000
	

	 

	Seventy-third
	8/1/2017
	3.98
	%
	Series due 2047
	150,000,000
	

	 

	 
	 
	3.98
	%
	Series due 2048
	75,000,000
	

	 

	Seventy-fourth
	12/1/2018
	4.47
	%
	Series due 2048
	75,000,000
	

	 

	Seventy-fifth
	4/1/2019
	4.30
	%
	Series due 2049
	200,000,000
	

	 

	
		
	(1)
	Paid in full at maturity.

	(2)
	This entire issue of Bonds was redeemed out of proceeds from the sale of First Mortgage Bonds, 3-3/8% Series due 1984.

	(3)
	This entire issue of Bonds was redeemed out of proceeds from the sale of First Mortgage Bonds, 4-5/8% Series due 1993

	(4)
	Redeemed in full prior to maturity.

	(5)
	$50,000,000 of such Medium Term Notes has matured and been paid in full.

	(6)
	Amended Section 14.01 of the Original Indenture.

which bonds are sometimes referred to herein as the "Bonds of the 1977 Series," "Bonds of the 1977 Second Series," "Bonds of the 1983 Series," "Bonds of the 1984 Series," "Bonds of the 1986 Series," "Bonds of the 47⁄8% Series due 1987," "Bonds of the 51⁄2% Series due 1987," "Bonds of the 1990 Series," "Bonds of the 1991 Series," "Bonds of the 45⁄8% Series due 1993," "Bonds of the 43⁄4% Series due 1993," "Bonds of the 1994 Series," "Bonds of the 1995 Series," "Bonds of the 1996 Series," "Bonds of the 1997 Series," "Bonds of the 1977 Third Series," "Bonds of the 2000 Series," "Bonds of the 2001 Series," "Bonds of the 2002 Series," "Bonds of the 2003 Series," "Bonds of the 2003 Second Series," "Bonds of the 1980 Series," "Bonds of the 1982 Series," "Bonds of the 1985 Series," "Bonds of the 2005 Series," "Bonds of the 2006 Series," "Bonds of the 1996 Second Series," "Bonds of the 2007 Series," "Bonds of the 1999 Series," "Bonds of the 1998 Series," "Bonds of the 2000 Second Series," "Bonds of the 2010 Series," "Bonds of the 2012 Series," "Bonds of the Extendable Series A," "Bonds of the 1995 Second Series," "Bonds of the 2016 Series," "Bonds of the Medium Term Note Series," "Bonds of the Medium Term Note Series I," "Bonds of the 2023 Series," "Bonds of the Medium Term Note Series II," "Bonds of the Medium Term Note Series III," "Bonds of the Medium Term Note Series IV," "Bonds of the Medium Term Note Series V," "Bonds of the 2002 Second Series," "Bonds of the Collateral Series," "Bonds of the Second Collateral Series," "Bonds of the 2010 Second Series," "Bonds of the 2012 Second Series," "Bonds of the 2013 Series," "Bonds of the 2033 Series," "Bonds of the 2004 Collateral Series," "Bonds of the Medium Term Note Series VI," "Bonds of the 2036 Series," "Bonds of the 2031 Series," "Bonds of the 2039 Series," "Bonds of the 2037 Series," "Bonds of the 2018 Series," "Bonds of the 2013 Second Series," "Bonds of the 2014 Series," "Bonds of the 2016 Series," "Bonds of the 2019 Series," "Bonds of the 2040 Series," "Bonds of the 2015 Series," "Bonds of the 2017 Series," "Bonds of the 2044 Series," "Bonds of the 2043 Series," "Bonds of the 2042 Series," "Bonds of the 2048 Series," "Bonds of the 2045 Series," "Bonds of the 2046 Series," "Bonds of the 2024 Series," "Bonds of the 2030 Series," "Bonds of the 2035 Series," "Bonds of the 2021 Series," "Bonds of the 2047 Series," "Bonds of the 2048 Series," "Bonds of the 2048 Series," and "Bonds of the 2049 Series," respectively; and

WHEREAS, the Original Indenture provides that the Company and the Trustee, subject to the conditions and restrictions in the Original Indenture contained, may enter into an indenture or indentures supplemental thereto, which shall thereafter form a part of said Original Indenture, among other things, to mortgage, pledge, convey, transfer, or assign to the Trustee and subject to the lien of the Original Indenture with the same force and effect as though included in the granting clauses thereof, additional properties acquired by the Company after the execution and delivery of the Original Indenture, and to provide for the creation of any series of bonds (other than the Bonds of the 1975 Series), designating the series to be created and specifying the form and provisions of the bonds of such series as therein provided or permitted, and to provide a sinking, amortization, replacement, or other analogous fund for the benefit of all or any of the bonds of any one or more series, of such character and of such amount, and upon such terms and conditions as shall be contained in such supplemental indenture; and

WHEREAS, the Company has heretofore executed and delivered to the Trustee seventy-five supplemental indentures amending in certain respects the Original Indenture (such Original Indenture as so supplemented and amended is hereinafter referred to as the "Mortgage"); and

WHEREAS, the Company desires to further amend the Mortgage in certain respects pursuant to Section 17.01 of the Original Indenture, and the Trustee has agreed to such amendments; and

WHEREAS, the Company desires to provide for the creation of two new series of bonds to be known as "First Mortgage Bonds, 3.34% Second Series due 2049" (sometimes herein referred to as the "Bonds of the 2049 Second Series") and “First Mortgage Bonds, 3.34% Series due 2050” (sometimes herein referred to as the “Bonds of the 2050 Series”) (collectively, sometimes herein referred to as the "Bonds"), and to specify the form and provisions of the Bonds, and to mortgage, pledge, convey, transfer, or assign to the Trustee and to subject to the lien of the Mortgage certain additional properties acquired by the Company since the execution and delivery of the Original Indenture; and

WHEREAS, the Company intends at this time to provide for the issuance of $110,000,000 aggregate principal amount of Bonds of the 2049 Second Series and $160,000,000 aggregate principal amount of Bonds of the 2050 Series under and in accordance with the terms of the Mortgage and this Supplemental Indenture (the Mortgage as so supplemented and amended by this Supplemental Indenture referred to as the "Indenture"); and

WHEREAS, the Bonds of the 2049 Second Series and the Trustee's authentication certificate to be executed on the Bonds of the 2049 Second Series are to be substantially in the following form, respectively:

(Form of Bond of the 3.34% Second Series due 2049)
[Face of Bond]
THIS BOND HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT").  THE HOLDER HEREOF, BY PURCHASING THIS BOND, AGREES FOR THE BENEFIT OF THE COMPANY THAT (A) THIS BOND MAY NOT BE RESOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT REGISTRATION UNDER THE SECURITIES ACT OR AN EXEMPTION THEREFROM (AND BASED UPON AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY, PROVIDED THAT IN-HOUSE COUNSEL TO AN INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(A)(1), (2), (3), OR (7) UNDER THE SECURITIES ACT SHALL BE DEEMED ACCEPTABLE) AND IN EACH CASE IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF EACH STATE OF THE UNITED STATES AND (B) IT WILL FURNISH TO THE COMPANY AND THE TRUSTEE SUCH CERTIFICATES AND OTHER INFORMATION AS THEY MAY REASONABLY REQUIRE TO CONFIRM THAT ANY TRANSFER BY IT OF THIS BOND COMPLIES WITH THE FOREGOING RESTRICTIONS, PROVIDED, HOWEVER, THAT SUCH CONFIRMATION BY THE COMPANY MUST BE MADE ON A TIMELY BASIS AND SHALL NOT BE UNREASONABLY WITHHELD.  THE HOLDER HEREOF, BY PURCHASING THIS BOND, REPRESENTS AND AGREES FOR THE BENEFIT OF THE COMPANY THAT IT IS (1) A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A OR (2) AN INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(A)(1), (2), (3), OR (7) UNDER THE SECURITIES ACT AND THAT IT IS HOLDING THIS BOND FOR INVESTMENT PURPOSES AND NOT FOR DISTRIBUTION OR (3) A NON-U.S. PERSON OUTSIDE THE UNITED STATES WITHIN THE MEANING OF REGULATION S UNDER THE SECURITIES ACT.

No. ______                                        $___________
CUSIP/PPN No. _______________

PORTLAND GENERAL ELECTRIC COMPANY
FIRST MORTGAGE BOND, 3.34% SECOND SERIES DUE 2049

ORIGINAL ISSUE DATE: ________________

Portland General Electric Company, an Oregon corporation (hereinafter sometimes called the "Company"), for value received, hereby promises to pay to __________________________, or registered assigns, the principal sum of _____________________________ Dollars on October 25, 2049 (the "Maturity Date"), except to the extent redeemed or repaid prior to the Maturity Date, and to pay interest thereon at the rate of 3.34 percent per annum (calculated on the basis of a 360-day year of twelve 30-day months) until the principal hereof is paid or made available for payment.  Interest will be paid semi-annually in arrears on April 15 and October 15 (each an "Interest Payment Date") each year from the Original Issue Date, which will be the date the first interest period commences, and on the Maturity Date. If the Maturity Date or an Interest Payment Date falls on a day which is not a Business Day, as defined below, principal or interest payable with respect to such Maturity Date or Interest Payment Date will be paid on the next succeeding Business Day with the same force and effect as if made on such Maturity Date or Interest Payment Date, as the case may be, and, in the case of an Interest Payment Date, but not the Maturity Date, no additional interest shall accrue.  The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, subject to certain exceptions, be paid to the person in whose name this bond (or one or more predecessor bonds) is registered at the close of business on the fifteenth day (whether or not a Business Day) next preceding such Interest Payment Date (the "Regular Record Date"); provided, however, that interest payable on the Maturity Date will be payable to the person to whom the principal hereof shall be payable.  Should the Company default in the payment of interest ("Defaulted Interest"), the Defaulted Interest shall be paid to the person in whose name this bond (or one or more predecessor bonds) is registered on a subsequent record date fixed by the Company, which subsequent record date shall be fifteen days prior to the payment of such Defaulted Interest.  As used herein, "Business Day" means any day, other than a Saturday or Sunday, on which banks in The City of New York are not required or authorized by law to close.

Payment of the principal of and interest on this bond will be made in immediately available funds at the office or agency of the Trustee located in Minneapolis, Minnesota or such other office of the Trustee that functions as its financial operations center, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts, with payment at maturity (or, if applicable, upon redemption) made against presentation of this bond at such office or agency for cancellation.  The Trustee, as paying agent of the Company, will make all payments of principal and interest by wire transfer of immediately available funds; provided, however, that appropriate written wire transfer instructions must have been received by the Trustee not less than sixteen days prior to the applicable Interest Payment Date, Maturity Date, or redemption date.

Reference is hereby made to the further provisions of this bond set forth on the reverse hereof, including terms of redemption, and such further provisions shall for all purposes have the same effect as though fully set forth at this place.

This bond shall not become or be valid or obligatory for any purpose until the authentication certificate hereon shall have been signed by the Trustee.

In Witness Whereof, Portland General Electric Company has caused this instrument to be executed manually or in facsimile by its duly authorized officers and has caused a facsimile of its corporate seal to be imprinted hereon.

Dated: _____________________

PORTLAND GENERAL ELECTRIC COMPANY
	
		
	By:
	 

	 
	James Lobdell

	 
	Senior Vice President - Finance,

	 
	Chief Financial Officer and Treasurer

Attest: _____________________
Secretary

(Form of Trustee's Authentication Certificate for
Bonds of the 3.34% Second Series due 2049)

This is one of the bonds, of the series designated herein, described in the within-mentioned Indenture.

WELLS FARGO BANK, NATIONAL 
ASSOCIATION, AS TRUSTEE
	
		
	By:
	 

	 
	Authorized Signatory

[Reverse of Bond]

This bond is one of the bonds of a series designated as First Mortgage Bonds, 3.34% Second Series due 2049 (sometimes herein referred to as the "Bonds of the 2049 Second Series") limited to a maximum aggregate principal amount of $110,000,000.  Bonds of the 2049 Second Series are bonds of an authorized issue of bonds of the Company known as First Mortgage Bonds, not limited as to maximum aggregate principal amount, all issued or issuable in one or more series under and equally secured (except insofar as any sinking fund, replacement fund, or other fund established in accordance with the provisions of the Indenture hereinafter mentioned may afford additional security for the bonds of any specific series) by an Indenture of Mortgage and Deed of Trust dated July 1, 1945, duly executed and delivered by the Company to Wells Fargo Bank, National Association (as successor to HSBC Bank USA, National Association), as Trustee, as supplemented, amended, and modified by seventy-five supplemental indentures and by the Seventy-sixth Supplemental Indenture (such Indenture of Mortgage and Deed of Trust as so supplemented, amended, and modified by such seventy-five supplemental indentures and the Seventy-sixth Supplemental Indenture being hereinafter called the "Indenture"), to which Indenture reference is hereby made for a description of the property mortgaged and pledged as security for said bonds, the nature and extent of the security, and the rights, duties, and immunities thereunder of the Trustee, the rights of the holders of said bonds and of the Trustee and of the Company in respect of such security, and the terms upon which said 

bonds may be issued thereunder.  Capitalized terms used herein and not defined herein shall have the respective meanings in the Indenture, unless otherwise noted.  

The Bonds of the 2049 Second Series are not subject to any sinking fund.

The Bonds of the 2049 Second Series may be redeemed by the Company prior to maturity as a whole, at any time, or in part, from time to time on notice given not more than ninety nor less than thirty days prior to the date of such redemption at the option of the Company at a price equal to the greater of (i) the principal amount of the portion of this bond to be redeemed or (ii) the sum of the present values of the remaining scheduled payments of principal and interest (not including any portion of such payments of interest accrued as of the date of redemption) due on this bond (or portion thereof) to be redeemed, discounted to the redemption date on a semi-annual basis (assuming a 360‐day year consisting of twelve 30-day months) at the Adjusted Treasury Rate, plus 50 basis points, together in each case with accrued and unpaid interest to the date of redemption.  Notwithstanding the foregoing, so long as no event of default as defined in the Indenture shall then exist, any prepayment made by the Company of all or any portion of the Bonds of the 2049 Second Series outstanding on or after April 25, 2049 shall be made at 100% of the principal so prepaid plus accrued and unpaid interest to the date of redemption.

If this bond or any portion thereof ($10,000 or an integral multiple thereof) is duly called for redemption and payment duly provided for as specified in the Indenture, this bond or such portion thereof shall cease to be entitled to the lien of the Indenture from and after the date payment is so provided for and shall cease to bear interest from and after the date fixed for such redemption. 

In the event of the selection for redemption of a portion only of the principal of this bond, payment of the redemption price will be made only upon surrender of this bond in exchange for a bond or bonds (but only of authorized denominations of the same series) for the unredeemed balance of the principal amount of this bond.

The Indenture contains provisions permitting the Company and the Trustee, with the consent of the holders of not less than seventy-five percent in principal amount of the bonds (exclusive of bonds disqualified by reason of the Company's interest therein) at the time outstanding, including, if more than one series of bonds shall be at the time outstanding, not less than sixty percent in principal amount of each series affected, to effect, by an indenture supplemental to the Indenture, modifications or alterations of the Indenture and of the rights and obligations of the Company and of the holders of the bonds and coupons if the modifications or alterations would adversely affect or diminish the rights of the holders of any bonds against the Company or its property; provided, however, that no such modification or alteration shall be made without the written approval or consent of all holders hereof which will (i) extend the maturity of this bond or reduce the rate or extend the time of payment of interest hereon or reduce the amount of the principal hereof, (ii) permit the creation of any lien, not otherwise permitted, prior to or on a parity with the lien of the Indenture, or (iii) reduce the percentage of the principal amount of the bonds upon the approval or consent of the holders of which modifications or alterations may be made as aforesaid. 
 
The transfer of this bond is registrable by the registered owner hereof in person or by such owner's attorney duly authorized in writing, at the corporate trust office of the Trustee in Minneapolis, Minnesota, upon surrender of this bond for cancellation and upon payment of any taxes or other governmental charges payable upon such transfer, and thereupon a new registered bond or bonds of the same series and of a like aggregate principal amount will be issued to the transferee or transferees in exchange therefor. 
 
The Company, the Trustee, and any paying agent may deem and treat the person in whose name this bond is registered as the absolute owner hereof for the purpose of receiving payments of or on account of 

the principal hereof and interest due hereon, and for all other purposes, whether or not this bond shall be overdue, and neither the Company, the Trustee, nor any paying agent shall be affected by any notice to the contrary. 

Bonds of this series are issuable only in fully registered form without coupons in denominations of $100,000 or any amount in excess thereof that is an integral multiple of $10,000.  The registered owner of this bond at its option may surrender the same for cancellation at said office of the Trustee and receive in exchange therefor the same aggregate principal amount of registered bonds of the same series but of other authorized denominations upon payment of any taxes or other governmental charges payable upon such exchange and subject to the terms and conditions set forth in the Indenture.  Bonds may be issued in a denomination of less than $100,000 (but in multiples of at least $10,000) if necessary to enable the registration of a transfer by a holder of its entire holding of bonds, or if necessary for the redemption of bonds.

If an event of default as defined in the Indenture shall occur, the principal of this bond may become or be declared due and payable before maturity in the manner and with the effect provided in the Indenture.  The holders, however, of certain specified percentages of the bonds (exclusive of bonds disqualified by reason of the Company's interest therein) at the time outstanding, including in certain cases specified percentages of bonds of particular series, may in certain cases, to the extent and as provided in the Indenture, waive certain defaults thereunder and the consequences of such defaults. 

No recourse shall be had for the payment of the principal of or the interest on this bond, or for any claim based hereon, or otherwise in respect hereof or of the Indenture, against any incorporator, shareholder, director, or officer, past, present, or future, as such, of the Company or of any predecessor or successor corporation, either directly or through the Company or such predecessor or successor corporation, under any constitution or statute or rule of law, or by the enforcement of any assessment or penalty, or otherwise, all such liability of incorporators, shareholders, directors, and officers, as such, being waived and released by the holder and owner hereof by the acceptance of this bond and as provided in the Indenture. 
 
The Indenture provides that this bond shall be deemed to be a contract made under the laws of the State of New York, and for all purposes shall be construed in accordance with and governed by the laws of said State.  

(End of Form of Bond of the 3.34% Second Series due 2049)

and

WHEREAS, the Bonds of the 2050 Series and the Trustee's authentication certificate to be executed on the Bonds of the 2050 Series are to be substantially in the following form, respectively:
(Form of Bond of the 3.34% Series due 2050)
[Face of Bond]
THIS BOND HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT").  THE HOLDER HEREOF, BY PURCHASING THIS BOND, AGREES FOR THE BENEFIT OF THE COMPANY THAT (A) THIS BOND MAY NOT BE RESOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT REGISTRATION UNDER THE SECURITIES ACT OR AN EXEMPTION THEREFROM (AND BASED UPON AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY, PROVIDED THAT IN-HOUSE COUNSEL TO AN INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(A)(1), (2), (3), OR (7) UNDER THE SECURITIES ACT SHALL BE DEEMED ACCEPTABLE) AND IN EACH CASE IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF EACH STATE OF THE UNITED STATES AND (B) IT WILL FURNISH TO THE COMPANY AND THE TRUSTEE SUCH CERTIFICATES AND OTHER INFORMATION AS THEY MAY REASONABLY REQUIRE TO CONFIRM THAT ANY TRANSFER BY IT OF THIS BOND COMPLIES WITH THE FOREGOING RESTRICTIONS, PROVIDED, HOWEVER, THAT SUCH CONFIRMATION BY THE COMPANY 

MUST BE MADE ON A TIMELY BASIS AND SHALL NOT BE UNREASONABLY WITHHELD.  THE HOLDER HEREOF, BY PURCHASING THIS BOND, REPRESENTS AND AGREES FOR THE BENEFIT OF THE COMPANY THAT IT IS (1) A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A OR (2) AN INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(A)(1), (2), (3), OR (7) UNDER THE SECURITIES ACT AND THAT IT IS HOLDING THIS BOND FOR INVESTMENT PURPOSES AND NOT FOR DISTRIBUTION OR (3) A NON-U.S. PERSON OUTSIDE THE UNITED STATES WITHIN THE MEANING OF REGULATION S UNDER THE SECURITIES ACT.

No. ______                                        $___________
CUSIP/PPN No. _______________

PORTLAND GENERAL ELECTRIC COMPANY
FIRST MORTGAGE BOND, 3.34% SERIES DUE 2050

ORIGINAL ISSUE DATE: ________________

Portland General Electric Company, an Oregon corporation (hereinafter sometimes called the "Company"), for value received, hereby promises to pay to __________________________, or registered assigns, the principal sum of _____________________________ Dollars on January 15, 2050 (the "Maturity Date"), except to the extent redeemed or repaid prior to the Maturity Date, and to pay interest thereon at the rate of 3.34 percent per annum (calculated on the basis of a 360-day year of twelve 30-day months) until the principal hereof is paid or made available for payment.  Interest will be paid semi-annually in arrears on January 15 and July 15 (each an "Interest Payment Date") each year from the Original Issue Date, which will be the date the first interest period commences, and on the Maturity Date. If the Maturity Date or an Interest Payment Date falls on a day which is not a Business Day, as defined below, principal or interest payable with respect to such Maturity Date or Interest Payment Date will be paid on the next succeeding Business Day with the same force and effect as if made on such Maturity Date or Interest Payment Date, as the case may be, and, in the case of an Interest Payment Date, but not the Maturity Date, no additional interest shall accrue.  The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, subject to certain exceptions, be paid to the person in whose name this bond (or one or more predecessor bonds) is registered at the close of business on the fifteenth day (whether or not a Business Day) next preceding such Interest Payment Date (the "Regular Record Date"); provided, however, that interest payable on the Maturity Date will be payable to the person to whom the principal hereof shall be payable.  Should the Company default in the payment of interest ("Defaulted Interest"), the Defaulted Interest shall be paid to the person in whose name this bond (or one or more predecessor bonds) is registered on a subsequent record date fixed by the Company, which subsequent record date shall be fifteen days prior to the payment of such Defaulted Interest.  As used herein, "Business Day" means any day, other than a Saturday or Sunday, on which banks in The City of New York are not required or authorized by law to close.

Payment of the principal of and interest on this bond will be made in immediately available funds at the office or agency of the Trustee located in Minneapolis, Minnesota or such other office of the Trustee that functions as its financial operations center, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts, with payment at maturity (or, if applicable, upon redemption) made against presentation of this bond at such office or agency for cancellation.  The Trustee, as paying agent of the Company, will make all payments of principal and interest by wire transfer of immediately available funds; provided, however, that appropriate written wire transfer instructions must have been received by the Trustee not less than sixteen days prior to the applicable Interest Payment Date, Maturity Date, or redemption date.

Reference is hereby made to the further provisions of this bond set forth on the reverse hereof, including terms of redemption, and such further provisions shall for all purposes have the same effect as though fully set forth at this place.

This bond shall not become or be valid or obligatory for any purpose until the authentication certificate hereon shall have been signed by the Trustee.

In Witness Whereof, Portland General Electric Company has caused this instrument to be executed manually or in facsimile by its duly authorized officers and has caused a facsimile of its corporate seal to be imprinted hereon.

Dated: _____________________

PORTLAND GENERAL ELECTRIC COMPANY

	
		
	By:
	 

	 
	James Lobdell

	 
	Senior Vice President - Finance,

	 
	Chief Financial Officer and Treasurer

Attest: _____________________
Secretary

(Form of Trustee's Authentication Certificate for
Bonds of the 3.34% Series due 2050)

This is one of the bonds, of the series designated herein, described in the within-mentioned Indenture.

WELLS FARGO BANK, NATIONAL 
ASSOCIATION, AS TRUSTEE
                            
	
		
	By:
	 

	 
	Authorized Signatory

[Reverse of Bond]

This bond is one of the bonds of a series designated as First Mortgage Bonds, 3.34% Series due 2050 (sometimes herein referred to as the "Bonds of the 2050 Series") limited to a maximum aggregate principal amount of $160,000,000.  Bonds of the 2050 Series are bonds of an authorized issue of bonds of the Company known as First Mortgage Bonds, not limited as to maximum aggregate principal amount, all issued or issuable in one or more series under and equally secured (except insofar as any sinking fund, replacement fund, or other fund established in accordance with the provisions of the Indenture hereinafter mentioned may afford additional security for the bonds of any specific series) by an Indenture of Mortgage and Deed of Trust dated July 1, 1945, duly executed and delivered by the Company to Wells Fargo Bank, National Association (as successor to HSBC Bank USA, National Association), as Trustee, as supplemented, amended, and modified by seventy-five supplemental indentures and by the Seventy-sixth Supplemental Indenture (such Indenture 

of Mortgage and Deed of Trust as so supplemented, amended, and modified by such seventy-five supplemental indentures and the Seventy-sixth Supplemental Indenture being hereinafter called the "Indenture"), to which Indenture reference is hereby made for a description of the property mortgaged and pledged as security for said bonds, the nature and extent of the security, and the rights, duties, and immunities thereunder of the Trustee, the rights of the holders of said bonds and of the Trustee and of the Company in respect of such security, and the terms upon which said bonds may be issued thereunder.  Capitalized terms used herein and not defined herein shall have the respective meanings in the Indenture, unless otherwise noted.  

The Bonds of the 2050 Series are not subject to any sinking fund.

The Bonds of the 2050 Series may be redeemed by the Company prior to maturity as a whole, at any time, or in part, from time to time on notice given not more than ninety nor less than thirty days prior to the date of such redemption at the option of the Company at a price equal to the greater of (i) the principal amount of the portion of this bond to be redeemed or (ii) the sum of the present values of the remaining scheduled payments of principal and interest (not including any portion of such payments of interest accrued as of the date of redemption) due on this bond (or portion thereof) to be redeemed, discounted to the redemption date on a semi-annual basis (assuming a 360‐day year consisting of twelve 30-day months) at the Adjusted Treasury Rate, plus 50 basis points, together in each case with accrued and unpaid interest to the date of redemption.  Notwithstanding the foregoing, so long as no event of default as defined in the Indenture shall then exist, any prepayment made by the Company of all or any portion of the Bonds of the 2050 Series outstanding on or after July 15, 2049 shall be made at 100% of the principal so prepaid plus accrued and unpaid interest to the date of redemption.

If this bond or any portion thereof ($10,000 or an integral multiple thereof) is duly called for redemption and payment duly provided for as specified in the Indenture, this bond or such portion thereof shall cease to be entitled to the lien of the Indenture from and after the date payment is so provided for and shall cease to bear interest from and after the date fixed for such redemption. 

In the event of the selection for redemption of a portion only of the principal of this bond, payment of the redemption price will be made only upon surrender of this bond in exchange for a bond or bonds (but only of authorized denominations of the same series) for the unredeemed balance of the principal amount of this bond.

The Indenture contains provisions permitting the Company and the Trustee, with the consent of the holders of not less than seventy-five percent in principal amount of the bonds (exclusive of bonds disqualified by reason of the Company's interest therein) at the time outstanding, including, if more than one series of bonds shall be at the time outstanding, not less than sixty percent in principal amount of each series affected, to effect, by an indenture supplemental to the Indenture, modifications or alterations of the Indenture and of the rights and obligations of the Company and of the holders of the bonds and coupons if the modifications or alterations would adversely affect or diminish the rights of the holders of any bonds against the Company or its property; provided, however, that no such modification or alteration shall be made without the written approval or consent of all holders hereof which will (i) extend the maturity of this bond or reduce the rate or extend the time of payment of interest hereon or reduce the amount of the principal hereof, (ii) permit the creation of any lien, not otherwise permitted, prior to or on a parity with the lien of the Indenture, or (iii) reduce the percentage of the principal amount of the bonds upon the approval or consent of the holders of which modifications or alterations may be made as aforesaid. 

The transfer of this bond is registrable by the registered owner hereof in person or by such owner's attorney duly authorized in writing, at the corporate trust office of the Trustee in Minneapolis, Minnesota, upon surrender of this bond for cancellation and upon payment of any taxes or other governmental charges 

payable upon such transfer, and thereupon a new registered bond or bonds of the same series and of a like aggregate principal amount will be issued to the transferee or transferees in exchange therefor.

The Company, the Trustee, and any paying agent may deem and treat the person in whose name this bond is registered as the absolute owner hereof for the purpose of receiving payments of or on account of the principal hereof and interest due hereon, and for all other purposes, whether or not this bond shall be overdue, and neither the Company, the Trustee, nor any paying agent shall be affected by any notice to the contrary.

Bonds of this series are issuable only in fully registered form without coupons in denominations of $100,000 or any amount in excess thereof that is an integral multiple of $10,000.  The registered owner of this bond at its option may surrender the same for cancellation at said office of the Trustee and receive in exchange therefor the same aggregate principal amount of registered bonds of the same series but of other authorized denominations upon payment of any taxes or other governmental charges payable upon such exchange and subject to the terms and conditions set forth in the Indenture.  Bonds may be issued in a denomination of less than $100,000 (but in multiples of at least $10,000) if necessary to enable the registration of a transfer by a holder of its entire holding of bonds, or if necessary for the redemption of bonds.

If an event of default as defined in the Indenture shall occur, the principal of this bond may become or be declared due and payable before maturity in the manner and with the effect provided in the Indenture.  The holders, however, of certain specified percentages of the bonds (exclusive of bonds disqualified by reason of the Company's interest therein) at the time outstanding, including in certain cases specified percentages of bonds of particular series, may in certain cases, to the extent and as provided in the Indenture, waive certain defaults thereunder and the consequences of such defaults. 

No recourse shall be had for the payment of the principal of or the interest on this bond, or for any claim based hereon, or otherwise in respect hereof or of the Indenture, against any incorporator, shareholder, director, or officer, past, present, or future, as such, of the Company or of any predecessor or successor corporation, either directly or through the Company or such predecessor or successor corporation, under any constitution or statute or rule of law, or by the enforcement of any assessment or penalty, or otherwise, all such liability of incorporators, shareholders, directors, and officers, as such, being waived and released by the holder and owner hereof by the acceptance of this bond and as provided in the Indenture. 
 
The Indenture provides that this bond shall be deemed to be a contract made under the laws of the State of New York, and for all purposes shall be construed in accordance with and governed by the laws of said State.  

(End of Form of Bond of the 3.34% Series due 2050)

and

WHEREAS, all acts and proceedings required by law and by the charter or articles of incorporation and bylaws of the Company necessary to make the Bonds to be issued hereunder, when executed by the Company, authenticated and delivered by the Trustee, and duly issued, the valid, binding, and legal obligations of the Company, and to constitute this Supplemental Indenture a valid and binding instrument, have been done and taken; and the execution and delivery of this Supplemental Indenture have been in all respects duly authorized;

NOW, THEREFORE, THIS SUPPLEMENTAL INDENTURE WITNESSETH, that, in order to secure the payment of the principal of, premium, if any, and interest on all First Mortgage Bonds at any 

time issued and outstanding under the Original Indenture as supplemented and modified by the seventy-five supplemental indentures hereinbefore described and as supplemented and modified by this Supplemental Indenture, according to their tenor, purport, and effect, and to secure the performance and observance of all the covenants and conditions therein and herein contained, and for the purpose of confirming and perfecting the lien of the Indenture on the properties of the Company hereinafter described, or referred to, and for and in consideration of the premises and of the mutual covenants herein contained, and acceptance of the Bonds by the holders thereof, and for other valuable consideration, the receipt whereof is hereby acknowledged, the Company has executed and delivered this Supplemental Indenture and by these presents does grant, bargain, sell, warrant, alien, convey, assign, transfer, mortgage, pledge, hypothecate, set over, and confirm unto the Trustee the following property, rights, privileges, and franchises (in addition to all other property, rights, privileges, and franchises heretofore subjected to the lien of the Original Indenture as supplemented by the seventy-five supplemental indentures hereinbefore described and not heretofore released from the lien thereof, all of which shall secure all bonds, including the Bonds), to wit:

CLAUSE I

Without in any way limiting anything in the Mortgage or hereinafter described, all and singular the lands, real estate, chattels real, interests in land, leaseholds, ways, rights-of-way, easements, servitudes, permits and licenses, lands under water, riparian rights, franchises, privileges, electric generating plants, electric transmission and distribution systems, and all apparatus and equipment appertaining thereto, offices, buildings, warehouses, garages, and other structures, tracks, machine shops, materials and supplies, and all property of any nature appertaining to any of the plants, systems, business, or operations of the Company, whether or not affixed to the realty, used in the operation of any of the premises or plants or systems or otherwise, which have been acquired by the Company since the execution and delivery of the Original Indenture and not heretofore included in any indenture supplemental thereto, and now owned or which may hereafter be acquired by the Company (other than excepted property as defined in the Mortgage).

CLAUSE II

All corporate, Federal, State, municipal, and other permits, consents, licenses, bridge licenses, bridge rights, river permits, franchises, grants, privileges, and immunities of every kind and description, owned, held, possessed, or enjoyed by the Company (other than excepted property as defined in the Mortgage) and all renewals, extensions, enlargements, and modifications of any of them, which have been acquired by the Company since the execution and the delivery of the Original Indenture and not heretofore included in any indenture supplemental thereto, and now owned or which may hereafter be acquired by the Company.

CLAUSE III

Also all other property, real, personal, or mixed, tangible or intangible (other than excepted property as defined in the Mortgage) of every kind, character, and description and wheresoever situated, whether or not useful in the generation, manufacture, production, transportation, distribution, sale, or supplying of electricity, hot water, or steam, which has been acquired by the Company since the execution and delivery of the Original Indenture and not heretofore included in any indenture supplemental thereto, and now owned or which may hereafter be acquired by the Company (other than excepted property as defined in the Mortgage).

CLAUSE IV

Together with all and singular the plants, buildings, improvements, additions, tenements, hereditaments, easements, rights, privileges, licenses, and franchises and all other appurtenances whatsoever belonging or in any wise pertaining to any of the property hereby mortgaged or pledged, or intended so to be, or any part thereof, and the reversion and reversions, remainder and remainders, and the rents, revenues, issues, earnings, income, products, and profits thereof, and every part and parcel thereof, and all the estate, right, title, interest, property, claim, and demand of every nature whatsoever of the Company at law, in equity, or otherwise howsoever, in, of, and to such property and every part and parcel thereof (other than excepted property as defined in the Mortgage).

TO HAVE AND TO HOLD all of said property, real, personal, and mixed, and all and singular the lands, properties, estates, rights, franchises, privileges, and appurtenances hereby mortgaged, conveyed, pledged, or assigned, or intended so to be, together with all the appurtenances thereto appertaining and the rents, issues, and profits thereof, unto the Trustee and its successors and assigns, forever:

SUBJECT, HOWEVER, to the exceptions, reservations, restrictions, conditions, limitations, covenants, and matters contained in all deeds and other instruments whereunder the Company has acquired any of the property now owned by it, and to permitted encumbrances as defined in Subsection B of Section 1.11 of the Mortgage;

BUT IN TRUST NEVERTHELESS, for the equal and proportionate use, benefit, security, and protection of those who from time to time shall hold the bonds authenticated and delivered under the Original Indenture and the seventy-five supplemental indentures hereinbefore described or this Supplemental Indenture, and duly issued by the Company, without any discrimination, preference, or priority of any one bond over any other by reason of priority in the time of issue, sale, or negotiation thereof or otherwise, except as provided in Section 11.28 of the Mortgage, so that, subject to said Section 11.28, each and all of said bonds shall have the same right, lien, and privilege under the Original Indenture and the seventy-five supplemental indentures hereinbefore described, or this Supplemental Indenture, and shall be equally secured thereby and hereby and shall have the same proportionate interest and share in the trust estate, with the same effect as if all of the bonds had been issued, sold, and negotiated simultaneously on the date of delivery of the Original Indenture;

AND UPON THE TRUSTS, USES, AND PURPOSES and subject to the covenants, agreements, and conditions in the Original Indenture and the seventy-five supplemental indentures hereinbefore described and herein set forth and declared.

ARTICLE ONE.
BONDS OF THE 2049 SECOND SERIES AND
CERTAIN PROVISIONS RELATING THERETO.

SECTION 1.01.    Certain Terms of Bonds of the 2049 Second Series.  There is hereby established a series of First Mortgage Bonds of the Company designated and entitled as "First Mortgage Bonds, 3.34% Second Series due 2049" (sometimes referred to as the "Bonds of the 2049 Second Series").  The aggregate principal amount of the Bonds of the 2049 Second Series shall be limited to $110,000,000, excluding, however, any Bonds of the 2049 Second Series which may be executed, authenticated, and delivered in exchange for or in lieu of or in substitution for other Bonds of such Series pursuant to the provisions of the Indenture.

The definitive Bonds of the 2049 Second Series shall be issuable in substantially the form as hereinabove set forth in fully registered form without coupons in the denomination of $100,000, or any amount in excess thereof that is an integral multiple of $10,000.

Notwithstanding the provisions of Section 2.05 of the Mortgage, each Bond of the 2049 Second Series shall be dated as of the date sold by the Company (the "Original Issue Date") and shall mature on  October 25, 2049 (the "Maturity Date"), except to the extent redeemed or repaid prior to the Maturity Date.  Each Bond of the 2049 Second Series shall bear interest from the Original Issue Date, which is the date the first interest period commences, at the rate of 3.34 per cent per annum (calculated on the basis of a 360‐day year of twelve 30‐day months), until payment of the principal thereof has been paid or made available for payment.  Interest will be payable semi-annually in arrears on April 15 and October  15 (each an "Interest Payment Date") each year commencing with the first Interest Payment Date occurring after the Original Issue Date, and on the Maturity Date.  If the Maturity Date or an Interest Payment Date falls on a day which is not a Business Day, as defined below, principal or interest payable with respect to such Maturity Date or Interest Payment Date will be paid on the next succeeding Business Day with the same force and effect as if made on such Maturity Date or Interest Payment Date, as the case may be, and, in the case of an Interest Payment Date, but not the Maturity Date, no additional interest shall accrue.  The person in whose name any Bond of the 2049 Second Series is registered at the close of business on the applicable Record Date (as defined below) with respect to any Interest Payment Date shall be entitled to receive the interest payable thereon on such Interest Payment Date notwithstanding the cancellation of such Bond of the 2049 Second Series upon any registration of transfer or exchange thereof subsequent to such Record Date and prior to such Interest Payment Date, unless the Company shall default in the payment of the interest due on such Interest Payment Date, in which case such defaulted interest shall be paid to the person in whose name such Bond of the 2049 Second Series is registered on a subsequent record date fixed by the Company, which subsequent record date shall be fifteen days prior to the payment of such defaulted interest; provided, however, that interest payable on the Maturity Date will be payable to the person to whom the principal thereof shall be payable.  As used herein the term "Business Day" means any day, other than a Saturday or Sunday, on which banks in The City of New York, New York are not required or authorized by law to close.  As used herein, the term "Record Date" with respect to any Interest Payment Date shall mean the fifteenth day (whether or not such day is a Business Day) next preceding such Interest Payment Date.  The principal of the Bonds of the 2049 Second Series shall be payable in any coin or currency of the United States of America which at the time of payment is legal tender for the payment of public and private debts at the office or agency of the Trustee located in Minneapolis, Minnesota or such other office of the Trustee that functions as its financial operations center, and interest on such Bonds of the 2049 Second Series shall be payable in like coin or currency at said office or agency, with payment at maturity (or, if applicable, upon redemption) made against presentation of such Bonds for cancellation.

Upon compliance with the provisions of Section 2.06 of the Mortgage and as provided in this Supplemental Indenture, and upon payment of any taxes or other governmental charges payable upon such exchange, Bonds of the 2049 Second Series may be exchanged for a new Bond or Bonds of the 2049 Second Series of different authorized denominations of like aggregate principal amount.  The Trustee hereunder shall, by virtue of its office as such Trustee, be the registrar and transfer agent of the Company for the purpose of registering permitted transfers of Bonds of the 2049 Second Series.

Notwithstanding the provisions of Section 2.11 of the Mortgage, no service charge shall be made for any exchange or registration of transfer of Bonds of the 2049 Second Series, but the Company or the Trustee at either of their option may require payment of a sum sufficient to cover any tax or other governmental charge incident thereto.

SECTION 1.02.    Redemption Provisions for Bonds of the 2049 Second Series.  The Bonds of the 2049 Second Series may be redeemed prior to maturity at any time, in whole or in part, upon prior notice given by mailing such notice to the respective registered owners of such Bonds of the 2049 Second Series not less than thirty nor more than ninety days prior to the redemption date and as otherwise required by the provisions of Article Nine of the Mortgage, at the option of the Company, at a redemption price equal to the greater of (i) 100 percent of the principal amount of the portion of the Bonds of the 2049 Second Series to be redeemed or (ii) the sum of the present values of the remaining scheduled payments of principal and interest (not including any portion of such payments of interest accrued as of the date of redemption) due on the Bonds of the 2049 Second Series (or portion thereof) to be redeemed, discounted to the redemption date on a semi-annual basis (assuming a 360‐day year consisting of twelve 30-day months) at the Adjusted Treasury Rate, plus 50 basis points, together in each case with accrued and unpaid interest to the date of redemption.  Notwithstanding the foregoing, so long as no event of default as defined in the Indenture shall then exist, any prepayment made by the Company of all or any portion of the Bonds of the 2049 Second Series outstanding on or after April 25, 2049 shall be made at 100% of the principal so prepaid plus accrued and unpaid interest to the date of redemption.  The Company shall give the Trustee notice of such redemption price immediately after the calculation thereof, and the Trustee shall have no responsibility for such calculation.

Notwithstanding the provisions of Section 9.03 of the Mortgage, in the case of any partial redemption of the Bonds of the 2049 Second Series, the principal amount of the Bonds to be redeemed shall be allocated pro rata among all holders of such Bonds of the 2049 Second Series at the time outstanding and in accordance with the unpaid principal amount thereof.

The following definitions shall apply for purposes of this Section 1.02:

(a)  "Adjusted Treasury Rate" means, with respect to any redemption date, the rate per annum equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, calculated using a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date.  The Adjusted Treasury Rate shall be calculated on the third Business Day preceding the redemption date.

(b)  "Comparable Treasury Issue" means the United States Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining term of the Bonds of the 2049 Second Series to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Bonds of the 2049 Second Series.

(c)  "Comparable Treasury Price" means, with respect to any redemption date, (A) the average of four Reference Treasury Dealer Quotations for the redemption date, after excluding the highest and lowest Reference Treasury Dealer Quotations for the redemption date, or (B) if the Independent Investment Banker obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such quotations.

(d)  "Independent Investment Banker" means an independent investment and banking institution of national standing appointed by the Company.

(e)  "Reference Treasury Dealer" means a primary U.S. Government securities dealer in New York City selected by the Independent Investment Banker.

(f)  "Reference Treasury Dealer Quotations" means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker at 5:00 p.m., New York City time, on the fourth Business Day preceding the redemption date.

SECTION 1.03.    Sections 4.04, 4.05, and 4.06 to Remain in Effect.  Notwithstanding the provisions of Sections 4.04, 4.05, 4.06, and 4.07 of the Mortgage, the provisions of Sections 4.04, 4.05, and 4.06 of the Mortgage shall remain in full force and effect and shall be performed by the Company so long as any Bonds of the 2049 Second Series remain outstanding.

SECTION 1.04.    Certain Requirements of Mortgage to Remain Applicable.  The requirements which are stated in the next to the last paragraph of Section 1.13 and in Clause (9) of Paragraph A of Section 3.01 of the Mortgage to be applicable so long as any of the Bonds of the 1975 Series are outstanding shall remain applicable so long as any of the Bonds of the 2049 Second Series are outstanding.

SECTION 1.05.    Certain Exceptions to Sections 2.06 and 2.10 of the Mortgage.  Notwithstanding the provisions of Section 2.06 or Section 2.10 of the Mortgage, the Company shall not be required (a) to issue, register, discharge from registration, exchange, or register the transfer of any Bond of the 2049 Second Series for a period of fifteen days next preceding any selection by the Trustee of Bonds of the 2049 Second Series to be redeemed or (b) to register, discharge from registration, exchange, or register the permitted transfer of any Bond of the 2049 Second Series so selected for redemption in its entirety or (c) to exchange or register the permitted transfer of any portion of a Bond of the 2049 Second Series which portion has been so selected for redemption.

SECTION 1.06.    Reference to Minimum Provision for Depreciation in Certificate of Available Additions.  So long as any Bonds of the 2049 Second Series remain outstanding, all references to the minimum provision for depreciation in the form of certificate of available additions set forth in Section 3.03 of the Mortgage shall be included in any certificate of available additions filed with the Trustee, but whenever Bonds of the 2049 Second Series shall no longer be outstanding, all references to such minimum provisions for depreciation may be omitted from any such certificate.

SECTION 1.07.    Reporting Obligations.  To the extent the Company is no longer required to file or does not voluntarily file the following documents with the Securities and Exchange Commission (the "SEC"), so long as any Bonds of the 2049 Second Series are outstanding, the Company shall furnish to the Trustee, within the time periods specified in the SEC's rules and regulations, the following:

(a)  All quarterly and annual financial information that would be required to be contained in a filing with the SEC on Forms 10‐Q and 10‐K if the Company were required to file such forms, including a "Management's Discussion and Analysis of Financial Condition and Results of Operations" that describes the financial condition and results of operations of the Company and its consolidated subsidiaries and, with respect to the annual information only, a report thereon by the Company's certified independent accountants.

(b)  All current reports that would be required to be filed with the SEC on Form 8-K if the Company were required to file such reports.

The Trustee shall retain such documents in accordance with its customary procedures.  

Delivery of such reports, information, and documents to the Trustee is for informational purposes only and the Trustee's receipt of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein (as to which the Trustee may rely solely on Officers' Certificates).

SECTION 1.08.    CUSIP, ISIN, Private Placement, or Common Code Numbers.  The Company in issuing the Bonds of the 2049 Second Series may use "CUSIP," "ISIN," "Private Placement," or "Common Code" numbers (if then generally in use) and, if so, the Trustee shall use such numbers in notices of redemption or repurchase as a convenience to holders; provided, however, that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the bonds or as contained in any notice of a redemption or repurchase and that reliance may be placed only on the other identification numbers printed on the bonds, and any such redemption or repurchase shall not be affected by any defect in or omission of such numbers.  The Company shall promptly notify the Trustee in writing of any change in "CUSIP," "ISIN," "Private Placement," or "Common Code" numbers.

SECTION 1.09    Duration of Article One.  This Article One shall be of force and effect only so long as any Bonds of the 2049 Second Series are outstanding.

ARTICLE TWO.
BONDS OF THE 2050 SERIES AND
CERTAIN PROVISIONS RELATING THERETO.

SECTION 2.01.    Certain Terms of Bonds of the 2050 Series.  There is hereby established a series of First Mortgage Bonds of the Company designated and entitled as "First Mortgage Bonds, 3.34% Series due 2050" (sometimes referred to as the "Bonds of the 2050 Series").  The aggregate principal amount of the Bonds of the 2050 Series shall be limited to $160,000,000, excluding, however, any Bonds of the 2050 Series which may be executed, authenticated, and delivered in exchange for or in lieu of or in substitution for other Bonds of such Series pursuant to the provisions of the Indenture.

The definitive Bonds of the 2050 Series shall be issuable in substantially the form as hereinabove set forth in fully registered form without coupons in the denomination of $100,000, or any amount in excess thereof that is an integral multiple of $10,000.

Notwithstanding the provisions of Section 2.05 of the Mortgage, each Bond of the 2050 Series shall be dated as of the date sold by the Company (the "Original Issue Date") and shall mature on  January 15, 2050 (the "Maturity Date"), except to the extent redeemed or repaid prior to the Maturity Date.  Each Bond of the 2050 Series shall bear interest from the Original Issue Date, which is the date the first interest period commences, at the rate of 3.34 per cent per annum (calculated on the basis of a 360‐day year of twelve 30‐day months), until payment of the principal thereof has been paid or made available for payment.  Interest will be payable semi-annually in arrears on January 15 and July 15 (each an "Interest Payment Date") each year commencing with the first Interest Payment Date occurring after the Original Issue Date, and on the Maturity Date.  If the Maturity Date or an Interest Payment Date falls on a day which is not a Business Day, as defined below, principal or interest payable with respect to such Maturity Date or Interest Payment Date will be paid on the next succeeding Business Day with the same force and effect as if made on such Maturity Date or Interest Payment Date, as the case may be, and, in the case of an Interest Payment Date, but not the Maturity Date, no additional interest shall accrue.  The person in whose name any Bond of the 2050 Series is registered at the close of business on the applicable Record Date (as defined below) with respect to any Interest Payment Date shall be entitled to receive the interest payable thereon on such Interest Payment Date notwithstanding the cancellation of such Bond of the 2050 Series upon any registration of transfer or exchange thereof subsequent to such Record Date and prior to 

such Interest Payment Date, unless the Company shall default in the payment of the interest due on such Interest Payment Date, in which case such defaulted interest shall be paid to the person in whose name such Bond of the 2050 Series is registered on a subsequent record date fixed by the Company, which subsequent record date shall be fifteen days prior to the payment of such defaulted interest; provided, however, that interest payable on the Maturity Date will be payable to the person to whom the principal thereof shall be payable.  As used herein the term "Business Day" means any day, other than a Saturday or Sunday, on which banks in The City of New York, New York are not required or authorized by law to close.  As used herein, the term "Record Date" with respect to any Interest Payment Date shall mean the fifteenth day (whether or not such day is a Business Day) next preceding such Interest Payment Date.  The principal of the Bonds of the 2050 Series shall be payable in any coin or currency of the United States of America which at the time of payment is legal tender for the payment of public and private debts at the office or agency of the Trustee located in Minneapolis, Minnesota or such other office of the Trustee that functions as its financial operations center, and interest on such Bonds of the 2050 Series shall be payable in like coin or currency at said office or agency, with payment at maturity (or, if applicable, upon redemption) made against presentation of such Bonds for cancellation.

Upon compliance with the provisions of Section 2.06 of the Mortgage and as provided in this Supplemental Indenture, and upon payment of any taxes or other governmental charges payable upon such exchange, Bonds of the 2050 Series may be exchanged for a new Bond or Bonds of the 2050 Series of different authorized denominations of like aggregate principal amount.  The Trustee hereunder shall, by virtue of its office as such Trustee, be the registrar and transfer agent of the Company for the purpose of registering permitted transfers of Bonds of the 2050 Series.

Notwithstanding the provisions of Section 2.11 of the Mortgage, no service charge shall be made for any exchange or registration of transfer of Bonds of the 2050 Series, but the Company or the Trustee at either of their option may require payment of a sum sufficient to cover any tax or other governmental charge incident thereto.

SECTION 2.02.    Redemption Provisions for Bonds of the 2050 Series.  The Bonds of the 2050 Series may be redeemed prior to maturity at any time, in whole or in part, upon prior notice given by mailing such notice to the respective registered owners of such Bonds of the 2050 Series not less than thirty nor more than ninety days prior to the redemption date and as otherwise required by the provisions of Article Nine of the Mortgage, at the option of the Company, at a redemption price equal to the greater of (i) 100 percent of the principal amount of the portion of the Bonds of the 2050 Series to be redeemed or (ii) the sum of the present values of the remaining scheduled payments of principal and interest (not including any portion of such payments of interest accrued as of the date of redemption) due on the Bonds of the 2050 Series (or portion thereof) to be redeemed, discounted to the redemption date on a semi-annual basis (assuming a 360‐day year consisting of twelve 30-day months) at the Adjusted Treasury Rate, plus 50 basis points, together in each case with accrued and unpaid interest to the date of redemption.  Notwithstanding the foregoing, so long as no event of default as defined in the Indenture shall then exist, any prepayment made by the Company of all or any portion of the Bonds of the 2050 Series outstanding on or after July 15, 2049 shall be made at 100% of the principal so prepaid plus accrued and unpaid interest to the date of redemption.  The Company shall give the Trustee notice of such redemption price immediately after the calculation thereof, and the Trustee shall have no responsibility for such calculation.

Notwithstanding the provisions of Section 9.03 of the Mortgage, in the case of any partial redemption of the Bonds of the 2050 Series, the principal amount of the Bonds to be redeemed shall be allocated pro rata among all holders of such Bonds of the 2050 Series at the time outstanding and in accordance with the unpaid principal amount thereof.

The following definitions shall apply for purposes of this Section 2.02:

(a)  "Adjusted Treasury Rate" means, with respect to any redemption date, the rate per annum equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, calculated using a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date.  The Adjusted Treasury Rate shall be calculated on the third Business Day preceding the redemption date.

(b)  "Comparable Treasury Issue" means the United States Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining term of the Bonds of the 2050 Series to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Bonds of the 2050 Series.

(c)  "Comparable Treasury Price" means, with respect to any redemption date, (A) the average of four Reference Treasury Dealer Quotations for the redemption date, after excluding the highest and lowest Reference Treasury Dealer Quotations for the redemption date, or (B) if the Independent Investment Banker obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such quotations.

(d)  "Independent Investment Banker" means an independent investment and banking institution of national standing appointed by the Company.

(e)  "Reference Treasury Dealer" means a primary U.S. Government securities dealer in New York City selected by the Independent Investment Banker.

(f)  "Reference Treasury Dealer Quotations" means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker at 5:00 p.m., New York City time, on the fourth Business Day preceding the redemption date.

SECTION 2.03.    Sections 4.04, 4.05, and 4.06 to Remain in Effect.  Notwithstanding the provisions of Sections 4.04, 4.05, 4.06, and 4.07 of the Mortgage, the provisions of Sections 4.04, 4.05, and 4.06 of the Mortgage shall remain in full force and effect and shall be performed by the Company so long as any Bonds of the 2050 Second Series remain outstanding.

SECTION 2.04.    Certain Requirements of Mortgage to Remain Applicable.  The requirements which are stated in the next to the last paragraph of Section 1.13 and in Clause (9) of Paragraph A of Section 3.01 of the Mortgage to be applicable so long as any of the Bonds of the 1975 Series are outstanding shall remain applicable so long as any of the Bonds of the 2050 Series are outstanding.

SECTION 2.05.    Certain Exceptions to Sections 2.06 and 2.10 of the Mortgage.  Notwithstanding the provisions of Section 2.06 or Section 2.10 of the Mortgage, the Company shall not be required (a) to issue, register, discharge from registration, exchange, or register the transfer of any Bond of the 2050 Series for a period of fifteen days next preceding any selection by the Trustee of Bonds of the 2050 Series to be redeemed or (b) to register, discharge from registration, exchange, or register the permitted transfer of any Bond of the 2050 Series so selected for redemption in its entirety or (c) to exchange or register the permitted transfer of any portion of a Bond of the 2050 Series which portion has been so selected for redemption.

SECTION 2.06.    Reference to Minimum Provision for Depreciation in Certificate of Available Additions.  So long as any Bonds of the 2050 Series remain outstanding, all references to the minimum provision for depreciation in the form of certificate of available additions set forth in Section 3.03 of the Mortgage shall be included in any certificate of available additions filed with the Trustee, but whenever Bonds of the 2050 Series shall no longer be outstanding, all references to such minimum provisions for depreciation may be omitted from any such certificate.

SECTION 2.07.    Reporting Obligations.  To the extent the Company is no longer required to file or does not voluntarily file the following documents with the Securities and Exchange Commission (the "SEC"), so long as any Bonds of the 2050 Series are outstanding, the Company shall furnish to the Trustee, within the time periods specified in the SEC's rules and regulations, the following:

(a)  All quarterly and annual financial information that would be required to be contained in a filing with the SEC on Forms 10‐Q and 10‐K if the Company were required to file such forms, including a "Management's Discussion and Analysis of Financial Condition and Results of Operations" that describes the financial condition and results of operations of the Company and its consolidated subsidiaries and, with respect to the annual information only, a report thereon by the Company's certified independent accountants.

(b)  All current reports that would be required to be filed with the SEC on Form 8-K if the Company were required to file such reports.

The Trustee shall retain such documents in accordance with its customary procedures.  

Delivery of such reports, information, and documents to the Trustee is for informational purposes only and the Trustee's receipt of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein (as to which the Trustee may rely solely on Officers' Certificates).

SECTION 2.08.    CUSIP, ISIN, Private Placement, or Common Code Numbers.  The Company in issuing the Bonds of the 2050 Series may use "CUSIP," "ISIN," "Private Placement," or "Common Code" numbers (if then generally in use) and, if so, the Trustee shall use such numbers in notices of redemption or repurchase as a convenience to holders; provided, however, that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the bonds or as contained in any notice of a redemption or repurchase and that reliance may be placed only on the other identification numbers printed on the bonds, and any such redemption or repurchase shall not be affected by any defect in or omission of such numbers.  The Company shall promptly notify the Trustee in writing of any change in "CUSIP," "ISIN," "Private Placement," or "Common Code" numbers.

SECTION 2.09    Duration of Article Two.  This Article Two shall be of force and effect only so long as any Bonds of the 2050 Series are outstanding.

ARTICLE THREE.
TRUSTEE.

SECTION 3.01.    Duties of Trustee.  The Trustee hereby accepts the trust hereby created.  The Trustee undertakes, prior to the occurrence of an event of default and after the curing of all events of default which may have occurred, to perform such duties and only such duties as are specifically set forth in the Original Indenture as heretofore and hereby supplemented and modified, on and subject to the terms 

and conditions set forth in the Original Indenture as so supplemented and modified, and in case of the occurrence of an event of default (which has not been cured) to exercise such of the rights and powers vested in it by the Original Indenture as so supplemented and modified, and to use the same degree of care and skill in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of his or her own affairs.

The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or the Bonds issued hereunder or the due execution thereof by the Company.  The Trustee shall be under no obligation or duty with respect to the filing, registration, or recording of this Supplemental Indenture or the re-filing, re-registration, or re-recording thereof.  The recitals of fact contained herein or in the Bonds (other than the Trustee's authentication certificate) shall be taken as the statements solely of the Company, and the Trustee assumes no responsibility for the correctness thereof.

ARTICLE FOUR.
MISCELLANEOUS PROVISIONS.

SECTION 4.01.    Date of this Supplemental Indenture.  Although this Supplemental Indenture, for convenience and for the purpose of reference, is dated October 15, 2019, the actual date of execution by the Company and by the Trustee is as indicated by their respective acknowledgments hereto annexed.

SECTION 4.02.    Relation to Original Indenture.  This Supplemental Indenture is executed and shall be construed as an indenture supplemental to the Original Indenture as heretofore supplemented and modified, and as supplemented and modified hereby, the Original Indenture as heretofore supplemented and modified is in all respects ratified and confirmed, and the Original Indenture as heretofore and hereby supplemented and modified shall be read, taken, and construed as one and the same instrument.  All terms used in this Supplemental Indenture shall be taken to have the same meaning as in the Original Indenture except in cases where the context clearly indicates otherwise.

SECTION 4.03.    Invalid, Illegal, or Unenforceable Provisions.  In case any one or more of the provisions contained in this Supplemental Indenture or in the Bonds shall for any reason be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Supplemental Indenture, but this Supplemental Indenture shall be construed as if such invalid or illegal or unenforceable provision had never been contained herein.

SECTION 4.04.    Counterparts.  This Supplemental Indenture may be executed in any number of counterparts, and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts, or as many of them as the Company and the Trustee shall preserve undestroyed, shall together constitute but one and the same instrument.

SECTION 4.05.    Conflicting Provision.  If any provision of this Supplemental Indenture conflicts with another provision of the Mortgage required to be included in indentures qualified under the Trust Indenture Act of 1939 (as enacted prior to the date of this Supplemental Indenture) by any of the provisions of said Act, such required provision shall control.

SECTION 4.06.    Headings.  Article and Section headings and the table of contents used herein are for convenience of reference only, are not part of this Supplemental Indenture, and are not to affect the construction of, or to be taken into consideration in interpreting, this Supplemental Indenture.

SECTION 4.07.    Governing Law.  THIS SUPPLEMENTAL INDENTURE SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK DETERMINED WITHOUT REFERENCE TO PRINCIPLES OF CONFLICTS OF LAWS (OTHER THAN SECTION 5‐1401 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK), PROVIDED THAT THE FOREGOING SHALL NOT APPLY TO THE CREATION OR ENFORCEMENT OF ANY LIEN ON REAL PROPERTY CREATED BY THE INDENTURE, WHICH SHALL BE GOVERNED BY THE LAWS OF THE STATE IN WHICH SUCH REAL PROPERTY IS LOCATED.

SECTION 4.08.    Addresses for Notices to the Trustee.  Any notice, direction, request or demand hereunder to or upon the Trustee shall be in writing (including facsimile and electronic mail in PDF format) and shall be deemed to have been sufficiently given or made, for all purposes, if given or served by overnight courier, facsimile, electronic mail in PDF format, or by being deposited postage prepaid by registered or certified mail in a post office letter box, addressed to the Trustee at: Wells Fargo Bank, National Association, Attn: Corporate, Municipal & Escrow Services, 333 S. Grand Avenue, 5th Floor Suite 5A, MAC E2604-05A, Los Angeles, CA 90071, Facsimile: 213.253.7598.  The Trustee, by notice to the Company, may designate additional or different addresses for subsequent notices or communications.

SECTION 4.09.    Tax Withholding.  By acceptance of any Bond issued hereunder, unless otherwise prohibited by law, each holder is deemed to agree to provide to the Company, the Trustee or any agent any information or certification that may be required under applicable law with respect to withholding, backup withholding or information reporting, and update or replace such form, information or certification in accordance with its terms or its subsequent amendments to the extent necessary.  Notwithstanding any other provision of this Supplemental Indenture, failure of a holder to provide the required tax certificates and information may result in amounts of tax being withheld from the payment to such holder without liability, provided that, except as otherwise required by applicable law, the Company and Trustee will not withhold from any applicable payment to be made to a holder of a Bond that is not a United States Person any tax so long as such holder shall have delivered to the Company (in such number of copies as shall be requested) on or about the date on which such holder becomes a holder under this Supplemental Indenture (and from time to time thereafter upon the reasonable request of the Company, the Trustee or any agent), copies of IRS Form W-8BEN or IRS Form W-8BEN-E, as applicable, as well as the applicable “U.S. Tax Compliance Certificate”, and any successor or additional form, information or certification as may be required by applicable law, in each case correctly completed and executed.  The Company, the Trustee, or any agent, as the case may be, shall make such payment after such withholding or deduction has been made and shall account to the relevant authorities for the amount so withheld or deducted.  The Company, the Trustee, or any agent, as the case may be, shall have no obligation to gross up any payment hereunder or pay any additional amount as a result of such withholding tax.  The Company agrees to provide to the Trustee, upon request, sufficient information about Bond holders or other applicable parties and/or transactions (including any modification to the terms of such transactions), to the extent that such information is in the possession of the Company, so as to enable the Trustee to determine whether it has tax related obligations under applicable law.  Nothing in this Section 4.09 shall require any holder to provide information that is confidential or proprietary to such holder unless the Company or Trustee is required to obtain such information under applicable law with respect to withholding, backup withholding or information reporting and, in such event, the Company and Trustee shall treat any such information it receives as confidential (except to the extent necessary to report to the applicable taxing authority).  The terms of this section shall survive the resignation or removal of the Trustee and the termination of this Supplemental Indenture.

 
In connection with any proposed transfer of a Bond, the transferor shall be required to use commercially reasonable efforts to provide or cause to be provided to the Trustee all information necessary to allow the Trustee to comply with any applicable tax reporting obligations, including without limitation any cost basis reporting obligations under Section 6045 of the Internal Revenue Code.  The Trustee shall be entitled to rely on information provided to it and shall have no responsibility to verify or ensure the accuracy of such information.
    

IN WITNESS WHEREOF, Portland General Electric Company has caused this Supplemental Indenture to be signed in its corporate name by its President or one of its Executive Vice Presidents or one of its Vice Presidents and its corporate seal to be hereunto affixed and attested by its Secretary or one of its Assistant Secretaries, and in token of its acceptance of the trusts created hereunder, Wells Fargo Bank, National Association has caused this Supplemental Indenture to be signed in its corporate name by one of its Vice Presidents or one of its Assistant Vice Presidents or one of its Corporate Trust Officers, all as of the day and year first above written.    

PORTLAND GENERAL ELECTRIC COMPANY
	
		
	By:
	/s/ James Lobdell

	Name:
	James Lobdell

	Title:
	Senior Vice President - Finance,

	 
	Chief Financial Officer and Treasurer

Attest:      /s/ Nora Arkonovich            
Name:    Nora Arkonovich
Title:    Secretary

(Seal)

WELLS FARGO BANK, NATIONAL
ASSOCIATION, as Trustee
	
		
	By:
	/s/ Maddy Hughes

	Name:
	Maddy Hughes

	Title:
	Vice President

State of Oregon      )
  ) ss.
County of Multnomah      )

The foregoing instrument was acknowledged before me on this 16th day of October, 2019 by James Lobdell, Senior Vice President of Finance, Chief Financial Officer & Treasurer of PORTLAND GENERAL ELECTRIC COMPANY, an Oregon corporation, on behalf of said corporation.

/s/ Kristina Benson            
                    
Notary Public for Oregon
My Commission Expires 7/14/2023         

[NOTARIAL SEAL]

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT                CIVIL CODE § 1189

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California    )
County of Los Angeles    )
On     October 17, 2019          before me,      Cecilia Garcia, Notary Public            ,
Date                        Here Insert Name and Title of the Officer
personally appeared     Maddy Hughes                                    
Name(s) of Signer(s)
,
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

	
				
	 
	 
	I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

	[NOTARIAL SEAL]
	 
	WITNESS my hand and official seal.

	 
	 
	Signature 
	/s/ Cecilia Garcia

	 
	 
	 
	Signature of Notary Public

Place Notary Seal Above

OPTIONAL
____________________________________________________________________________________________
Though this section is optional, completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.
Description of Attached Document: Seventy-sixth Supplemental Indenture for $270 million
Title or Type of Document: First Mortgage Bonds     Document Date: October 15, 2019
Number of Pages:                     Signer(s) Other Than Named Above:      
Capacity(ies) Claimed by Signer(s)
Signer’s Name:     Maddy Hughes            Signer’s Name:     
□ Corporate Officer - Title(s):  Vice President    □ Corporate Officer - Title(s):     
□ Partner -    □ Limited     □ General        □ Partner -    □ Limited     □ General
□ Individual            □ Attorney in Fact        □ Individual            □ Attorney in Fact
□ Trustee               □ Guardian or Conservator        □ Trustee               □ Guardian or Conservator
□ Other:         □ Other:     
Signer Is Representing:         Signer is Representing:     
            

____________________________________________________________________________________________
    

©2015 National Notary Association  www.NationalNotary.org    1-800-US NOTARY (1-800-876-6827)    Item #5907

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]